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Abstract
One of the hallmarks of Alzheimer’s disease (AD) is the pathological accumulation of βamyloid (Aβ) in the brains of AD patients. Oligomeric and fibrillar aggregates of Aβ have
been shown to be neurotoxic to neurons and hippocampal slices. Therefore, limiting Aβ
production is an important area of research in order to delay or stop AD progression. Aβ is
produced by amyloidogenic cleavage of amyloid precursor protein (APP). Amyloidogenic
cleavage requires ectodomain removal by β-secretase and intramembrane γ-cleavage by γsecretase to release Aβ products ranging from 38-43 residues. Work from our lab has shown
that APP and γ-secretase are resident proteins of the lysosome. Furthermore, the acidic
environment of lysosomes that promotes the aggregation of Aβ. While many lines of
evidence demonstrate that APP internalization is important to the Aβ production, the
intracellular itinerary of APP, from production to cleavage, is unclear.
In order to follow the intracellular trafficking of APP and Aβ, we have applied various
microscopy techniques, in combination with fluorescently-tagged proteins. Using a
photoactivatable mutant of GFP (paGFP), we accurately photoactivated nascent APP and
followed its trafficking to lysosomes. To our surprise, we found that APP was delivered to
lysosomes, where it is cleaved by γ-secretase, through an entirely intracellular pathway. This
intracellular pathway was dependent upon an interaction between APP and adaptor protein 3.
We found that the interaction between APP and AP-3 is dependent on the 709YTSI712 tyrosine
motif. Furthermore, phosphorylation of the serine within this motif, by PKCε, can disrupt this
interaction. By decreasing APP trafficking to lysosomes, through disrupting the APP/AP-3
interaction we decreased the production of Aβ. While lysosomes have traditionally been
thought to be responsible for cellular waste disposal, they also have a secretory role in a
number of cell types; including neurons. We demonstrate that lysosomes are not only
responsible for the production of Aβ, but may also be responsible for the secretion of
lysosomal Aβ into the extracellular space. This research may provide new therapeutic targets
to limit the production and release of Aβ.
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Chapter 1

1

Introduction and Literature Review

Alzheimer’s disease (AD) is the most common form of dementia. The major risk factor for AD is
age. Between age 65-90 the risk for AD doubles every 5 years [1]. In 2010, AD cost the
American economy $179 billion to care for AD patients. These numbers are closely mirrored in
Canada. Because there is no cure for AD, the cost is expected to rise above $1 trillion by 2050
[2]. It is estimated that there are 500 000 AD patients in Canada, with the number expected to
rise to more than 1 million by 2038 [3]. The cost of caring for these patients is estimated to be
$15 billion/year and is expected to increase ten-fold by 2038 [3]. Without intervention, AD
presents a pressing public health issue to Western economies. In AD, long-term memory is
typically preserved, but short-term episodic memory is lost. Short-term episodic memory is
typically one of the earliest clinical signs of AD. The clinical symptoms are indicative of the
underlying neuronal damage. The two main pathological hallmarks found in AD are the
neurofibrillary tangles (NFTs) and amyloid plaques.
NFTs are intracellular aggregates, which accompanies the neuronal loss [4,5]. Electron
microscopy studies of NFTs revealed that they were composed of smaller units known as paired
helical filaments [6]. However, it was over two decades before hyperphosphorylated tau was
uncovered as the major constituent of PHFs and NFTs [7]. While tau has important roles in
maintaining microtubule stability [8], these properties of tau are lost with hyperphosphorylated
tau [9-13].
Perhaps because of the close relationship between NFTs and neuronal survival, NFTs afflict
brain areas that correspond with neurological deficits that appear in AD patients [14]. For
example, AD typically begins with the loss of memory. The transentorhinal and entorhinal
cortex, which serve as critical relay stations to the hippocampus, are the first areas to be afflicted
with abnormal accumulation of neurofibrillary tangles (NFTs) [14]. Over the course of AD, tau
pathology spreads from the medial limbic region to other areas of the neocortex; including the
prefrontal, parietal, and temporal cortices [14]. Neuronal damage in these areas is associated with
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deficits in areas of cognition; including language, visuospatial function, frontal executive
function, and praxis. At the end-stage of the disease, the patient succumbs to AD or a related
comorbidity. AD prognosis from diagnosis until death is approximately 5-8 years [15].
Despite the strong association between the clinical presentation of AD and tau pathology, NFTs
and tau do not fully explain AD pathology. A transgenic mouse model over-expressing human
tau can recapitulate NFTs found in AD. However, this process requires 22-months and only
correlates to pathology found quite early in AD [16]. In addition, NFTs on their own are not
sufficient to disrupt neuronal networks in mice [17,18]. Furthermore, tau mutations in humans,
which cause NFT pathology, cannot recapitulate amyloid deposition found in AD. Rather, these
mutations lead to diseases with different phenotypes, such as Frontotemporal Dementia (FTD)
and Amylotrophic Lateral Sclerosis (ALS). Consequently, tau pathology does not sufficiently
account for all aspects of AD pathology.
Perhaps, the aetiology of AD lies with the amyloid plaques, which are the other prominent
feature found in AD. The main constituent of these plaques was found to be aggregates of βamyloid (Aβ) [19]. Aβ is produced by amyloidogenic cleavage of the amyloid precursor protein
(APP). APP is first cleaved by β-secretase to release the large ectodomain into the luminal
compartment. The subsequent cleavage, of the remaining carboxyl terminal fragment, by γsecretase complex produces Aβ species ranging from 38-43 residues. The Aβ42 has a higher
propensity to aggregate and is the major constituent of amyloid plaques [20,21] (Figure 1.1).
Insoluble fibrillar aggregates have been shown to be neurotoxic to cells in culture and
hippocampal slices [22-26]. There is evidence suggesting that Aβ pathology is upstream of tau
pathology. For example, rat hippocampal neurons treated with fibrillar aggregates of Aβ cause
the generation of phosphorylated tau [27]. Furthermore, transgenic mouse models of AD lacking
tau were protected from cognitive decline [28]. Therefore, Aβ aggregation and accumulation
may play a central role in AD pathology.
While fibrillar aggregates of Aβ were shown to be neurotoxic in cell culture and hippocampal
slices [22-26], the progression of Aβ deposition does not follow the clinical signs of AD.
According to the Braak staging of AD, amyloid deposits are initially found in the prefrontal,
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parietal, and temporal cortices [14]. However, recent work has shown that when total Aβ
(aggregated and soluble) is accounted for, Aβ levels in the brain correlate well with disease
progression. As patients progress from cognitively normal to early AD there is a 6-7 fold
increase in Aβ in the entorhinal cortex [29]. In support of these findings, other work has shown
that soluble oligomeric Aβ is neurotoxic and synaptotoxic to cells and hippocampal slices [3034].
Because of its central role in AD pathology, it has been suggested that pathological accumulation
of Aβ in the brain can lead to AD [35,36]. Known as the amyloid cascade hypothesis, this
hypothesis has been the main motivation for much of the research in AD. Despite the success of
Aβ reducing therapies in mouse models, this initial success has not translated into viable
therapeutics for human AD patients, suggesting further research is required to further our
understanding of the underlying disease processes [37,38].
One area in need of further research is to determine the exact subcellular organelle responsible
for APP cleavage and the mechanism regulating trafficking to and away from this compartment.
Several lines of evidence suggest that the specific intracellular locale of APP can influence the
production of Aβ. For example, the carbon length of phospholipid membranes of different
organelles may determine the processivity of the γ-secretase complex [39]. Furthermore,
deacdification of intracellular organelles lowers Aβ production. Work from our lab has identified
that PS1, the catalytic component of the γ-secretase complex, has an acidic optimal pH [40].
Moreover, our lab has shown that APP and members of the γ-secretase complex have been
identified as resident proteins of the lysosomes [40,41]. Although many subcellular
compartments have been implicated in AD, work from our lab implicates the lysosome in Aβ
production.
The subcellular sorting of APP is important in controlling the levels of Aβ produced. Synaptic
activity can increase the production of Aβ, in an endocytosis dependent manner [42,43].
Pharmacological and genetic disruption of APP internalization to endosomes and lysosomes can
also decrease the production of Aβ [42,44]. Moreover, retrograde trafficking of APP from
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endosomes and lysosomes to the Golgi limit the production of Aβ, and has been implicated in
AD pathology [45-47].
In this thesis, we will review the specifics of amyloid production and the amyloid cascade
hypothesis. Then we will review the trafficking of APP and other proteins towards and away
from the endosomal/lysosomal system; including adaptors and other protein machinery required
to facilitate this trafficking. Then we will present data describing a new pathway for APP
trafficking to the lysosome and subsequent cleavage. Furthermore, we will present data
demonstrating that lysosomes are critical for the secretion of Aβ.

1.1 Amyloid Precursor Protein
1.1.1

Non-amyloidogenic or amyloidogenic cleavage

APP can be processed by the amyloidogenic or non-amyloidogenic pathway. Amyloidogenic
cleavage of APP produces the neurotoxic Aβ species ranging from 38-43 residues. Conversely,
cleavage of APP in the non-amyloidogenic pathway decreases the production of Aβ by cleaving
APP within the Aβ region. It has been suggested there is competition between the amyloidogenic
and non-amyloidogenic pathways for limited APP substrate [48,49] (Figure 1.1). Cleavage in
both pathways depends on removal of the large N-terminal ectodomain. In the nonamyloidogenic pathway, removal of the large, luminal ectodomain is mediated by α-secretase
cleavage, which produces a soluble APP ectodomain (APPsα) product and an 83-residue
carboxyl-terminal fragment (CTF). The candidates for α-secretase have been suggested as
members of the ADAM (a disintegrin and metalloprotease) family. Of the 21 members of the
ADAM family, ADAM10 and ADAM17 are the likely α-secretases [50-52]. ADAM10 is
responsible for constitutive α-cleavage of APP, while cleavage by ADAM17 is up-regulated by
PKC activation [48,51,53,54]. However, there is at least one report of ADAM17 facilitating
constitutive shedding of the APP ectodomain in HEK cells [55]. ADAM10, BACE, and APP
mRNA are all expressed within the same neuronal population [49], which suggests that
ADAM10 may be the relevant secretase in vivo. In addition, over-expression of ADAM10 in
mice expressing APPLon increased non-amyloidogenic cleavage of APP, decreased plaque load,
and improved cognition [56].
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The delicate balance between non-amyloidogenic and amyloidogenic cleavage is critical in
managing the levels of Aβ. Recent studies in a Finnish population has revealed that elderly
individuals bearing the A673T mutation in APP are protected from cognitive decline [57]. The
A673 residues is immediately carboxyl terminal to the β-cleavage site in APP. Membrane
anchored aspartic proteinase of the pepsin family-2 (Memapsin-2, also known as β-site APPcleaving enzyme 1, BACE1) was identified as the enzyme responsible for catalyzing the first
step in amyloidogenic cleavage of APP [58,59]. While proteolytically active ADAM10 is
localized to the cell surface [51,60], active BACE1 appears to be localized to early endosomes.
BACE1 has an optimal pH of 4.5, and is not active at the cell surface; suggesting involvement of
the endosomal/lysosomal system [58]. Furthermore, BACE1 has been localized to early
endosomes by fluorescence resonance energy transfer (FRET) [61]. In healthy neurons, the
intracellular levels of BACE1 are controlled by lysosomal degradation. However, depletion of
the adaptor GGA3 (discussed later) in AD decreases lysosomal degradation of BACE1, and
promotes amyloidogenic cleavage of APP [62-65].
BACE cleavage of APP produces a 99-CTF, which is processed by γ-secretase. The 99-CTF and
83-CTF produce monomeric Aβ and p3, respectively, after cleavage by γ-secretase. While the γsecretase can cleave many substrates (including Notch, E-cadherin, and LRP) [66], γ-secretase is
of interest, because of its role in Aβ production. A functional γ-secretase complex is composed
of at least Aph-1 (anterior pharynx-defective 1), Pen-2 (presenilin enhancer 2), nicastrin, and
Presenilin 1 (PS1). The CTF stub produced, after α- or β- secretase cleavage, is recognized by
nicastrin, which serves as a ‘gatekeeper’ to the γ-secretase complex [67]. PS1 is a large protein
with 9-10 transmembrane domains, and serves as the catalytic component of γ-secretase. In order
to form a functional γ-secretase complex, it is believed that Aph-1 and nicastrin form a subcomplex, which binds to PS1 and Pen-2 sequentially. Alternatively, the Aph-1/nicastrin subcomplex may bind directly as a PS1-Pen-2 sub-complex to generate mature, active presenilin
[68].
The importance of PS1 to AD pathology is illustrated by over 160 mutations known to cause
familial early-onset AD. Although the effects of these mutations are not completely understood,
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it is generally accepted that many FAD PS1 mutations increase the relative levels of Aβ42 with
respect to Aβ40 [69]. Aβ42 is the primary constituent of amyloid plaques and is more likely to
aggregate in solution [20,21]. Aβ species range from 38-43 residues, and the wide variation is
due to the imprecise γ-cleavage of APP by γ-secretase. Cleavage of the APP-CTF begins with
cleavage at the ε site by γ-secretase, which is approximately 48-49 residues distal to the βcleavage site. After ε–cleavage, the carboxyl end of the remaining transmembrane stub is cleaved
3-4 peptides at a time to yield Aβ species of varying lengths [70]. The processivity of PS1
depends upon its intracellular milieu. Slight changes to the length and fatty acid chain isomer
have profound effects on the activity of γ-secretase and the Aβ42/40 ratio [39]. Furthermore,
studies from our lab have shown that γ-secretase has an optimal pH of ~4.5 [40]. In fact, PS1 and
nicastrin have been localized to lysosomes, suggesting they likely resident lysosomal membrane
proteins [40,41]. These results have been corroborated by Nixon and colleagues, which showed
γ-secretase activity in lysosomal and autophagic compartments [71]. Furthermore,
deacidification of lysosomes pharmacologically or genetically, severely hampers cleavage of
APP CTFs [72,73].
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Figure 1.1: Non-Amyloidogenic and Amyloidogenic Cleavage
Amyloid precursor protein (APP) can be cleaved via either an amyloidogenic or nonamyloidogenic manner. Non-amyloidogenic pathway precludes the formation of Aβ by cleavage
of APP by α-secretase. α-cleavage results in the release of the APPsα luminal domain and an 83
residue carboxyl-terminal fragment (CTF). The CTF is cleaved by γ –secretase to release p3 into
the lumen and an APP intracellular domain (AICD) to the lysosome. Conversely, cleavage of
APP by β-secretase removes the APPsβ luminal domain, but preserves the Aβ domain in the
membrane attached 99-residue CTF. Aβ is produced by γ-cleavage of CTF99.
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1.1.2

Amyloid Cascade Hypothesis

One of the hallmarks of AD is the accumulation of the 4kDa fragment known as Aβ. It was
identified as the dominant protein in neuritic plaques in AD and Down syndrome patients [19].
As first postulated by John Hardy, the amyloid cascade hypothesis states that Aβ accumulation is
central to AD pathology, and leads to neurofibrillary tangles, cell loss, vascular damage, and
dementia [35]. More recently, this hypothesis has been revised to include the latest discovery of
neurotoxic Aβ oligomers [36]. Despite its role in AD pathology, Aβ is normally, constitutively
produced in all cells, and tissues including human and rat cortical cultures [74-76], suggesting a
possible physiological role [77].
An important step in our understanding of amyloid plaques occurred when Aβ was identified as
the major constituent of plaques and its protein sequence from plaques in the brains of AD
patients and from Down’s syndrome (DS) patients [19,78]. Invariably, patients with DS have
amyloid plaques and the characteristic pathology of AD and most show clinical signs of AD
[79,80]. In DS, chromosome 21 fails to separate during meiosis, which results in trisomy 21.
Therefore, amyloid precursor protein (APP), which is encoded on chromosome 21, is over
expressed in these individuals [81]. While AD pathology may be caused by any number of genes
on chromosome 21, familial AD has been found in families with only the gene for APP
duplicated [82]. This suggests that there is a gene-dosage effect of APP. Transgenic mice overexpressing APP also show cognitive deficits and Aβ deposition [83].
In a small percentage of AD cases, there is early-onset of AD and are thus named early-onset
familial AD (FAD). Of these mutations, 10-15% are mapped to APP [84], which further
implicates APP in AD pathology. In agreement with the findings from DS patients, some of
these FAD mutations lead to a pathological increase in APP expression. FAD mutations have
been identified in the promoter for APP, which causes a two-fold increase in promoter activity
[82]. Other FAD mutations can cause duplication of the APP gene, which also leads to APP
overexpression [85,86]. Alternatively, other mutations have been identified on exon 16 and 17,
which encode the Aβ region in APP. These mutations affect the processivity of α-, β-, and γ-
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secretase. For example, the Swedish mutation (APPSwe), is located at the β-cleavage site and
promotes β-cleavage of APP by 10-fold [87]. Consequently, there is a dramatic increase in Aβ
production [88-90]. Recently, a mutation carboxyl to the β-cleavage site that reduced the
amyloidogenic cleavage of APP and protected against AD [57].
Mutations can also affect the γ-cleavage of APP and lead to AD. For example the London
mutation (APPLon), which causes a relative increase in Aβ42 production, by changing specificity
of the γ-cleavage site (residue 717 by APP 751 numbering) [91-93]. In addition, the French and
German FAD mutations were found two residues upstream at valine 715, which both caused a
relative increase in the amount of Aβ42 species produced as compared to Aβ40 [94,95]. A
similar increase in the Aβ42/ Aβ40 ratio is also seen in patients with the Florida FAD mutation
[95]. Interestingly, the French mutation decreases the total level of Aβ produced, but
preferentially decreases Aβ40 production. Furthermore, the French mutation also increases αcleavage of APP [95]. These findings suggest that while increasing the total Aβ produced is
important, the relative increase in Aβ42 may also be critical for AD pathology.
In addition to the secretase cleavage sites, FAD mutations have also been identified in the Aβ
region itself. The Dutch (E693Q), Flemish (A692G), Osaka (E693Δ), and Arctic (E693G)
mutations lead to presenile dementia, parenchymal amyloid deposition, and cerebral amyloid
angiopathy [96-101]. The Flemish, Dutch, Osaka, and Arctic mutations make Aβ resistant to
cleavage by neprilysin [102], which is one of the main proteases for Aβ [103]. Moreover, Aβ
bearing either the Dutch or the Arctic mutation have a higher propensity to form protofibrils and
fibrils, despite a lower Aβ 42/40 ratio, as compared to wild-type APP [100,104,105].
Interestingly, the Osaka mutation did not enhance fibrillization, but enhanced formation of
oligomeric species. These oligomeric species inhibited hippocampal long-term potentiation more
potently than the wild-type peptide (Aβ oligomers are discussed in further detail below)[106].
Furthermore, the Flemish mutation causes a conformational change in APP, which facilitates γsecretase cleavage of APP [107,108]. Therefore, FAD mutations in APP can cause AD pathology
by changing secretase cleavage and promoting fibrilization or oligomerization of Aβ.
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Early-onset FAD mutations were also mapped to chromosomes 14, which encodes presenilin 1
(PS1), and chromosome 1 which encodes it homologue presenilin 2 PS2 [109]. PS1 contains
catalytic component of the heterotetrameric γ-secretase complex, and contains an aspartic acid
residue at its active site that cleaves various membrane-bound carboxyl-terminal fragments.
Plasma and fibroblasts from patients with FAD mutations in PS1 and PS2 have increased Aβ42
levels relative to Aβ40 [110]. When PS1 and PS2 FAD mutations are over-expressed in cell
lines, a relative increase of Aβ42 was also observed [69,110,111]. Mutations in PS1 and PS2 are
not localized to a specific region of the protein, which suggests there are multiple mechanisms
for regulating Aβ production. It is unclear if these mutations result in a gain-of-function (increase
in Aβ42 production) or loss-of-function (decrease in Aβ40 production [69]. However, it is clear
that there is an increase in the Aβ42/40 ratio, which leads to the pathology seen in AD.
Despite the evidence implicating Aβ in FAD pathology, FAD only accounts for 1% of all AD
cases. The majority of AD cases are late-onset AD (LOAD), and the aetiology of these cases is
unclear. AD prevalence studies in twins show that 80% of the risk for developing AD is heritable
[112]. Through a number of genome wide association studies (GWAS), the locus for
apolipoprotein E has been repeatedly implicated in AD. There are three alleles for APOE (ε2, ε3,
and ε4). The ε3 allele is the most common followed by ε4 and finally ε2. The ε2 allele is known
to have a protective affect in AD, while the ε4 allele exacerbates AD [113]. Individuals
heterozygous for the ε4 allele have a 2-3 fold increased risk for AD, and homozygous individuals
have a 12-fold increased risk [114].
Homozygosity for the ε4 allele increases Aβ deposition in the middle frontal gyrus, superior
temporal gyrus, and inferior parietal lobule of human AD patients [115]. Concomitantly, patients
bearing the ε4 allele have lower levels of Aβ 42 in their CSF, which is indicative of Aβ
deposition in the brain [116]. However, the mechanism by which ApoE increases brain
deposition of Aβ is unclear. Some studies suggest that ApoE is critical for Aβ fibrillogenesis.
Transgenic AD mice with ApoE KOs have lower levels of Aβ deposition, which can be
increased by expression of human ApoE. If the ε4 variant is introduced into these mice, Aβ
deposition is even further increased [117]. During in vitro studies, the presence of ApoE
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accelerates Aβ fibrillization, and is further increased by the presence of the ε4 isoform [118,119].
ApoE may also be involved in clearance of Aβ from the brain parenchyma. In transgenic AD
mice expressing the different isoforms of ApoE, the ε4 allele decreases the clearance of Aβ from
the CSF [116]. ApoE also promotes the proteolytic clearance of Aβ by microglia, in a lysosomedependent manner [120]. The evidence from the ApoE studies demonstrates that Aβ is also an
important component of late-onset AD (LOAD) pathology.
The deposition of Aβ appears to be an age dependent process [121], in agreement with the agedependent increase in AD risk. Furthermore, DS patients also initially present with diffuse
plaques, which gradually aggregates into dense core plaques, like the ones seen in AD [122].
Initially, plaques are enriched in the Aβ42 species, and mature plaques incorporate Aβ 40
[123,124]. The presence of plaques in the brains of AD patients suggests that the aggregation of
Aβ is critical for its neurotoxicity. In agreement, early experiments showed that insoluble,
fibrillar aggregates of Aβ neurotoxic and were likely responsible for AD pathology [23,125]. The
toxicity and ability to aggregate is dependent on the hydrophobic C-terminal of the Aβ peptide.
The hydrophobic tail promotes Aβ aggregation and is crucial for Aβ toxicity [126]. Treatment of
hippocampal cultures with fibrillar aggregates, but not amorphous aggregates of Aβ 1-40,
decreased neuronal viability and synaptic density [127-129]. Inhibition of Aβ fibrillation was
capable of rescuing cell viability [25,26,127], and prevents Aβ accumulation in a transgenic
mouse model [130]. However, more recent work suggests that soluble Aβ oligomers may be the
pathologically relevant Aβ species (see below for discussion).

1.1.3

Aβ Oligomers

For the first 2 decades after the sequencing of Aβ, the field of AD was dominated by the idea that
insoluble fibrillar Aβ was the main neurotoxic species. However, the pattern of Aβ deposition
does not correlate with the appearance of clinical signs of AD [131-133]. Aβ deposition first
occurs in the prefrontal cortex before afflicting the memory centres in the medial temporal lobe
[14,134]. Recently, soluble oligomers of Aβ have come to the forefront as the toxic species in
AD [135]. When soluble forms of Aβ are measured, there is a 6-7 fold increase in the levels of
Aβ in the entorhinal cortex before increasing in the neocortex [29]. The pattern of increased Aβ
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matches the pattern of NFT pathology observed by Braak and Braak [14]. Furthermore soluble
Aβ species can be detected in the brains of AD and DS patients, but not in cognitively normal
controls [30,136,137]. The Aβ oligomers (AβOs) were neurotoxic to hippocampal slices and
cultured cells [30,31,138,139].
The identity of the AβO receptor still remains to be elucidated and may be important for the
development of the next generation of therapeutics. Laurén et al. [140] identified the AβO
receptor as the prion protein PrPc. Knockout of PrPc abrogated the long-term potentiation
impairment after treatment with AβOs [31,139-142]. PrPc was also shown to mediate cell death
after treatment with AβOs [139]. However, the role of the prion protein in AD pathology was
challenged when other investigators found that PrPc expressing and PrPc-null neurons were
equally vulnerable to treatment with AβOs [143]. Furthermore, removal of all PrPc from the cell
surface did not abolish AβOs binding to the cell surface. Synaptosomes treated with trypsin
could not bind AβOs, which suggests a membrane protein receptor [144]. Furthermore, AβOs
treatment appeared to directly increase the clustering of metabotropic glutamate receptor 5
(mGluR5); suggesting mGluR5 as the receptor for AβOs [145]. Supporting this idea, mGluR5
knockout animals crossed with mice expressing APP and PS1 with FAD mutations had lower
levels of plaque deposition and were protected from cognitive deficits [146].
A possible solution to this ambiguity is that there may be multiple proteins involved in AβO
signal transduction. As PrPc is a glycophosphatidylinositol (GPI) anchored protein, it necessitates
a transmembrane receptor to transduce the signal from the extracellular to the intracellular space.
PrPc is a promiscuous protein and can interact with various proteins to form cell-surface
signalling platforms [147]. PrPc was shown to co-immunoprecipitate with mGluR5 and knock
out of either protein was sufficient to abrogate the synaptic dysfunction in response to AβOs
[148]. Therefore, PrPc and mGluR5 may act as co-receptors to mediate cellular and synaptic
toxicity characteristic of AD.
AβOs also cause a pathological increase of intracellular calcium, because of an increase in
NMDA receptors (NMDAR) at the cell surface [145,148]. A pathological activation of
extrasynaptic NR2b can cause cell death [149,150]. Furthermore, kainite-induced excitotoxicity
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in the mouse hippocampus leads to the activation of compensatory mechanisms seen in AD, and
can be prevented by tau knockout [151]. Activation of the PrPc/mGluR5 co-receptor by AβOs
can activate the Src kinase, Fyn, which can phosphorylate the NR2b receptor at Y1472.
Phosphorylation of NR2b increases the level of NR2b containing NMDARs at the cell surface
[148,152]. The phosphorylation of NMDAR depends on Fyn translocation to the dendritic spine.
Fyn translocation to dendritic spines depends on its interaction with tau [153]. PHF associated
phosphorylation of tau can promote the delivery of tau to the dendritic spine [154]. Therefore,
the synaptic receptor scaffold, consisting of tau, Fyn, PrPc, and mGluR5, may be responsible for
the toxic effects of AβOs.

1.1.4

Structure of the Amyloid Precursor Protein Carboxyl-Terminal Tail

Aβ was identified as the major constituent of senile plaques and the amino acid composition and
N-terminal sequence was identified [19,78]. From the N-terminal sequence, a cDNA expressing
the amyloid precursor protein (APP), containing the Aβ sequence, was identified and mapped to
chromosomes 21 [155-157]. The APP gene spans over 170kbp and contains 19 exons [158].
There are 8 isoforms of APP, which are produced by alternatively splicing. The three main
isoforms of APP contain 695, 751, or 770 residues [159,160].
While the extracellular domain of APP has interesting biology, this thesis will focus on the Cterminal tail and the motifs found therein. Nuclear magnetic resonance (NMR) studies of the
APP cytoplasmic tail (last 49 residues) have revealed that this region does not adopt a stable
folded structure. Rather, it is a dynamic region, which is capable of adopting transient structural
features [161,162]. The N-terminal end of the APP C-terminal (residues 649-670) adopts a
predominately random-coil structure, while the carboxyl end (residues 670-695) adopts a
predominately α-helical structure [162].
Of note, there are two type 1 reverse turn conformations at 668TPEE671 and 684NPTY687
[161,162]. In relation to APP physiology, the TPEE and NPTY motifs are essential for the
interaction of APP and various adaptor proteins that modulate APP processing and signalling
[163-168]. The NPXY (where X is any amino acid) is an internalization motif found on the
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cytoplasmic domains of many putative cell-surface receptors [169-172]. In addition to serving as
an internalization motif (the role of NPXY motifs in internalization will be discussed more
thoroughly in another section), the NPXY motifs are bindings sites for phosphotyrosine-binding
(PTB) domains [173-176]. The β-sheet structure of the NPTY motif nestles in the pleckstrin
homology (PH)-fold formed by anti-parallel sheets in the PTB domains of adaptor proteins such
as Mint1 and Fe65 [177,178].
Apart from the NPTY motif, residues preceding and following the motif also play critical role in
APP binding to the PTB motifs of Mint and Fe65. Residues N680 to T686 participate in
hydrogen bonding with β-strands in the Mint1 PTB [178]. The hydrophobic region, C-terminal to
the NPTY motif, also participates in hydrophobic interactions with Mint1 and Fe65 PTB
domains [177,178]. Binding of APP is also influenced by the distant TPEE motif, which forms a
N-terminal helix cap. The N-terminal helix cap maintains a α-helix that is critical in the
interaction with Fe65 PTB2. Phosphorylation of Thr668 can disrupt the cap and reduce APP
interaction with Fe65 [177,179].
Thr668 is followed immediately by a proline, which can adopt either a cis or a trans isomer.
Phosphorylation of Thr668 promotes the adoption of the cis isomer, which disrupts interaction
with adaptors that can influence APP signalling, trafficking, and processing [177,180,181]. The
relative abundance of cis and trans isomers is under the control of Peptidyl-prolyl cis-trans
isomerase NIMA-interacting 1 (Pin1). Pin1 catalyzes the transition from cis to trans isomer
[181]. Pin1knockdown also increases the interaction of APP with Fe65, by promoting cis
conformation [180]. Pin1 knockout increases amyloidogenic processing of APP, by increasing
the levels of the cis isomer [181].

1.1.5

Amyloid Precursor Protein Phosphorylation by Protein Kinase C

The phosphorylation of APP on residue T668 appears to be involved in the control of the cell
cycle [182]. As such, residue T668 has been shown to be phosphorylated by cell cycle control
proteins, such as cyclin D kinase 5, GSK3β, and cell division cycle protein 2 [182-184]. In
addition to T668, there are eight possible phosphorylation sites [185]. Y653, S655, T668, S675,
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Y682, T686, and Y687 have been shown to be phosphorylated in the brains of AD patients
[185]. APP can be phosphorylated at these residues by a variety of kinases; including protein
kinase C (PKC), calmodulin-dependent protein kinase II (CaMKII), Abl kinase, and the cell
cycle kinases mentioned above [186-189].
Perhaps the most interesting candidate is the PKC family. Activation of PKC promotes the nonamyloidogenic cleavage of APP [190-194]. PKC can be activated by M1 and M3 muscarinic
acetylcholine receptors and up-regulates the non-amyloidogenic cleavage of APP [195,196]. The
activation of nicotinic receptors can also stimulate the activation of PKC [197]. The ability to
stimulate non-amyloidogenic cleavage of APP may lend itself to the effectiveness of cholinergic
treatments in AD. Our most effective pharmacological interventions in AD (such as Donepezil,
Rivastigmine, and Galantamine) are based on the finding that cholinergic neurons are
preferentially loss in AD {Kasa:1997ht}. Despite these AChE inhibitors, they are not capable of
stopping or reversing the disease, but only delay the progression of AD [198-200].
G protein-coupled receptors, such as M1 and M3 acetylcholine receptors (AChR) can activate
PKCs through activation of phospholipase C [201-203]. M1 and M3 AChR are Gq/G11 protein
coupled and ligand binding activates PLC [202-206]. PLC activation leads to the formation of
inositol trisphosphate (IP3) and diacylglycerol (DAG) [205]. IP3 binds to IP3 receptors to induce
the release of calcium from the ER. Calcium and DAG are potent signalling molecules, which
can lead to the activation of PKC. PKCs are sorted into three families in accordance with their
response to IP3 and DAG signals [207]. Conventional PKCs (cPKCs) comprise PKCα, PKCβ,
and PKCγ, and are activated by a combination of DAG (or lipid) and calcium binding.
Conversely, novel PKCs (nPKCs) (δ, ε, θ, and η) are activated in response to DAG or lipids.
Finally, atypical PKCs (aPKCs) (ι and ζ) are not responsive to either calcium or DAG [208].
Rather, aPKCs are activated via an interaction with the partitioning defective 6 (PAR6)- CDC42
complex [209].
Phosphorylation of the APP C-terminal tail by PKC may influence the intracellular trafficking of
APP and modulate its metabolism. Indeed, PKC activation appears to favour non-amyloidogenic
cleavage of APP at the expense of amyloidogenic cleavage [48]. Perhaps the most poignant
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example is the phosphorylation of S655 in the APP tail [186,210,211]. Phosphorylation of S655
diverts APP away from the cell surface and endosomes and increases APP localization to the
Golgi apparatus [210,211] (Figure 1.4, Step 4). In addition to influencing the trafficking of APP,
PKC activation also appears to up-regulate the function of α-secretases. PKC activation
increased the levels of mature, enzymatically active ADAM10 and ADAM17 (putative αsecretases) [212]. Furthermore, PKC activation also decreased the cellular levels of β-secretase,
which resulted in reduced Aβ production [212]. Therefore, PKC activation likely plays an
important role in controlling APP metabolism. The presence or absence of phosphorylation may
also influence the binding of APP adaptor proteins, which can influence APP metabolism and
cellular signaling.

1.1.6

Amyloid Precursor Protein Adaptors

Mint, Fe65 and other adaptor proteins that interact with the NPXY motif can modify APP
processing and intracellular trafficking. Furthermore, some of these adaptors can act as signalling
platforms and modulate cell activity. The Mint family of proteins appear to be involved in
regulating the trafficking of APP. Mint 2 and 3 (also known as X11 β and γ) are localized to the
Golgi apparatus [167,213,214]. Mint 3 has been shown to be recruited to Golgi vesicles in the
presence of APP and modulates the egress of APP from the Golgi apparatus to lysosomes
[167,214] (Figure 1.4, Step 1). Mint 1 and 2 have also been suggested to be important for APP
internalization [166,215]. Knock-out of all Mint proteins decreases APP internalization, but this
can be rescued by expression of phosphorylated Mint 2 [166]. Mint 1 expression appears to be
crucial for activity induced APP internalization and subsequent production of Aβ [42,43,215].
Mint 1 KO neurons produce lower levels of Aβ, which can be rescued by expression of Mint 1GFP [215]. However, precise role of Mint in regulating Aβ production is unclear. At least one set
of experiments demonstrate that over expression of Mint 1 can also decrease Aβ secretion [163].
More study into the role of Mint in APP trafficking and processing must be completed to fully
understand the role of the Mint proteins.
Fe65 can also regulate the production of Aβ [179,216,217]. Initial experiments with MarineDarby canine kidney cells demonstrated that Fe65 and APP co-localize in the perinuclear area,
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and over expression of Fe65 increased APP expression at the cell-surface. The increased cellsurface levels of APP is correlated with increased release of the soluble APP ectodomain (APPs)
and Aβ [216]. In agreement with these studies, primary cortical neurons from Fe65 knockout
animals have lowered production of Aβ [217]. The Fe65-regulated processing of APP may be a
cellular response to extracellular signals. N-methyl-D-aspartate (NMDA) treatment increases
intracellular levels of APP CTF and decreases Aβ production [217]. With NMDA receptor
activation, there is a phosphorylation of APP at Thr668, which, as described earlier, reduces APP
interaction with Fe65 [177,179,217]. Signalling through APP-mediated mechanisms may depend
upon the formation of a tripartite complex formed between APP, Fe65, and low-density
lipoprotein (LDL) receptor-related protein (LRP) [218,219]. LRP-deficient mouse fibroblasts
had increased cell-surface APP levels and reduced the production of Aβ, which is similar to the
phenotype in Fe65 knockout cells [219].
Fe65 may also link APP to proteins that regulate the actin cytoskeleton [220-222]. Fe65 forms a
tripartite complex with Fe65, APP, and Mena. Mena binds to the WW motif of Fe65 and can
organize the actin cytoskeleton [223]. In accordance with this role, APP, Fe65, and Mena are
localized to the leading edge of migrating cells and localized to focal adhesions [220]. Extending
these results into neurons, Fe65 and APP are both localized to the highly motile growth cone
[221].
The role of APP at growth cones at the leading edge can also be facilitated by interactions with
disabled 1 (Dab1). The disabled family of genes is evolutionarily conserved and regulates the
correct positioning of neurons in the brain [224-226]. Dab1 interacts with APP family members
through an interaction between the Dab1 PTB domain and the NPTY motif [227,228]. Dab1 and
APP colocalize in growth cones of cultured hippocampal neurons [227]. Dab1 and APP
knockdown neurons do not migrate successfully from the subventricular zone to the cortical
plate [229]. The abnormally placed neurons may relate to an extracellular matrix protein known
as reelin. Reelin is the defective protein in reeler mice that have malformations of the cerebral
cortex [230]. Mutations in reelin disrupt the positioning of neurons in the cerebral cortex, and
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this phenotype is also seen in mice with mutations in Dab1 [224-226]. In agreement, with these
findings, APP can bind to reelin, and this interaction promotes neurite outgrowth [231].
Therefore, the interaction between APP and Dab1 may serve as a signalling platform for reelin
and control growth cone motility. Reelin promotes the interaction between Dab1 and APP, which
increased APP ectodomain release and APP CTF production, and decreased Aβ production
[232]. Dab1 also recruits the Src family kinase, Fyn, to the APP/Dab1 complex [233]. This may
serve to modulate the strength of interaction between Dab1 and APP. Fyn recruitment results in
the phosphorylation of APP at Tyr682 and tyrosines on Dab1 [233]. APP and Dab1
phosphorylation have divergent effects. APP phosphorylation at Y682 increases the affinity of
APP for Dab1. While phosphorylation of Dab1, decreases the affinity of Dab1 for APP [233].
Tyrosine phosphorylated APP and Dab1 preferentially sort to signalling platforms known as lipid
rafts through an increased affinity of tyrosine phosphorylated APP for Dab1 [234-236]. APP
sequestered into lipid rafts by Dab1, also loses the ability to interact with other adaptors such as
Fe65 and Mint [232,234].
The Dab family of proteins may also direct the internalization of APP and other cargo. The
NPXY motifs of several transmembrane receptor proteins, including APP, LDLR and related
receptors, and others, interact with the PTB domain of Dab [175,227,237]. Dab2 has been
localized to clathrin coated pits (CCPs) [237]. At the CCPs, Dab regulates the formation of the
clathrin lattice [238]. Consistent with these findings, Dab2 has been shown to mediate the
loading of LRP6 into CCPs and away from the caveolin endocytosis pathway [239]. Dab2 can
also interact with another AP-2, a heterotetrameric adaptor protein involved in clathrin
endocytosis [237,240] (Figure 1.4, Step 2a). Therefore, Dab2 may aid in sorting cargo to CCPs
through its interaction with cellular machinery for clathrin-mediated endocytosis.
The NPTY motif in APP is also responsible for interactions with JNK-interacting proteins (JIPs)
[165,241]. The JIP family proteins serve as a scaffolding protein for the mitogen-activated
protein kinase (MAPK) and c-Jun NH2-terminal protein kinases (JNKs) [242,243]. JNKs have
important roles in regulating apoptosis, stress-response, neuronal migration, and microtubule
stability [244]. Co-expression of JIP, JNK, and APP increases phosphorylation of APP at Thr668
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[165,245-247]. Inhibition of JNK with an inhibitory peptide can shift APP processing towards
non-amyloidogenic processing [245]. In the TgCRND8 mouse model of AD, the same inhibitory
peptide lowered the levels of Aβ oligomers in the brain, reversed LTP deficits, lowered plaque
area, and improved performance on memory tasks [246]. In addition to its role in regulating APP
metabolism, JIPs also connect APP to kinesin light chain (KLC), thus APP serves as a vesicle
tether [165,248]. Neurons depend on anterograde transport (kinesin dependent) to move newly
synthesized components from the cell body to axon terminals. Retrograde transport (dynein
dependent) is equally important in transporting neurotrophic signals and endosomes from the
axon terminals to the cell body. Disruption of the JNK signalling pathway results in the aberrant
accumulation of synaptic proteins in the axon [249]. In agreement with these findings, APPeGFP vesicles undergo more retrograde excursions at the expense of anterograde trafficking in
JIP-1 deficient neurons [248].

1.2

Lysosomal Trafficking

Lysosomes are membrane bound organelles that are present in all nucleated eukaryotic cells.
Morphologically, lysosomes typically range from 0.1μm-2μm in diameter, and appear as electron
dense vesicles by electron microscopy. Lysosomes have an intraluminal pH of approximately
4.5, which is maintained by an ATP-dependent proton pump (vacuolar ATPases).
The acidity in lysosomes promotes the activity of the resident acidic hydrolases present within
the lysosomal lumen. The hydrolases perform the primary cellular function of the lysosomes,
which is to degrade and recycle macromolecules. Within lysosomes, there are approximately 50
different hydrolases [250]. The diversity of hydrolases allows lysosomes to digest a multitude of
macromolecules, including proteins, nucleic acids, carbohydrates, and lipids.
Lysosomes also have integral membrane proteins and membrane associated membrane proteins.
Proteomic studies have identified 215 integral membrane proteins and 55-membrane associated
proteins. These proteins perform numerous functions including vesicular trafficking, metabolism,
molecular transport, membrane structure, immunity, and other functions [251]. Two of the major
integral membrane proteins are LAMP1 and LAMP2. Due to the heavy glycosylation of LAMP1
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and LAMP2 they were originally thought to protect the lysosomal membrane from luminal
hydrolases and maintain membrane integrity [252-254]. More recent work has now revealed that
LAMP2 may have multiple roles, including autophagosome maturation and uptake of cytosolic
proteins for chaperone-mediated autophagy [254].

1.2.1

Adaptor Proteins in lysosomal protein trafficking

One of the major pathways to the lysosome is through internalization at the cell surface. The best
characterized mechanism is through clathrin coated vesicles [255]. Clathrin is recruited to cargo
destined for internalization and forms a polygonal lattice on the cytoplasmic side of the
membrane [256,257]. The membrane invaginates and detaches from the membrane before
delivery to intracellular targets [258]. The signals responsible for internalization typically lie
within 30Å from the membrane [259], but the clathrin lattice is 100Å from the membrane [260].
Therefore, endocytosis of cargo necessitates an adaptor to connect the cargo to the clathrin
lattice. Electron microscopy of coated vesicles reveal a ‘fuzzy’ coat between the cargo and
clathrin lattice [261]. These adaptor proteins were later identified as members of the
heterotetrameric complex, AP-2. AP-2 is localized to the cell surface and is important in
clathrin-mediated internalization. AP-2, and other members of this adaptor protein family, is
composed of two large (α and β2, ~100kDa), one medium (μ2, 50kDa), and one small subunit
(σ2, 17kDa). The large subunits are composed of three regions; a trunk domain, an ear domain,
and a hinge domain. The trunk domains of the large subunits, σ2, and μ2 form the core of the
AP-2 complex. The hinge domains connect the core to the ear domains [262]. The β2 subunit
hinge domain has a clathrin-binding sequence and interacts with the clathrin heavy chain and
promotes lattice formation [263,264]. AP-2 binding to clathrin can be abrogated by serine
phosphorylation within the hinge region [265]. The α subunit has also been suggested to interact
and promote the assembly of the clathrin lattice [266]. The μ2 subunit interacts with tyrosine
internalization motifs (discussed later) and with phosphatidylinositol 4,5-bisphosphate (PI4,5P)
[267]. PI4,5P is enriched at the plasma membrane, therefore the μ2 domain may help localize
AP-2 to the cell surface, where it is critical for clathrin mediated internalization of cell surface
proteins.

22

As in the AP-2 complex, the other members of this family are heterotetrameric complexes, which
are composed of two large subunits, one medium subunit, and one small subunit [268]. The two
large subunits of AP-1 are γ1 and β1. The medium and small subunit are μ1 and σ1, respectively
[269]. AP-1 is localized to endosomes and the trans-Golgi network (TGN), and has important
roles in TGN export to lysosomes and endosomes, recycling at the plasma membrane, and
retromer function [270-278]. As with the β2 subunit of AP-2, the β1 subunit interacts with
clathrin and can promote clathrin lattice formation [263]. This interaction is also negatively
regulated by serine phosphorylation within the hinge region [265]. There are two different
isoforms of AP-1 and are distinguished by their different μ1-adaptin, A and B. The μ1A and μ1B
adaptin are differentially localized in the cell, and associate with different cargo [274]. μ1A sorts
cargo from the TGN to endosome [279], and is preferentially localized to the TGN. μ1A
deficient mice have drastic misrouting of lysosomal hydrolases [280]. Conversely, the μ1B
adaptin preferentially colocalizes to sorting endosomes [273,274,276], and directs cargo to the
basolateral membrane at the sorting endosome [274,276,277,281]. In the absence of μ1B, μ1A
containing complexes can also sort cargo to the basolateral membrane, albeit less efficiently than
μ1B-containing complexes [276]. However, μ1B cannot adequately substitute for μ1A, as μ1AKD is embryonically lethal in mice [280]. μ1A deficient mice also have drastic misrouting of
lysosomal hydrolases [280].
The third member of the adaptor protein family is AP-3. AP-3 has two large >100kDa (β and δ)
subunits, one medium ~50kDa subunit (μ3), and small ~25kDa subunit (σ 3) [282-284]. The β3,
μ3, and σ3 subunits are represented in A and B isoforms. The A isoform of AP-3 is ubiquitously
expressed, but the B isoform is mainly expressed in neuronal tissue [282,283,285,286]. The role
of AP-3 was first elucidated in yeast, where deletions of any of the AP-3 subunits disrupted
delivery of alkaline phosphatase to the vacuole [287-289]. Disruption of the heterotetrameric
AP-3 complex led to the retention of alkaline phosphatase (ALP) within the yeast Golgi [287].
These results were echoed in drosophila bearing the garnet or ruby mutation, which present with
abnormal eye pigmentation due to mutations in the δ and β3A subunits, respectively [283,290].
Electron microscopy of retinal cells from drosophila revealed a dramatic decrease in the numbers
of pigment granules, suggesting a deficit in pigment granule biogenesis [291]. Mice with
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mutations in the β3A or δ subunit also had fewer pigment granules in the retinal epithelium and
fewer platelet dense granules [292-294]. In humans, a mutation in the β3A subunit was seen in a
subtype of patients with Hermansky-Pudlak syndrome. These patients presented with
oculocutaneous albinism, immunodeficiency and bleeding diathesis [295-297]. The
melanosomes, cytolytic granules and platelet dense granules, which mediate skin pigmentation,
immune function, and blood clotting, contain lysosomal proteins and are known as lysosomerelated organelles (LROs) [298,299]. Therefore, AP-3 may have a role in lysosome and LRO
biogenesis.
The AP-3 complex is localized to the tubulovesicular structures near the TGN and endosomes
[282,284,300]. AP-3 is proposed to select cargo at the TGN or endosomal membrane for delivery
to the lysosome. Human and mouse fibroblasts deficient in AP-3 misrouted LMPs (LAMP-1,
CD63) to the cell surface [301,302]. Furthermore, cytosol depleted of δ3 subunit was unable
facilitate formation of melanosome protein and LAMP1 positive vesicles from donor Golgi
membrane. Interestingly, loss of the δ3 subunit had no effect on mannose-6-phosphate receptor
(M6PR) vesicle formation [303]. Therefore, the function of AP-3 likely sequesters cargo into
vesicles at the TGN or endosome for delivery to lysosomes. However, it remains to be
determined if these vesicles are clathrin-coated. Initial studies could not identify AP-3 in
clathrin-coated vesicles (CCV) fractions or by electron microscopy [282,286]. However, a later
study identified a clathrin-binding motif on the trunk domain of β3 and localized AP-3 to clathrin
at the TGN and endosomes [304].
The most recently discovered AP complexes are AP-4 and AP-5 [305,306]. AP-4 was first
discovered by a BLAST sequence search for expressed sequences tags (EST) with similarity to
subunits in AP 1-3. The search revealed a heterotetrameric complex with two large subunits (β4
and ε), one medium (μ4), and one small (σ 4) subunits. Unlike AP-1 and AP-3, only one isoform
of AP-4 is known [305,306]. The new subunits localized strongly to the TGN and sequestered
cargo into non-clathrin coated vesicles [305-307]. Initial studies on its function revealed it was
responsible for sorting cargo to the basolateral membrane [307]. However, a more recent study
by Burgos and colleagues [308] revealed a role for TGN to endosome trafficking. μ4 KD
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increased retention of APP in the TGN and increased Aβ production [308]. Interestingly, AP-1
and AP-4 both sort cargo to the basolateral membrane from the TGN. With AP-1 being the more
abundant isoform, AP-4 may serve as a specialized cargo adaptor [309]. However, when the
cellular machinery for forming AP-1 clathrin coated vesicles was disrupted, there was a
significant increase in the formation of AP-4 coated vesicles [310,311]. While the current
evidence is unclear, it appears that AP-4 is responsible for sorting cargo to endosomes or the
basolateral membrane from the TGN.
The newest member of the AP family is AP-5. Like the other members of the family, it contains
two large subunits (β5 and ζ), one medium subunit (μ5), and one small subunit (σ5). AP-5
strongly colocalizes with LAMP1 positive vesicles. Although the AP-5 cargo and functions
remains to be fully revealed, early findings suggest a role for AP-5 in endosome and lysosome
trafficking [312].

1.2.2

GGA Adaptors

Another family of proteins was discovered based on their homology to γ-adaptin [313-315].
These monomeric proteins colocalized mainly to the TGN [313-317]. Localization to the TGN
was abrogated in the presence of the Arf-GEF inhibitor, Brefeldin A [313,318]. The protein
family was named γ-ear containing, Golgi-localized, Arf-binding protein (GGA).
The GGA family consists of three related proteins. Each protein contains a conserved VHS
(Vps27, Hrs, Stam) domain, GAT (GGA and Tom1) domain, and a γ-adaptin ear (GAE) domain.
The VHS domain is responsible for cargo interaction [319]. The GAT domain is sufficient for
TGN localization, and is recruited by GTP bound Arf proteins [314,320]. GGAs were found on
the TGN or in nearby tubulovesicular structures, and were frequently associated with clathrincoated buds [313,318]. Expression of a dominant negative mutant of GGA1 in HeLa cells
resulted in impaired TGN-endosome trafficking, and resulted in mannose-6-phosphate receptor
(M6PR) retention at the TGN [318].
GGA contains a clathrin-binding domain in the hinge region between the GAT and GAE domain
[318]. The GAE domain interacts with accessory proteins that may participate in membrane
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trafficking [321,322]. These findings suggest that GGA, like AP-1, may have a role in nucleating
CCV formation at the TGN. However, GGA could not be detected in the clathrin-coated vesicle
(CCV) fraction [313]. There are two possibilities that may resolve this paradox. GGA may
facilitate the formation of vesicles distinct from AP-1 vesicles or GGA and AP-1 may work
cooperatively to nucleate vesicle formation at the TGN. More recent studies are in support of the
latter theory. Doray and colleagues [323] found that the GGA hinge domain interacts directly
with the γ-ear of AP-1. Furthermore, casein kinase 2 (CK2) associates with AP-1 and can
phosphorylate GGA1 [279,323]. CK2 phosphorylates GGA1 and GGA3 at a serine preceding an
internal DXXLL (where X is any amino acid) motif. Serine phosphorylation increases the
affinity of this motif for the DXXLL binding site on the VHS domain of GGA [323]. The
phosphorylated internal motif outcompetes the DXXLL motif on the cargo for the binding site on
the VHS domain. The auto-inhibition, by the internal DXXLL motif, decreases GGA’s affinity
for cargo and could facilitate the transfer of cargo from GGA adaptors to AP-1 adaptors.
While the majority of GGA localization is with the TGN, there is also colocalization between
GGA and endosomes [313-317,320,324,325]. In live-cell imaging experiments, GGA1 is
visualized leaving an endosome for the TGN-area [324], which suggests a possible role for GGA
in retrograde trafficking.
GGA2 in yeast and GGA3 in mammalian cells can also interact with ubiquitin tagged cargo
through their GAT domains [325-327]. Yeast with a GGA2 knockdown failed to delivery
ubiquitinated cargo to the vacuole and misrouted ubiquitinated cargo to the cell surface [326].
Similarly, knockdown of GGA3 in mammalian cells leads to accumulation ubiquitinated EGF
receptor and ubiquitinated BACE (memapsin 2) in early endosomes, which leads to a failure of
BACE and EGFR degradation [325,327].

1.2.3

Trafficking of Lysosomal Hydrolases

The initial steps of lysosomal hydrolase synthesis are shared with other secretory proteins. The
proteins are inserted into the endoplasmic reticulum lumen, and subsequent cleavage of the
signal sequence. They are then glycosylated on selected asparagine residues by preformed
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oligosaccharides. Recognition and transport of lysosomal hydrolases depends on the M6P
marker. After glycosylation, the mannose residues are phosphorylated as the protein transits
through the ER and Golgi [328]. The importance of mannose-6 phosphorylation is evident in
patients with forms of mucolipidosis (I-Cell disease, Pseudo-Hurler polydystrophy). Cells from
patients with mucolipidosis fail to phosphorylate M6P, and acidic hydrolases are secreted instead
of properly sorted into lysosomes [329,330].
M6P is recognized by 2 distinct M6P receptors (M6PR). There is a cation-independent (CI)
M6PR with a molecular mass of 300kDa and a cation-dependent (CD) M6PR with a mass of
46kDa. The CI M6PR contains 15 contiguous repeats, with each repeat being approximately 147
residues [328]. Each CI M6PR is capable of binding one completely phosphorylated hydrolase
[331]. The CD M6PR is 159 residues and has 14-28% homology to each of the repeats in CI
M6PR [328]. It exists as a dimer, and each dimer binds one hydrolase [331-333].
At the TGN, the M6PR are sorted into CCVs at the TGN, which then fuse with endosomes [334336] (Figure 1.2, Step 1). Efficient sorting of M6PR to endosomes depends on dileucine motifs
(LLHV and HLLPM) within the carboxyl terminals of CI M6PR and CD M6PR [320,337,338].
Mutagenesis of both motifs results in CatD secretion to the extracellular space [338]. The
dileucine motifs found in the tail of M6PR, and other cytoplasmic tails, can interact VHS domain
of GGA [319,324,339-341].
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Figure 1.2: Trafficking of Lysosomal Hydrolases
Soluble lysosomal hydrolases are transported to the lysosome via the mannose-6-phosphate
receptor (M6PR). The M6PR recognizes M6P moieties on the lysosomal hydrolase. 1) It is
believed that GGA1 and AP-1 may work cooperatively recruit and transport M6PR to the
endosome. 2) A small proportion (3-10) of M6PR, both cation dependent (CD) and cation
independent (CI), can also be transported to the cell surface. 3) At the cell surface, CI M6PR can
internalize lysosomal hydrolases into endosomes. 4) At the late endosome, M6PRs are recycled
back to the Golgi, while the hydrolases continue on to the lysosome.
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In addition to interacting with GGA proteins, M6PRs can also interact with a hetero-tetrameric
adaptor protein (AP) family [342-345]. There are two binding sites for AP-1 within the CD
M6PR tail (amino acids 28-42 and 49-67) [342]. As discussed earlier, there is evidence
suggesting that GGAs and AP-1 work cooperatively to package M6PRs into CCVs at the TGN
[323]. Active GGAs are purported to retain M6PRs in non-clathrin coated regions of the TGN
[346]. The hinge region of GGA1 can interact with AP-1 and may be crucial in transferring
M6PR into AP-1 positive CCVs [323]. Deletion of the hinge region results in AP-1 binding
deficient GGA1 and traps M6PR in the TGN [320,323,347].
Beyond cargo sorting, GGAs and AP-1 also aid in CCV trafficking and fusion with early
endosomes. While clathrin is released from vesicles relatively quickly after vesicle formation
[348-352], AP-1 remains associated for an extended period. The β-subunit of AP-1 interacts with
kinesin 13A, which could transport the M6PR towards intracellular targets [353]. Furthermore,
the GAE domain of GGA and the γ subunit of AP-1 can interact with rabaptin5 [347]. Rabpatin5
interacts with Rab5 and likely aids in fusion of the vesicle with early endosomes [354-357].
Eventually, the lysosomal hydrolases are delivered into lysosomes through fusions between
endosomes and lysosomes. However, the M6PR that deliver the hydrolases are recycled and do
not appear in the lysosomes [358] (Figure 1.2, Step 4). On the C-terminal of M6PR there is a
phenylalanine-tryptophan (FW) endosome retention motif recognized by TIP47 [359]. TIP47
also interacts with GTP bound Rab9 and this complex recycles M6PR from late endosomes;
preventing M6PR from entering lysosomes [359-361]. Alternatively, M6PRs can be returned to
the TGN via the actions of the Phosphofurin acidic cluster sorting protein 1 (PACS-1). PACS-1
directly interacts with AP-1 and M6PR at early endosomal membrane and mediates recycling
from early endosomes [362,363] (Figure 1.2, Step 1).
While the majority of lysosomal hydrolases traffic directly to endosomes, a small proportion of
both M6PRs (3-10% of total cellular M6PR) are present at the cell surface (Figure 1.2, Step 3).
However, only CI-M6PR is responsible for endocytosis of M6P-containing ligands [336,364].
Rapid internalization of CI M6PR from the cell surface is dependent on the YSKV motif in the
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cytosolic tail [365-367]. AP-2 can bind tyrosine and dileucine motifs and are crucial in the
internalization of M6PR from the cell surface [368].

1.2.4

Sorting of Lysosomal Membrane proteins

While soluble lysosomal hydrolases are responsible for the digestive role of lysosomes,
membrane proteins (LMPs) are responsible for a number of important functions; including
maintaining the acidity of the lysosomal lumen, formation of a protective glycocalyx [369],
translocation of macronutrients to the cytosol from the lysosomal lumen, and lysosomal
homotypic and heterotypic fusion. Lysosomal biogenesis is dependent on cooperation between
the endocytic and biosynthetic systems of the cell. There are two pathways for LMPs to reach
lysosomes. The first is directly from the TGN to the endosomal system. Other LMPs are
delivered indirectly, by transiting through the cell surface before reaching the endosomal system
(Figure 1.3). Sorting of LMPs by these pathways is dependent upon sequences within the
cytosolic tail of LMPs. These motifs are degenerate sequences, of 4-7 residues and dependent on
critical residues for their function. The main motifs can be separated into two main classes,
named for their critical residuals; namely tyrosine- and dileucine-based motifs. These sorting
motifs are saturatable, which suggests a dependence upon adaptor proteins.
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Figure 1.3: Trafficking of Lysosomal Membrane Proteins
1) Membrane proteins destined for the lysosome can first be presented at the cell surface, and 2)
subsequently internalized by clathrin-mediated endocytosis. 3) The proteins are eventually
delivered to the lysosomal membrane. 4) Lysosomal membrane proteins can also traffic directly
to the late endosome and lysosomes via an intracellular pathway, which does not pass through
the cell surface.
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1.2.4.1

NPXY Motifs

The importance of tyrosine motifs was seen in patients with familial hypercholesterolemia.
Mutant alleles of the LDL receptor (LDLR) produced protein lacking the cytoplasmic domain
were internalization defective [169]. This suggested an important motif within the cytoplasmic
domain of LDLR. A mutation found in patient J.D. recapitulated the internalization defect, with a
tyrosine to cysteine mutation in the cytoplasmc domain [170]. The critical tyrosine was later
discovered to be within the NPVY motif of the LDLR. Mutation of any residues in the NPVY
motif to alanine also diminished internalization of the LDL [370]. A minimal consensus NPXY
motif was found in a subset of type 1 integral membrane proteins, and is responsible for rapid
internalization of these proteins (where X represents a non-conserved residue). These proteins
include family members of integrins, amyloid precursor protein, and LDL receptor. The μ2
(~50kDa) and δ2 (~17kDa) subunits form the core of AP-2 and recognize tyrosine-based motifs,
including NPXY motifs. AP-2 interacts with the FDNPVY motif of LDLR through the μ2 adaptin subunit [259].
While the NPXY portion is the minimal motif shared among these proteins, there are other
factors the influence the trafficking of these proteins. For example, mutation of a phenylalanine
two residues preceding the asparagine also disrupts LDLR internalization [170]. Furthermore,
replacing the transferrin receptor internalization motif with the minimal NPVY motif from
LDLR does not promote rapid internalization of the transferrin receptor. However,
transplantation of the entire motif, including the phenylalanine residue (FDNPVY), recapitulates
rapid endocytosis in the transferrin receptor [171]. In contrast, internalization of APP is
dependent on the longer GYENPTY motif [89,371]. The GYENPTY motif contains a tyrosine at
position occupied by phenylalanine in the LDL receptor.
In some cases, the NPXY motif may also tolerate a phenylalanine at the critical tyrosine [372].
β1 integrins contain two NPXY motifs in its cytoplasmic tail. However, tyrosine to
phenylalanine mutations to both motifs does not interfere with protein internalization. In fact,
mutated integrins are delivered more efficiently to lysosomes. However, β1-integrin dependent
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viral infection is hampered in Spinner-adapted murine L929 cells [172]. Tyrosine, but not
phenylalanine, can be phosphorylated, which suggests that phosphorylation of the NPXY motif
can regulate intracellular trafficking.

1.2.4.2

YXXØ Motifs

AP-2 also interacts with another tyrosine motif of the form YXXØ (where X is any amino acid
and Ø is any bulky amino acid) [259,373-376]. The μ2-adaptin domain of AP-2 recognizes the
YXXØ motif, albeit at different residues from the NPXY motifs. Unlike the NPXY motif, the
critical tyrosine residue cannot be substituted with phenylalanine. Recognition of the YXXØ
motif absolutely requires the presence of tyrosine and bulky amino acid [373,375,377]. The
crystal structure of μ2-adaptin bound to YXXØ peptides from EGFR and TGN38 has been
resolved and revealed hydrophobic pockets that facilitate the binding of tyrosine and the bulky
amino acid [378].
Deviations from the YXXØ motif can occur. The P2X4 receptor contains two YXXØ motifs
(canonical: YKVL and non-canonical: YEQGL). Mutation of the canonical, but not the noncanonical motif interferes with P2X4 internalization [379]. While the distance between the
critical tyrosine residue and the hydrophobic residue is highly conserved in the YXXØ motif, the
presence of the glycine in the non-canonical YEQGL motif does not interfere with AP-2
interaction. The tyrosine and leucine occupy the same hydrophobic pockets as the canonical
motif, as the glycine affords sufficient flexibility to the main chain [380].
In addition to the required tyrosine and hydrophobic amino acid, AP-2 also has a third
hydrophobic pocket. P-selectin has a leucine residue, 3 residues preceding (L-3) the critical
tyrosine that can interact with the third hydrophobic pocket. In P-selectin, mutagenesis the
YGVF motif to AGVF or YGVA, unexpectedly, had little effect on internalization [381], which
suggests the participation of other residues. Crystallography revealed the presence of binding
pocket for a L-3 [382]. The cytoplasmic tail of the GABAAR γ2 subunit also has a hydrophobic
residue upstream of the YXXØ motif that binds to the same hydrophobic pocket [383].
Therefore, some motifs may depend on a ‘third-prong’ to interact with the μ2 subunit of AP-2.
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As in NPXY motifs, there is evidence that tyrosines within the YXXØ motif can be
phosphorylated. Tyrosine residues in the YGYECL are phosphorylated with in the γ2 subunit of
the GABAAR. Phosphorylation of these residues abrogates μ2-adaptin interaction with
YGYECL motif in vivo [383]. Mice expressing the γ subunit with a phenylalanine mutation at
these tyrosines increases the post-synaptic level of GABAR and increases the frequency of
miniature inhibitory post-synaptic potentials [384]. These results are substantiated by the failure
of the phosphorylated TGN38 YXXØ motif to interact with μ2-adaptin [374,375].
In addition to phosphorylation of the tyrosine motif, the interaction between cargo and the AP-2
domain can also be regulated by phosphorylation of adaptin subunits in AP-2. The kinase
interacts with the α adaptin subunit and phosphorylates residue 156 of μ2 -adaptin. This
phosphorylation increases affinity of μ2-adaptin for YXXØ [385,386]. AP-2 can also be
phosphorylated within the hinge region of large α and β subunits and disrupts clathrin coatassembly. Therefore, there is exquisite balance of phosphorylation and dephosphoylation of the
AP-2 complex that regulates CCV formation.
While the tyrosine and hydrophobic residues in the YXXØ motif are critical, the internal X
residues also dictate binding specificity. The μ2 domain has the broadest binding specificity and
highest affinity for YXXØ motifs. The μ2 domain will tolerate a wide range of residues at the
Y+1 and Y+2 positions [374,375,387]. The μ2 domain prefers basic amino acids at Y+1 and
Y+2, with a particularly strong preference for arginine at Y+2 [375,387]. Interestingly,
internalization signals, but few lysosomal targeting signals have basic residues between the Y
and Ø residues [366,367]. This agrees with the findings that AP-2 is responsible for
internalization at the plasma membrane. Conversely, μ3a and μ3b, from AP-3, have a preference
for glutamic acid at Y+1, which is characteristic of many lysosomal targeting YXXØ motifs. In
addition μ3a is also the only domain that prefers glycine at position Y-1, which is a residue also
found in many lysosomal targeting signals [387]. This suggests a role for AP-3 in lysosomal
targeting. The μ1 domain has a preference for aspartic acid and leucine at Y-1, but the functional
consequences of μ1 amino acid preference remain unclear [387].
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1.2.4.3

Dileucine Motifs

Dileucine motifs, like tyrosine motifs, can signal protein internalization and delivery to
endosomes and lysosomes. Dileucine motifs are present on lysosomal proteins (LIMP-II, NPC1),
LRO proteins (TRP-1, Pmel17, and QNR-17). The dileucine motif was first discovered by
Letourneur and Klausner who studied the rapidly internalizing CD3-γ chain of the T-cell antigen
receptor [388]. Despite deletion of the YQPL motif in the CD3-γ chain tail, the protein was still
rapidly internalized into endosomes and degraded in lysosomes. However, the combination of
YQPL deletion and mutation of leucines, in the DKQTLL sequence, to alanine abrogated protein
internalization and degradation [388]. The role of dileucine motif in internalization and
lysosomal targeting was later confirmed in CD4 down-regulation by Nef, the HIV protein [389].
The motif was also found to be crucial for basolateral sorting in NPP1, CD44, FcRII β2 receptor
[390-392].
In addition to the critical leucines, an acidic cluster 3-4 residues preceding the initial leucine
were also important for protein internalization [393]. Mutation of the acidic cluster (typically
aspatric acid or glutamic acid) to the basic amino acid, arginine, results in misrouting of protein
to the cell surface [394]. The spacing of the acidic cluster from the initial leucine is also crucial.
Increasing the spacing of the acidic cluster from the leucines also disrupts protein trafficking
[394]. The entire dileucine motif takes the form of [DE]XXXL[LI] or DXXLL.
The adaptor protein family can interact with dileucine motifs. Despite sharing an adaptor with
the tyrosine motifs, there is no competition [395]. However, the nature of the dileucine binding
site has not been confirmed. The β adaptins and μ adaptins have been suggested as possible
binding sites for dileucine motifs [396,397]. More recent evidence has suggested that the
hemicomplexes formed by σ 1/γ1, σ 2/α2, or σ3a and b/δ3 can interact with dileucine motifs
[398-402]. The σ2 subunit provides a hydrophobic patch that facilitates the binding of the
dileucine residues. A basic patch on the σ subunit interacts with the acidic cluster preceding the
leucine residues [402]. These binding domains can also be found on hemicomplexes from AP-1
and AP-3 [400].
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The non-conserved residues in dileucine motifs may offer some specificity to adaptor protein
binding as well. A proline is preferred at one residue preceding the first leucine, because it
allows for a protein conformation that facilitates binding [401]. The proline is not absolutely
required by AP-2, which reflects the flexibility of AP-2 in substrate binding. However, the
absence of proline appears to negatively affect AP-1 binding, but has a milder effect on AP-3
interaction [401]. This suggests that slight modifications to the X residues in dileucine motifs
can influence adaptor binding [401]. A prime example is lysosome integral membrane protein II
(LIMPII), which can bind AP-3, but not AP-1 or AP-2 [403].
GGA proteins also interact with dileucine motifs via its VHS domain. Crystallography has
revealed that the VHS domain of GGA forms a super-helix of eight helixes. Helixes 6 and 8 form
a binding pocket that allows for hydrogen bonding between the helixes and the acidic residues on
the dileucine motifs (aspartic or glutamic acid). There is also a hydrophobic pocket that buries
the leucines within the VHS domain [319]. Mutation of the acidic residues or the leucines to
alanine disrupts internalization and lysosomal delivery of cargo.

1.3

Trafficking of the Amyloid Precursor Protein

In addition to serving as a binding site for PTB proteins, the NPTY motif is also involved in
internalization of APP [44,371]. As discussed earlier, the NPTY motif is part of a family of
NPXY internalization motifs [404]. In the cytoplasmic terminus of APP, the NPTY motif is part
of a larger motif (GYENPTY), which contain residues that contribute to APP internalization
[44,371]. AP-2 binds to NPXY motifs via its μ2 subunit, and facilitates internalization [259,370].
AP-2 serves as a connector between the cytoplasmic tail of cargo to clathrin and other protein
machinery involved in clathrin-mediated endocytosis (CME) [405]. AP-2 can
immunoprecipitated with APP, and AP-2 knockdown decreases the internalization of APP
[406,407]. After AP-2 recruitment, the membrane deforms and is coated with clathrin, and the
vesicle is released from the membrane by dynamin scission [405]. Knockdown of dynamin and
clathrin reduced APP internalization and reduced Aβ production [42,408,409] (Figure 1.4, Step
2a).
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Figure 1.4: The trafficking of Amyloid Precursor Protein
The known trafficking pathways for APP. After synthesis in the endoplasmic reticulum and
glycosylation in the Golgi, 1) it is generally accepted that APP is delivered in secretory vesicles
to the cell surface. 2a) Subsequently, APP is internalized by clathrin-mediated endocytosis
(clathrin depicted as gray shading) into early endosomes. 3) APP is eventually delivered to
lysosomes and processed to form Aβ. 2b) Alternatively, recent work from our lab has
demonstrated that APP can be internalized rapidly via macropinocytosis into lysosomes. 4) APP
can also be recycled to the Golgi from the endosome, by an interaction with the retromer.
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Lipoprotein receptor-related protein 1 (LRP1) can also interact with APP and regulate its
internalization [218,219,410]. The cytoplasmic tail of LRP contains two NPXY motifs, which
participate in AP-2 mediated internalization [170,259,370]. The α isoform of LRP1 promotes
internalization, and increases Aβ production, while the β isoform decreases internalization and
promotes non-amyloidogenic processing of APP [411].
APP also interacts with other members of the heterotetrameric adaptor protein family
(AP-1b and AP-4) [281,308]. AP-1b and AP-4 are involved in basolateral cargo sorting in
polarized epithelial cells [281,307,412]. Neurons are also polarized cells and are divided into an
axonal compartment and a somatodendritic compartment [413]. APP is delivered first to the
axonal compartment [414,415], before being endocytosed from the axonal plasma membrane and
delivered to dendrites [414]. The AP-1 complex in C. elegans is responsible for targeting of
multiple proteins to the dendritic compartment [416]. In a similar way, disruption of the AP-4
complex in mouse neurons results in the misrouting of AMPA receptors to axonal
autophagosomes [417,418]. Although the exact roles of AP-1 and AP-4 in neuronal cells remains
to be elucidated, they may serve to regulate the polarized sorting of APP, and thereby control the
amount of Aβ produced (Figure 1.4, Step 1).
Recent work from our lab suggests that APP may also be internalized rapidly (within 15 minutes
after appearance at the cell surface) into lysosomes [419]. This rapid internalization appears to be
Arf6-dependent [420] (Figure 1.4, Step 2b). Electron microscopy revealed that APP is
internalized into structures reminiscent of macropinosomes [421,422]. Furthermore, previous
work has demonstrated that macropinosomes are capable of rapidly internalizing cargo to
lysosomes within 15-minutes [422]. We have also demonstrated that rapid APP internalization
depends on antibody cross-linking [420], which suggests that this pathway is dependent on the
transduction of extracellular signals. Fe65, an APP interacting protein (described in detail
above), has been shown to interact with Arf6 [222]. Therefore, it is tempting to suggest a
signaling complex between APP, Fe65, and Arf6. The activation of Arf6 in this complex may
activate downstream effectors of Arf6 (Rac1, phospholipase D1, PIP5K) to regulate cell shape
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and APP macropinocytosis [423]. However, further evidence will be required to confirm the
presence of this proposed signaling pathway. Indeed, recent work from the Annaert lab [424]
suggests it is BACE1, and not APP that is internalized in an Arf6-dependent manner in nonneuronal cells. Therefore, further work will be required to elucidate the role of Arf6 in APP
trafficking.

1.4

Lysosomal Pathology in Alzheimer’s Disease

Lysosomes also appear to have a critical, yet not fully understood role, in AD pathology [425427]. Perhaps the first evidence of lysosomal involvement in AD aetiology was the presence of
active lysosomal enzymes (i.e. Cathepsin D, β-hexosaminidase) as a major constituent of senile
plaques [428-430]. The enzymes were associated with membrane-delimited lipofuscin granules,
which contain are the lipid and protein remains of failed lysosomal degradation [428]. Enlarged
early endosomes and lysosomes are among the earliest abnormalities observed in AD, and appear
before the appearance of neurofibrillary pathology or extracellular amyloid-plaques [431-434].
Strikingly, these enlarged endosomes are found in layers of the cortical mantle that are afflicted
in the early stages of AD suggesting that endosomal/lysosomal pathology may precede the more
traditional markers (neurofibrillary tangles and amyloid plaques) of AD [14,431,434].
Fibroblasts of Down syndrome patients, who invariably develop AD pathology by age 30, also
have enlarged early endosomes and abnormal endocytosis [435]. Furthermore, these fibroblasts
redistribute CatD from lysosomes to early endosomes. CD-MPR expression is increased in AD
and over expression of CatD in murine fibroblasts increases CatD localization to early
endosomes [434,436]. CD-MPR over expression in cultured cells can recapitulate the mislocalization of CatD and increase the secretion of Aβ40 and Aβ42 [436]. CatD expression is
abnormally increased in AD, and follows the laminar pattern seen with NFT and enlarged
endosomes [428,430,437-440].
The abnormal increase of CatD expression, and other lysosomal hydrolases, is recapitulated in
various mouse models of AD [441,442]. In TgCRND8, a mouse model of AD, there is an
increase in the number of enlarged CatD-positive lysosomes. These vesicles also stained for
ubiquitin and LC3, which suggests an accumulation of undigested proteins in autolysosomes
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[442]. Restoring CatD activity reduced the number of abnormal lysosomes and autophagosomes,
decreased amyloid plaque load, and improved cognition [442]. Up-regulation of lysosomal
activity can increase the clearance of intracellular Aβ [443]. In animals bearing FAD mutants of
PS1 and APP, there was a significant increase in autophagic bodies in the cell bodies and
neurites of neurons [444]. The increased number and size of autophagic vacuoles can also be
found in the brains of AD patients [444,445]. These autophagic vacuoles are enriched in
dystrophic neurites, which are found surrounding the core of the amyloid plaque [445,446]. Aβ
can be immunolocalized to autophagic vacuoles and lysosomes, and Aβ production can be
potentiated by activation of autophagy [444]. Treatment of neurons with fibrillar aggregates of
Aβ can increase neurite dystrophy [447]. There appears to be a deficiency in lysosomal
proteolysis in AD.
Lysosomes serve as an optimal intracellular milieu to nucleate Aβ. Indeed, Hu et al. [448]
demonstrated that Aβ accumulated in lysosomes can seed the formation of Aβ fibrils in vitro.
The lysosomes offer an acidic environment, which is optimal for Aβ aggregation [449]. The
acidic environment also promotes the insertion of Aβ into the lipid membranes, which protects
Aβ from degradation [450]. Interestingly, Aβ can interact with ganglioside clusters to form a
complex, which encourages Aβ fibrilization [451,452]. Transgenic AD mice treated with an
antibody against the ganglioside/Aβ complex reduced plaque deposition [453]. Therefore, the
acidic milieu and the lipid composition of the lysosomal membrane can promote lysosomal
aggregation of Aβ.
The deficiency of lysosomal enzyme activity can cause the accumulation of lipids and
gangliosides in the lumen. These enzyme deficiencies cause lysosomal storage diseases and
result in the accumulation of Aβ in the neurons of mouse models and human patients. For
example, in HEXB KO mice (Sandhoff disease mouse model), there was an accumulation of
ganglioside/Aβ complexes in endosomes and lysosomes [454]. Pharmacologically-induced
accumulation of GM1 recapitulates the endosomal fibrilization of Aβ on ganglioside clusters
[455]. The secondary accumulation of Aβ can also be seen in animal models of Niemann Picks
Disease (NPD), which accumulate cholesterol in the lysosomal lumen. In rabbits fed a high

43

cholesterol diet, there were perturbed lysosomal protease activity, enlarged endosomes and
lysosomes, and increased the intracellular accumulation of Aβ in the brain [432]. Furthermore,
addition of excess cholesterol in the cell culture media of cultured rat neurons also resulted in
lysosomal pathology and an increase in Aβ production [456]. The cholesterol-induced
enlargement of endosomes and lysosomes are also seen in NPD type C [457]. Therefore, the
accumulation of lipids, reminiscent of lysosomal storage diseases, can promote the secondary
accumulation of Aβ.
The aberrant accumulation of cholesterol may also affect the activity of secretases participating
in APP metabolism. The accumulation of cholesterol can influence the function of secretases
involved in the processing of APP. High concentrations of cholesterol can decrease the
membrane fluidity and decrease the interaction of α-secretase and APP [458]. The decreased αsecretase cleavage of APP can result in the increased amyloidogenic cleavage [48]. The
accumulation of cholesterol in NPD type C can also modulate the localization and activity of βsecretase [459]. CHO cells with a NPC knockout have an increased production of β–CTF, which
suggests increased β-secretease cleavage; despite no change in enzyme activity. [460]. It was
later revealed that in CHO NPC KO cells, β-secretease (BACE) is localized to early endosomes,
and the trafficking defect can be rescued by correcting cholesterol accumulation [461].
Furthermore, cerebrospinal fluid from NPD type C patients revealed a relative increase in the
amount of neurotoxic Aβ42, which suggests the modulation of γ-secretase cleavage [462].
Conversely, the accumulation of intracellular Aβ may inhibit the activity of lysosomal proteases.
While the most obvious aggregates of amyloid in AD are extracellular, there is accumulating
evidence of intracellular lysosomal amyloid aggregates; well before the appearance of
extracellular plaques [463]. Perhaps the first observation of intracellular amyloid was seen in
human foreskin fibroblasts, which accumulated exogenous Aβ intracellularly [464]. Shortly
after, there were observations of endogenous Aβ accumulating intracellularly in neuronal cell
lines and human primary neuronal cultures [52,141,465,466]. Interestingly, these intracellular
aggregates appear to be resistant to degradation [52,464], and accumulate in the
endosomal/lysosomal system [463,467,468] [432,439,456,469].
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In addition FAD mutations in PS1 may also play a role in regulating lysosomal enzyme activity
through maintaining lysosomal pH. PS1 is the catalytic component of the γ-secretase complex,
but may have other roles; including regulate lysosomal pH and ER-calcium storage [470,471].
Lysosomes in PS1-/- neurons have increased pH, which leads to the accumulation of autophagic
vacuoles [471,472]. However, it should be noted that these results are controversial, as these
findings were not replicated by other laboratories [473-475]. The effects of PS1-/- are
independent of PS’s catalytic activity, because inhibition of γ-secretease does not result in the
accumulation of autophagic bodies [472]. Introducing PS1 FAD mutants to PS1-/- fibroblasts
does not re-acidify lysosomes and cannot rescue lysosomal proteolysis [471]. However, the
effect of PS1 FAD mutants on lysosomal activity remains to be elucidated, as a conflicting study
found that reintroduction of PS1 FAD mutants can clear cells of autophagic bodies [472]. More
recently, fibroblasts from patients expressing the PS1 FAD mutation, A246E, also have a
decrease in lysosomal pH and decreased maturation of CatD [476]. This suggests that PS1 may
have an important role in maintaining lysosomal pH.
The intracellular accumulation may have several deleterious consequences to neurons. Luminal
aggregates of Aβ make the lysosomal membrane more labile, which leads to the leaking of
lysosomal proteases into the cytosol [450]. Indeed, the release of lysosomal hydrolases into the
cytosol can precede apoptotic cell death [477-479]. In some cases, the intracellular Aβ may lead
to cell rupture. The immunohistochemical examination of entorhinal and hippocampal cortex
from AD patients revealed the presence of ruptured cells, which more numerous surrounding
amyloid plaques [480]. Alternatively, it has also been suggested that the intracellular aggregates
of Aβ can be released into the extracellular space by exosomes and seed the fibrilization of Aβ
(intraluminal vesicles in endosomes and lysosomes) [481]. The trans-cellular spread of
intracellular aggregates is not restricted to amyloid, but can also be observed in Parkinson’s
disease in the exosomal release of α-synuclein [482,483].

1.5

Lysosomal Secretion

Lysosomes are commonly viewed as the disposal system of the cell, but are recognized to have a
secretory function in many cell types [484]. Lysosomes are secreted to the cell surface for
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membrane repair [485,486]. Furthermore, in neurons lysosomes potentially provide the
membrane required for neurite outgrowth [487]. They are involved in the secretion of thyroid
hormone, pulmonary surfactant, albumin, and cytotoxic molecules from cytotoxic T lymphocytes
(CTLs) [485,488,489]. Vesicles carrying these cargo belong to a family of lysosome-related
organelles (LROs) [490]. LROs share some hydrolases and membrane proteins with lysosomes,
but are unique in the cargo they carry to perform specialized roles.
The mechanism underlying LRO and conventional lysosome secretion is complex and requires
the cooperation of many proteins. Before successful degranulation, each secretory granule must
be delivered to the cell surface, tethered, docked, and stimulated to release by increased
intracellular calcium [491]. Genetic disruption of steps in LRO release can lead to familial
hemophagocytic lymphohistiocytosis (FHL) or Griscelli syndrome (GS).
Griscelli syndrome is a autosomal recessive disease that is characterized by partial albinism and
immunodeficiency [492]. There are three types of GS and they affect genes expressing a group
of three interacting proteins (myosin Va, Rab27a, and melanophilin). Type 2 GS is caused by a
mutation in Rab27a [493]. In GS, melanocytes accumulate pigment in melanosomes and natural
killer (NK) cells have decreased cytotoxic activity [494]. Expression of dominant negative
mutants of Rab27b (a brain expressed isoform) [495] in PC12 cells decreases ACTH secretion
from dense core granules [496]. These deficits are likely due to disrupted LRO trafficking and
plasma membrane docking. Rab27a deficient melanocytes missort melanosomes to the
perinuclear region [497]. Expression of dominant negative mutants of Rab27a in a melanocyte
cell line phenocopies the melanosome distribution [498]. In addition to vesicle delivery to the
subplasmalemmal region, Rab27 likely also participates in vesicle docking. Lytic granules in
CTLs from ashen mice (Rab27a KO mice) can polarize towards the target cell, but do not dock
at the plasma membrane [499]. Furthermore, knockdown of Rab27a or Rab27b leads to
increased mobility of lysosomes at the cell surface, which suggests that Rab27 may participate in
lysosomes and LRO docking [500]. Therefore, Rab27 has an important role governing the
transport and docking of LROs, and likely lysosomes.
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The function of Rab27 depends on the function of its many effectors. Rab27 effectors have an
amino terminal Rab interacting domain and, typically, two carboxyl terminal C2 domains. The
C2 domains are not present in all interacting proteins [501]. These effectors facilitate the docking
and transport functions of Rab27 by facilitating interaction with microtubules, actin filaments,
and SNARE complexes [501,502].
Melanophilin (Mlph) is a Rab27 interacting protein and mutations that impair its interaction with
Rab27 result in GS type 3 [503]. In addition to Rab27, Mlph also interacts with the actin motor,
Myosin Va (MyoVa), which results in a tripartite complex [504]. Mutation of any of these three
proteins results in GS [505]. Indeed, expression of the Rab27 binding domain of Mlph acts as a
dominant-negative, likely by sequestering active Rab27, causing melanosomes to accumulate in
the perinuclear area [504]. Interestingly, Mlph also tracks the plus end of microtubules, through
an interaction with the microtubule associated end binding protein 1 (EB1). This suggests that it
may participate in melanosome delivery to cell periphery [506]. MyoVa also tracks the
microtubule plus end in a Mlph dependent manner [506]. However, in the absence of MyoVa,
bidirectional microtubule transport of melanosomes is normal [507]. However, in the absence of
MyoVa, melanosomes are not captured in the actin-rich periphery and become concentrated in
the perinuclear region [508,509]. Therefore, the Rab27a, Mlph, and MyoVa complex is involved
in vesicle trafficking to the cell periphery and efficiently dock them at the cell membrane.
Another Rab27 effector, Exophilin 7 in neutrophils, is involved in the organization of actin
filaments. Exophilin 7 interacts with the RhoA-GTPase-activating protein (GAP), Geminteracting protein (GMIP), and participates in actin filament deploymerization [510]. Cortical
actin serves as a physical barrier between vesicles and the cell membrane [511,512]. At the cell
periphery, azurophilic granules, from human neutrophils, can traverse cortical actin barrier by
depolymerizing actin. However, preventing actin depolymerisation, by loss of GMIP-mediated
RhoA inactivation, decreases granule attachment to the membrane [510].
In addition to trafficking and docking to the cell periphery, there is also cellular machinery to
facilitate the fusion of lysosomes and LROs with the cell surface. The mechanism responsible is
the SNARE machinery, which was first identified in studies of synaptic vesicle exocytosis. In
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synaptic vesicle exocytosis, the formation of the SNARE complex is thought to provide the
energy needed for membrane fusion. Target SNARE (t-SNARE) proteins on the plasma
membrane (SNAP-23, synaptobrevin 2) interact with vesicular SNARE (v-SNARE) proteins to
form a four-helix bundle [513].
The exact SNARE machinery for LRO and lysosome exocytosis is likely dependent on the celltype in question. In cells of the hemopoietic lineage, syntaxin 11 is required for the formation of
the SNARE complex with vesicle associated membrane protein 8 (VAMP8) and SNAP-23 [514].
Mutations in syntaxin 11 leads to the development of familial hemophagocytic
lymphohistiocytosis (FHL) 4 [515]. Platelets and CTLs from FHL 4 patients have a deficit in
LRO degranulation [514,516].
FHL can also be caused by mutations in Munc13-4 and Munc 18, which cause FHL 3 and FHL
5, respectively [517]. Munc 13-4 complexes with Rab27 and is critical for docking secretory
lysosomes to the cell surface after stimulation. Mutation of critical residues that participate in
Rab27 binding abrogates vesicle tethering to the cell surface and decreases lysosome secretion
[517]. Munc 18-2 likely catalyzes membrane fusion between lysosomes and the cell surface. In
synaptic vesicles, Munc 18 proteins are absolutely required for the fusion of synaptic vesicles
with the presynaptic membrane [513]. In agreement, natural killer cells properly polarize
cytotoxic granules to the immunological synapse, but do not degranulate and result in decreased
cell killing [518,519].

1.6

Rationale and Hypothesis

According the amyloid cascade hypothesis, the pathological production and accumulation of Aβ
is thought to be the initiating factor in AD pathology [35]. Work from our lab and others have
implicated the endosomal/lysosomal system in Aβ production [40,42,44,419]. Recent work has
revealed that endosomes and lysosomes accumulate intraluminal Aβ [439,463,464,467]. These
intracellular Aβ aggregates are resistant to degeneration and can seed the formation of Aβ fibrils
in vitro [52,464].
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In AD, the production and accumulation of Aβ appears to be a critical part of the disease process.
Despite the importance of APP trafficking to lysosomes in production of Aβ, the process is not
fully understood. The intracellular trafficking of nascent APP to the endosomal/lysosomal
system is relatively understudied, due to the difficulty in tagging nascent proteins for
microscopy. APP also contains three tyrosine motifs, which have been shown to be involved in
endocytosis and basolateral sorting [44,281]. However, the role of these motifs, if any, in the
sorting of nascent APP from the Golgi apparatus is unknown. While it is thought that Aβ is
produced intracellularly in lysosomes, the mechanism, which allows these intracellular stores to
access the extracellular space has yet to be elucidated. It is hypothesized that APP can traffic
intracellularly to lysosomes to produce Aβ, which can be secreted via lysosome exocytosis.

1.7

Objectives

To test this hypothesis, the following objectives were studied. 1) Using a photoactivatable
version of GFP attached to the C-terminal end of APP, we will demonstrate the intracellular
trafficking of APP from the Golgi to lysosomes, without first transiting the cell surface. 2) We
will to modulate the intracellular trafficking of APP by genetically and pharmacologically
manipulating the C-terminal sorting signals of APP. 3) Finally, we will determine the eventual
fate of Aβ produced in the lysosome.
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Chapter 2

2

The Amyloid Precursor Protein is rapidly transported from
the Golgi apparatus to the lysosome and where it is
processed into beta-amyloid.

Alzheimer’s disease (AD) is characterized by cerebral deposition of β-amyloid peptide (Aβ). Aβ
is produced by sequential cleavage of the Amyloid Precursor Protein (APP) by β- and γsecretases. Many studies have demonstrated that the internalization of APP from the cell surface
can regulate Aβ production although the exact organelle in which Aβ is produced remains
contentious. A number of recent studies suggest that intracellular trafficking also plays a role in
regulating Aβ production, but these pathways are relatively under studied.
Using APP tagged with photoactivatable Green Fluorescent Protein (paGFP), we show that APP
is rapidly trafficked from the Golgi apparatus to the lysosome where it is rapidly cleared.
Chloroquine and the highly selective γ-secretase inhibitor L685, 458 cause the accumulation of
APP in lysosomes implying that APP is being cleaved by secretases in the lysosome. The
Swedish mutation dramatically increases the rate of lysosomal APP processing, which is also
inhibited by chloroquine and L685, 458. Lysosomal transport of APP is reduced by siRNA
knockdown of AP-3 and reduces secreted Aβ by more than a third.
These data suggests that AP-3 mediates rapid delivery of APP to lysosomes, and that the
lysosome is a likely site of Aβ production.

2.1 Introduction
Alzheimer’s disease is the leading cause of dementia in adults [1]. A neuropathological hallmark
of AD is the accumulation of β-amyloid (Aβ) in plaques in the brain [2]. Aβ is produced through
sequential cleavage of amyloid precursor protein (APP) by secretases. Cleavage by β-secretase
removes the N-terminal ectodomain, leaving a 99 residue C-terminal fragment (CTF) containing
Aβ [3-5]. The CTF is then processed by γ-secretase [6] to produce Aβ species ranging from 39 to
43 residues in length [7]. The 42-amino acid form of Aβ (Aβ42) has a higher propensity to
aggregate, is toxic to cells in culture, and is the dominant component of amyloid plaques [8-11].
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Many experiments suggest that the production of Aβ occurs in the endosomal/lysosomal system.
Work in our laboratory has demonstrated that lysosomes are highly enriched in APP and γsecretase proteins (composed of at least presenilin, APH1, PEN-2 and nicastrin) and γ-secretase
activity (the ability to cleave APP to produce Aβ) [12,13]. Others have also described APP and
γ-secretase activity in lysosome-related autophagosomes and phagosomes [14,15]. In agreement
with these findings, deacidification of the endosomal/lysosomal system decreases Aβ production
[16,17]. When proteolysis is blocked with protease inhibitors or by presenilin knock-out (which
abolishes γ-secretase activity), amyloidogenic fragments of APP accumulate in lysosomes [1820].
While many studies have shown that endocytosis of APP is crucial for Aβ production [21-23], a
number of studies have suggested that the intracellular trafficking of APP might also play an
important role in Aβ generation. For example, Aβ production is decreased in MDCK cells when
APP is sorted to the basolateral membrane [24]. More recent studies demonstrate that Aβ
production is decreased by retrograde sorting of APP from endosomes to the trans-Golgi network
(TGN) [25-27]. Because the TGN serves as sorting station for nascent cargo from the ER and
protein recycled from endosomes [28], an understanding the trafficking of APP into and out of
the Golgi will increase our understanding of Aβ production.
While cell-surface proteins are amendable to many labeling techniques, intracellular proteins are
more difficult to track. Photoactivatable-Green Fluorescent Protein (paGFP) has provided a new
tool to examine intracellular trafficking. paGFP is a form of GFP that has low basal fluorescence,
but develops strong, stable green fluorescence after being activated by 413 nm laser light
[29,30]. Constructs using paGFP [30,31] have been used to examine the turnover of peroxisomes
[32] and autophagosomes [33] and to examine actin dynamics in neuronal dendritic spines[34].

Fluorescent protein tags have previously been used to examine movement of APP containing
vesicles [35,36], including tubular-vesicular structures emanating from the Golgi apparatus [37].
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APP-paGFP constructs have been used to visualize APP undergoing fast axonal transport [38]
and to image the trafficking of APP out of the perinuclear region, although these authors did not
identify the compartments involved [39,40].
Our aim was to examine the trafficking of APP from the Golgi apparatus and to identify
downstream compartments and identify sites of cleavage. We used targeted activation of APPpaGFP in the Golgi apparatus (identified using Galactosyltransferase fused to Cyan Fluorescent
Protein (GalT-CFP) [41], and followed activated APP-paGFP using confocal microscopy
fluorescence imaging to intracellular compartments labeled with compartment marker proteins
fused to red fluorescent proteins including Rab5 (early endosomes) [42-44], Rab9 (late
endosomes) [45,46]and LAMP1 (lysosomes) [47,48]. Tracking the disappearance of green
fluorescent APP-paGFP from these downstream compartments allows us to examine the
intracellular site of cleavage and degradation; essentially performing pulse chase experiments in
single cells. Surprisingly, we show that a large fraction of APP traffics rapidly to LAMP1labeled lysosomes within seconds after photoactivation in the Golgi, and is subsequently cleaved
by a γ-secretase-like activity. This pathway is mediated by an interaction between APP and
Adaptor Protein 3 (AP-3). Knocking down AP-3 blocks lysosomal transport and reduces Aβ
secretion into the media by about 33%. This suggests that direct lysosomal transport of APP is an
important source of Aβ.

101

2.2
2.2.1

Materials and Methods
Antibodies

The antibodies used were: Rabbit anti-APP C-terminal (1:1000, Cat. No. A8717; Sigma), mouse
anti-HA (1:1000, Cat. No. 12CA5; Roche); mouse anti-γ-adaptin (Cat No. 610386; BD
Bioscience). The AP-3 δ3 subunit- mouse- SA4 (1:1000), developed by Peden et al. [117] was
obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH
and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.
Secondary antibodies used were donkey anti-mouse HRP (1: 10 000, Cat No. 711-0350150,
Jackson Immunoresearch) and goat-anti rabbit HRP (1: 10 000; Biorad). α-tubulin was stained
using a mouse monoclonal antibody (Cat No. T5168, Sigma). For immunostaining, donkey antirabbit Alexa Fluor 488 (A-11034; Invitrogen) and goat anti-mouse Alex Fluor 546 (A-11003;
Invitrogen).

2.2.2

Cell Culture and Transfection

SN56 cells (a gift from Dr. Jane Rylett) were cultured in Dulbecco's Modified Eagle medium
(DMEM) (Gibco) supplemented with 10%v/v of fetal bovine serum (FBS; Gibco) and 50 μg/ml
of penicillin/streptomycin (P/S), in 5% CO2 at 37°C. Cells were subcultured every 3 days. For
confocal studies, 5 × 105 cells were seeded on to glass-bottomed culture dishes (MatTek) the day
before transfection in DMEM supplemented with 10% FBS. Cells were transiently transfected
using Lipofectamine (Invitrogen) according to manufacturer’s instructions. To differentiate the
cells, the media was replaced 24 hours after transfection with DMEM supplemented with
50 μg/ml P/S and 1 mM dibutyryl cyclic AMP (dbcAMP; Sigma). Cells were differentiated for
24 hours and imaged or harvested. Primary cortical neurons were prepared from embryonic day
15 CD1 mouse embryos as described previously [118].
For silencing RNA (siRNA) mediated knockdown of the δ subunit of AP-3, the Stealth Select 3
RNAi™ set (Invitrogen) was used. Sequence 3 of this set was found to knockdown the δ3
subunit (5’GAGAAGCUGCCUGUCCAGAAACAUA3’). The ubiquituously expressed γ1
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subunit of AP-1 was knocked down using 5’UAAUAUAUCAUUCAUAGCU3’ with a 3’ TT
overhang. Stealth RNAi™ siRNA Negative Control Med GC (12935-300; Invitrogen) was used
as a control. The control RNAi was tagged on the 5’ end with Alexa 647 to determine which
cells were transfected with siRNA. For each 35 mm dish, 200nM of siRNA was transfected
using Lipofectamine 2000 according to manufacturer’s instructions. During the knockdown
experiments, 1nM of negative control siRNA was co transfected with the siRNA against δ3 or γ1
to confirm the transfection of siRNA into the cell.

2.2.3

DNA Constructs

A cDNA encoding APP 750 fused to yellow fluorescent protein (YFP) was a kind gift from Dr.
Bradley Hyman (Massachusetts General Hospital). Constructs expressing full length or
shortened (last 112 amino acids) APP (βAPP) with an amino terminal hemagglutinin (HA) tag
and enhanced cyan FP (eCFP) on the carboxy terminus were generated as previously described
[50]. The plasmids encoding photoactivatable GFP (paGFP) was a kind gift of Dr. Jennifer
Lippincott-Schwartz [30]. βAPP was recloned such that paGFP is placed on the C-terminal
cytoplasmic tail of the protein. The Swedish mutation (KM670/671NL) was introduced into the
βAPP-ECFP construct using PCR [50], and was recloned into the paGFP vector.
Rab5-mRFP, Rab9-mCherry, and LAMP1-mRFP were generated as previously described [50].
The VSVG-paGFP construct was purchased from Addgene (http://www.addgene.org).

2.2.4

Confocal Microscopy

A Zeiss LSM-510 META laser- scanning microscope using a Zeiss 63× 1.4 numerical aperture
oil immersion lens was used to obtain images (Carl Zeiss, Oberkochen, Germany). The optical
section thickness was typically 1 μm. To visualize Alexa Fluor 488 and paGFP fluorescence, the
samples were excited with a 488 nm laser and filtered using a band pass (BP) 500-530-nm
emission filter set. For Alexa Fluor 546, mCherry and mRFP fluorescence, a 543 nm excitation
laser and BP 560-615 filter set were used. To collect ECFP fluorescence, a BP 475-525 emission
filter set was used after excitation with a 458 nm lasers. Alexa Fluor 647 fluorescence was
imaged using 633 nm excitation lasers, and a LP 650 filter.
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2.2.5

Live Cell Imaging

For live cell imaging, the cells were washed twice with PBS, and the culture media was replaced
with 37°C Hank’s Balanced Salt Solution (HBSS; Cat. No. 14025-092, Invitrogen). To maintain
a constant temperature of 37°C, the 35 mm plate was placed on a heated stage (heated insert P;
PeCon GmbH) connected to a Tempcontrol 37-2 digital 2-channel (PeCon GmbH).
Using the Ziess Physiology package, regions of interest (ROI) were selected in the Golgi
apparatus, which was demarcated by GalT-CFP fluorescence and these were carefully monitored
during the experiment to ensure that they remained over the Golgi apparatus if the cell or the
Golgi apparatus apparatus moved. In a typical experiment, cells were imaged approximately
every 30 seconds. For the first 15 minutes, ROIs in the Golgi apparatus were irradiated with
405 nm laser light to photoactivate APP-paGFP before imaging. After the initial 15-minute pulse
period, images were taken without irradiation and the movement/degradation of paGFP
fluorescence was followed for approximately 45 minutes.
To inhibit APP-paGFP cleavage, cells were treated with chloroquine (Cat. No. C6628, Sigma) or
L685, 458 (Cat. No. 565771, EMD Millipore). Cells were treated with 100 μM choloroquine
30 minutes before imaging to deacidify lysosomes. Deacidification of lysosomes was confirmed
using 75nM Lysosensor™ Green (Cat. No. L-7534, Invitrogen). To inhibit cleavage using a
specific γ-secretase inhibitor, SN56 cells were treated with 0.5 μM L685, 458 for 24 h before
imaging.

2.2.6

Colocalization Analysis

Colocalization analysis was performed on using Imaris 7.0 Imaris Colocalization module
(Biplane). Imaris software was used to create IsoSurfaces corresponding to the paGFP and RFP
fluorescence channels following the manufacturer’s directions (www.bitplane.com webcite)
[119]. This is a computer assisted method to set fluorescence intensity thresholds to detect
fluorescence in an organellar distribution that can then be used to automatically follow
fluorescence intensity and colocalization over time. The co-localization of APP and LAMP1
over time was plotted using Prism 5.0 software (Graphpad, La Jolla CA) and curves were fit
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using the nonlinear regression by least squares to fit a one phase exponential decay.
To colocalize AP-3δ and APP we adopted a strategy we have previously employed [50] and
described by Hutcheon et al. [120] (also discussed in [121,122]), which sets thresholds based on
a fixed percentage of the brightest pixels in an image. This allows for the identification of
positive pixels that is unbiased (it does not require the judgment of the observer on an image to
image basis) and is relatively unaffected by parameters of image acquisition or the level of
protein expression. To colocalize AP-3δ and APP, the brightest 2% of pixels was selected, and
the percentage of pixels colocalized was recorded [50]. Prism Graphpad 5.0b was used for all
graphing and statistical analysis. A One-way ANOVA was performed with a Dunn’s post-hoc
test, and P values under 0.05 were considered significant.

2.2.7

Immunostaining

SN56 cells or mouse cortical neurons were fixed for 15 minutes with 4% paraformaldehyde
(Alfa Aesar; Cat No. 43368). Cells were permeabilized for 5 minutes with 0.1% TritonX-100 in
PBS and blocked with 2% BSA for 1 h. Cells were incubated with primary antibodies overnight
at 4°C, washed twice with PBS, and stained with secondary antibody for 1 h. After staining,
confocal plates were store at 4°C in PBS, and coverslips were mounted on glass slides with
ImmunoMount (Fisher) and stored at 4°C.

2.2.8

Proximity Ligation Assay (PLA)

SN56 cells were transiently transfected with βAPP-eCFP, and fixed for 15 minutes with 4%
paraformaldehyde at room temperature. Cells were permeabilized and blocked in the same
manner as immunostaining. PLA was performed using a commercially available kit (Duolink;
Olink Bioscience) according to manufacturer’s instructions. Briefly, primary antibodies were
washed off cells with PBS, and species specific PLA secondary probes were applied to cells. If
secondary PLA probes are within 40 nm of each other, their complementary DNA strands are
ligated and are amplified. Complementary fluorescent oligonucleotides bind to the amplified
sequence, which results in a fluorescent dot where there are two interacting proteins.
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2.2.9

Cell Lysis and Western Blots

SN56 cells (1.5×106 cells) were seeded on 60 mm tissue culture dishes (Becton Dickinson) and
transfected with plasmids or siRNA using Lipofectamine 2000 according to manufacturer’s
instructions. Cells were harvested in lysis buffer (1% Nonidet P-40, 150 mm NaCl, 50 mM TrisCl) supplemented with pepstatin and complete protease inhibitor cocktail (Roche). Lysates were
clarified by centrifugation at 13,000 g for 20 min. To facilitate equal loading, the amount of total
protein was determined by bicinchoninic acid (BCA; Thermo Fisher Scientific). Samples were
electrophoresed on SDS-PAGE and transferred to PVDF membranes (Cat No. 162-01777;
Biorad). Densitometry was performed in ImageJ (NIH), and was normalized to α-tubulin band
density. Graphs were plotted in Prism 5.0b (Graphpad, La Jolla, CA), a one-way ANOVA was
performed with a Tukey’s post-hoc test. Results were significant if p<0.05.
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2.3
2.3.1

Results
APP-paGFP can be followed as it traffics from the Golgi apparatus
to LAMP1-labeled compartments

In order to study the intracellular trafficking of APP from the Golgi apparatus in live cells, we
generated expression constructs (Figure 2.1) containing full length APP (FL-APP) fused to an Nterminal HA epitope tag and photoactivatable Green Fluorescent Protein (paGFP) at its Cterminal cytoplasmic tail. To avoid any confounding effects of uncharacterized N-terminal APP
cleavage and sorting signals [49], we also examined a shortened construct (referred to as βAPP)
fused to the C-terminal 112 amino acids of APP containing both the β- and γ-cleavage sites. This
construct also contains an N-terminal HA- epitope tag. βAPP-CFP colocalizes with full length
FL-APP-GFP and has the same subcellular distribution as endogenous APP in primary neurons
[50]. These constructs are cleaved by secretases (Figure 2.2) and produce Aβ (ELISA data
below). In fixed cells, the N-terminal HA-tag of these constructs are well colocalized with the Cterminal Fluorescent protein tag, implying that much of the intracellular APP is trafficked before
cleavage (Figure 2.3). We have previously demonstrated that βAPP-CFP and FL-APP-GFP are
also trafficked to the cell surface and internalized to endosomes and lysosomes [50]. After
photoactivation of βAPP-paGFP and FL-APP-paGFP constructs, regions or compartments
exhibiting APP accumulation of Golgi-derived APP are predicted to appear as regions of
increased green fluorescence. At sites where γ-cleavage occurs, cleavage is expected to release
the APP C-terminal and its paGFP tag into the cytoplasm, decreasing the fluorescent signal over
time.
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Figure 2.1: Schematic of constructs.
APP constructs were generated including the full length APP 751 fused to paGFP on its Cterminus. A shorter construct consisting of the C-terminal 112 amino acids of APP fused to
paGFP. Both constructs include a linker with includes an N-terminal HA epitope tag, and both
constructs contain α-, β- and γ- cleavage sites. Cleavage at the γ-site will release the C-terminal
tail of APP along with the paGFP tag into the cytoplasm.
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Figure 2.1
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Figure 2.2: Cleavage of βAPP-paGFP
βAPP-paGFP and full-length APP are cleaved by that γ-secretase in a similar manner. SN56 cells
were transiently transfected with plasmids expressing GFP, full-length APP-paGFP (FL-APPpaGFP), or βAPP-paGFP. Twenty-four hours before harvesting protein for western blotting, cells
were treated with DMSO or with L685, 458. Cell lysate was run on a 12% SDS polyacrylamide
gel, and transferred onto nitrocelluose membrane. Membrane was probed for APP using APP Cterminal antibody (Sigma). Membranes were reprobed for α-tubulin, as a loading control. Full
length APP-paGFP is cleaved to produce fragments of the predicted size, with a β-cleaved
fragment at ~37 kDA (which is GFP (27kDa) the 10 kDa β-cleaved APP). The addition of the γsecretase inhibitor L685, 458 causes the accumulation of the 37 kDa band. This pattern is
repeated for the shorter βAPP-paGFP construct.
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Figure 2.3: Colocalization of HA-tag and βAPP-CFP
Most of the trafficked APP in the cell is uncleaved. SN56 cells were transiently transfected with
plasmids expressing βAPP-CFP, and immunostained with an anti-HA antibody, which binds to
the HA-epitope on the N-terminus of the construct. In the merged image, it is possible to see that
there is extensive colocalizaition of the N-terminal HA and the C-terminal CFP tag, implying
that much of the intracellular APP is being trafficked uncleaved.
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These studies were performed in the SN56 cell line, which is a hybrid cell created by fusing
dissociated embryonic mouse septal neurons with N18TG2 neuroblastoma cells. SN56 cells were
chosen because they are easily transfectable, have a neuronal morphology, and have a
cholinergic phenotype when differentiated [51,52]. For each experiment, SN56 cells were cotransfected with an APP-paGFP construct along with a marker of the Golgi apparatus (GalTCFP) [41] and subcellular compartment marker fused to a modified red fluorescent protein
(mRFP or mCherry). Compartment markers were LAMP1 (lysosomes), Rab5 (early endosomes)
and Rab9 (late endosomes). LAMP1 is a 120kDa protein that is localized to the limiting
membrane of lysosomes [47,48]. Rab5 localizes to the early endosomal membrane and is
involved in homoegenous or heterogenous vesicle fusion [42-44]. Rab9 localizes to late
endosomal membrane and evidence suggests that Rab9 is involved in returning cargo from the
late endosome to the Golgi [45,53]. Although many authors use Rab7 as a late endosomal
marker, Rab7 also labels lysosomes extensively [54]. Before imaging, SN56 cells were
differentiated for 24 hours in serum free DMEM supplemented with dbcAMP. Cells with normal
morphology, no inclusions, and normal compartment marker distribution were imaged live on a
Zeiss LSM510 laser scanning confocal microscope. Regions of interests (ROIs; the irradiation
targets, typically 0.1-0.2 μm2) were drawn on the Golgi apparatus using the Zeiss Physiology
package. During a 15-minute photoactivation period, cells were alternately imaged and then
briefly irradiated with 405 nm laser light (25 mW) for 20 iterations (typically 2 seconds) within
each of the ROI’s to photoactivate APP-paGFP to produce a video time course. The irradiation
targets were carefully monitored throughout the experiments to ensure that they did not drift
outside the Golgi apparatus. Because of the very small irradiation targets, and APP’s rapid
movement through the Golgi apparatus, multiple rounds of photoactivation were required to
create a strong green fluorescent signal. Images were acquired after each photoactivation cycle,
approximately every 30 seconds, and colocalization analysis was performed using Imaris
software (Bitplane). After the initial photoactivation period, cells were imaged for up to an hour
to follow the movement of APP out of the Golgi and its clearance.
When we started these experiments, we expected APP to move primarily to the cell surface and
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then to be internalized into lysosomes after 30 minutes to 1 hour. Instead, within seconds of
photoactivation, activated bright green fluorescent APP-paGFP colocalized with LAMP1-mRFP,
implying rapid transport to lysosomes. A typical experiment is shown in Video 2.1, where βAPPpaGFP from the Golgi apparatus (blue) and can be seen moving within seconds to lysosomes
(red). After 15 minutes of alternately photoactivating and imaging, cells were imaged (chased)
for a further hour. During the chase period most of the green fluorescent APP disappeared,
suggesting that it was being cleared.
In these experiments, both photoactivated FL-APP-paGFP and βAPP-paGFP appear to be
rapidly colocalized with the LAMP-1 compartment (Figure 2.4a; top and middle panels). To
confirm that this trafficking occurs in neurons, we then transfected GalT-CFP, βAPP-paGFP and
LAMP1-mRFP into primary mouse cortical neurons. After photoactivating βAPP-paGFP in the
Golgi, green fluorescence appears within 30 seconds to a minute in LAMP1-mRFP labeled
compartments. (Figure 2.4a; bottom panel). To further demonstrate that the LAMP1
compartment rapidly received photoactivated APP-paGFP, we performed imaging at high
magnification in closely cropped cells with βAPP-paGFP. In the earliest time points, it was
possible to observe green fluorescent APP-paGFP arriving rapidly within LAMP1 compartments
(Figure 2.4b). We quantitated the fraction of fluorescent activated paGFP colocalized with
LAMP-mRFP after 15 minutes of photoactivation, we found that 34±5 % (Mean±SEM) of FLAPP and 34±4 % of βAPP was colocalized with LAMP1 (not statistically different)
(Figure 2.4c). Because the trafficking of the shorter construct was indistinguishable and
generated brighter images, the βAPP-paGFP construct was used for the remainder of these
experiments. Enlarged images from these experiments along with colocalization analysis are
shown in Figure 2.5. These images are very similar to the trafficking of LAMP1-paGFP from the
Golgi to lysosomes reported by Patterson et al. [30].
To rule out the possibility that transport to the LAMP1 compartment was due to overexpression
of the paGFP tag, we examined the transport of the Vesicular Stomatitis Virus Glycoprotein
(VSVG); a classic secretory trafficking protein. VSVG was tagged with paGFP at its cytoplasmic
C-terminus [55,56] similar to our APP constructs. We transfected SN56 cells VSVG-paGFP.
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These cells were subjected to the same imaging protocol as βAPP-paGFP transfected cells. After
the 15-minute pulse-period, VSVG-paGFP appeared on the cell surface and exhibited minimal
transport to a LAMP1 compartment (Figure 2.4d), in concordance with previous results [31,56].
Therefore, we conclude the paGFP tag did not alter the trafficking of APP.
To verify the accuracy of βAPP-paGFP photoactivation in the Golgi apparatus and that we were
not photoactivating βAPP-paGFP in nearby structures, SN56 cells were transfected with GalTCFP, βAPP-paGFP and LAMP1-mRFP and pretreated with nocodazole and/or cytocholasin D to
block transport out of the Golgi [57]. Cells were then photoactivated and imaged for 15 minutes
using the Golgi apparatus marker GalT-CFP as a target, and a Z-stack was taken immediately
after the photoactivation period. During the entire experiment, photoactivated APP-paGFP
remained almost exclusively within the Golgi apparatus (Figure 2.4e; Video 2.2). Inspection of
the post-irradiation Z-stack also revealed that photoactivated βAPP-paGFP was localized
principally within the Golgi apparatus, with almost no fluorescence evident in other
compartments or at the cell surface (Figure 2.4f).
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Figure 2.4: APP is rapidly trafficked from the Golgi apparatus to LAMP1-labeled compartment.
Photoactivation targets were drawn on the Golgi apparatus (white dots with arrows). For 15
minutes, cells were alternately imaged and irradiated (photoactivated) with 405 nm laser light
within the targets. White arrowheads point to APP-paGFP colocalized with Lamp1-mRFP. Scale
Bar = 5 μm. a) Demonstrates rapid transport of Full length-APP- paGFP (top panel) and βAPPpaGFP (middle panel) from Golgi apparatus to a LAMP1-labeled compartment. The same
trafficking occurs in mouse primary neurons (lower panel) (See Video 2.1). b) Higher
magnification images of βAPP-paGFP trafficking rapidly to a LAMP1 labeled compartment.
Scale Bar = 1 μm. c) Comparison of the colocalization of activated FL-APP-paGFP (n = 9) and
activated βAPP-paGFP (n = 8). d) SN56 cells transiently transfected with the secretory protein
Vesicular Stomatitis Virus Glycoprotein-paGFP (VSVG-paGFP), GalT-CFP (blue), and
LAMP1-mRFP (red) to demonstrate that very little of the green photoactivated VSVG-paGFP
arrives in the LAMP1 compartment; paGFP does not alter trafficking. Scale bars = 5 μm. e)
Transfected SN56 cells were treated for 5 minutes with nocodazole before imaging (See Video
2.2). Scale bars = 5 μm. f) Z-stack of the same cell taken immediately following 15 minutes of
photoactivation demonstrating that green signal remains inside the Golgi.
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Figure 2.5: Enlarged images of APP trafficking
Colocalization of photo-activated APP-paGFP with LAMP1. SN56 cells were transiently
transfected with plasmids expressing GFP, βAPP-paGFP and GalT-CFP. a) Shows the initial
image of an SN56 cell before photoactivation, with the Golgi apparatus labeled blue (GalT-CFP)
and lysosomes labeled red with LAMP1-mRFP. Thresholds were set in the red and blue channels
to identify the Golgi apparatus and Lysosomes using Imaris software, and a colocalization
channel is generated and overlaid in white. Although the Golgi apparatus and Lysosomes are
closely apposed, the fluorescent protein markers demonstrate minimal colocalization. Panel b
shows the same cell after 15 minutes of Golgi-targeted photoactivation with activated βAPPpaGFP in green and lysosomes labeled red with LAMP1-mRFP. The inset is magnified as figure
c. Panel c shows the red LAMP1-mRFP and green photoactivated βAPP-paGFP channels
separately. Thresholds were set in the red and green channels to identify the lysosomes and the
majority of the APP fluorescent signal using Imaris software, and a colocalization channel is
generated and overlaid in white. This channel demonstrates extensive colocalization of APPpaGFP and LAMP1. Furthermore, many regions of APP labeled fluorescence have the same
shape as the underlying LAMP1 label, implying that they are indeed colocalized in these
confocal images.

119

Figure 2.5

120

2.3.2

APP-paGFP traffics preferentially to lysosomes from the Golgi
apparatus

Next, we examined APP trafficking from the Golgi apparatus to early and late endosomes. In
these experiments, βAPP-paGFP was co-transfected with GalT-CFP along with either Rab5mRFP (early endosomes) or Rab9-mCherry (late endosomes). Rab5 is highly associated with
early endosomal membranes and is routinely used as a marker for early endosomes [42,43]. Rab9
localizes to late endosomal membrane and evidence suggests that Rab9 is involved in returning
cargo from the late endosome to the Golgi [45,46,54]. Rab7 is also a late endosomal marker [45],
but Rab7 also defines a population of lysosomes [54]. Therefore, to avoid mis-identification of
late endosomes as lysosomes we chose Rab9 as our late endosomal marker.
Cells were then alternately irradiated with 405 nm within targets placed over the Golgi apparatus
and imaged to produce a time course of images. In these experiments, a small amount of βAPPpaGFP can be seen colocalizing with Rab9 and Rab5 (Figure 2.6a and b; respectively) at the end
of the photoactivation period. At the end of the 15-minute pulse period, 37±5% (Mean ± SEM)
of photoactivated βAPP-paGFP colocalized with LAMP1 labeled compartments. Trafficking to
Rab9 and Rab5 compartments was significantly lower at 17 ±4% and 6±3%, respectively
(p<0.05)(Figure 2.6c). Although some LAMP1 labeling is found in early and late endosomes, the
fact that significantly more APP was co-localized with LAMP1 than Rab5 or Rab9 suggests that
APP is in bona fide lysosomes.
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Figure 2.6: APP is primarily transported to a LAMP1 compartment.
SN56 cells were cotransfected with plasmids expressing APP-paGFP, GalT-CFP (blue), and a
compartment marker (red). Photoactivation targets were drawn on the Golgi apparatus (white
dots with arrows). βAPP-paGFP trafficking was visualized from the from Golgi apparatus to Rab
9 labelled late endosomes (a) and Rab 5 labelled early endosomes (b). Scale bars represent 5 μm.
c) Percent of APP-paGFP fluorescence colocalized with respective compartment markers after
15 minutes of photoactivation in the Golgi (circles: LAMP1 (n = 9), squares: Rab9 (n = 10),
triangles: Rab5 (n = 7)). Error bars represent standard deviation. (* = p < 0.05).

122

Figure 2.6

123

2.3.3

APP-paGFP is cleaved in a LAMP1 positive compartment

Subcellular fractionation has shown that γ-secretase proteins and APP are bona fide residents of
the lysosomal membrane [13]. Furthermore, in vitro assays revealed that γ-secretase has an
acidic optimal pH (4.5-5) [13]. Therefore, we hypothesized that inhibiting γ-secretase or
lysosomal enzyme function could inhibit both secretase cleavage and nonspecific degradation of
βAPP, which would result in paGFP fluorescence accumulation at the lysosome membrane.
Therefore, we followed the extinction of paGFP fluorescence from LAMP1 positive vesicles
after the end of the photoactivation period. We found that there was nearly complete extinction
of photoactivated βAPP-paGFP (Figure 2.7a; Video 2.1) and FL-APP-paGFP (Figure 2.8)
fluorescence from the LAMP1 compartment within 1 hour. First we examined the effects of
nonspecific inhibition of lysosomal function, using chloroquine. Chloroquine has been reported
to alkalinize the endosomal/ lysosomal system and to inhibit APP clearance and Aβ production
[17,58,59]. Cells were treated with 100 μM chloroquine for 30 minutes before imaging. The
increase in pH was confirmed by loss of LysoSensor Green signal (a pH-dependent fluorescent
probe, Invitrogen) from LAMP1 compartments Figure 2.9. As in the untreated control cells,
βAPP-paGFP fluorescent signal was observed trafficking directly from the Golgi apparatus to
LAMP1-mRFP labeled lysosomes (Figure 2.7b, Video 2.3). However, in cells treated with
chloroquine, there was an accumulation of βAPP-paGFP fluorescence in LAMP1-labeled
compartments.
Next we assessed the ability of the highly potent and specific γ-secretase inhibitor L685,458 [60]
to block the cleavage of βAPP-paGFP. SN56 cells were pretreated with 0.5 μM of L685,458 for
24 hours before imaging. L685,458 treatment caused marked accumulation of photoactivated
βAPP-paGFP in lysosomes during the photoactivation phase, and significantly reduced the
clearance of APP from lysosomes. (Figure 2.7c; Video 2.4).
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We hypothesized that if APP were cleaved at the lysosomal membrane by secretase enzymes, the
cytoplasmic tail of APP along with activated paGFP would be released into the cytoplasm
resulting in loss of fluorescence from this compartment. Furthermore, this process would appear
with kinetics order greater than 0. In contrast, the loss of fluorescence due to photobleaching
would be directly proportional to the amount of time that the fluorophore was irradiated, and
should therefore and fall off linearly, with 0 order kinetics. To quantitate APP-paGFP clearance
from the lysosome after the photoactivation period, we measured the number of pixels of APPpaGFP fluorescence colocalized with LAMP1-mRFP using Imaris software for each time point,
normalizing the highest value of colocalization (after the photoactivation period) to 100%. In
these experiments, FL-APP-paGFP and βAPP-paGFP disappear from the lysosomes with nonlinear kinetics. The disappearance of βAPP-paGFP was modeled using Prism 5 (GraphPad, La
Jolla, CA) from the lysosome can be accurately modeled using the integrated rate equation for a
first order reaction (k=0.00153 sec-1, r2=0.96) (Figure 2.7d). We attempted to model the data
with two and three phase exponential decay curves, but these resulted in worse fit. This suggests
that APP is cleaved with first order kinetics in lysosomal compartments, suggesting enzymatic
clearance.
Because of our long imaging protocol, some of the loss fluorescence from activated paGFP could
be the result of photobleaching. Therefore, we constructed photobleaching curves using
enhanced-GFP (EGFP), as EGFP and paGFP have nearly identical photobleaching
characteristics [30]. SN56 cells were transiently transfected with EGFP, and fixed with 4%
paraformaldehyde. Cells were then imaged using the same imaging protocol, as in the previous
live cell imaging experiments. The normalized number of green pixels at each time point was
quantitated, and plotted on the same graph as our βAPP-paGFP clearance data (Figure 2.7d).
βAPP-paGFP fluorescence decayed faster and became significantly lower than GFP fluorescence
(One-way ANOVA; Tukey’s Post Hoc; p<0.05). Therefore, the loss of βAPP-paGFP
fluorescence appears to be the result of a first order enzymatic reaction (Figure 2.7d).
Next, we quantified the effect of inhibitors on APP clearance (Figure 2.7e). After chloroquine
treatment, photoactivated APP-paGFP in the lysosome decreased linearly over time during the
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chase phase, suggesting that it was not cleared by an enzymatic cleavage. There was no
significant difference from loss of fluorescence due to photobleaching (One-way ANOVA;
Tukey’s Post Hoc p<0.05) (Figure 2.7e). In cells treated with L685,458 or chloroquine, the loss
of βAPP-paGFP fluorescence from lysosomes during the chase phase was also not significantly
different from the rate of loss of GFP fluorescence due to photobleaching (One-way ANOVA;
Tukey’s Post Hoc; p<0.05) (Figure 2.7e). Cells treated with L685,458 also consistently exhibited
accumulation of photoactivated βAPP-paGFP at the cell surface (Figure 2.7c middle and right
panels). This is in agreement with a previous study that showed APP internalization was
decreased by treatment with γ-secretase inhibitors [61,62]. Our data therefore suggests that
βAPP-paGFP clearance from lysosomes is performed by both a pH-dependent protease (as
expected for a β-secretase) and by the γ-secretase. The accumulation of APP in these LAMP1
compartments following inhibition of proteases suggests that they represent terminal lysosomes
and not an endosomal intermediate.
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Figure 2.7: APP is processed in the lysosome by a γ-secretase like activity.
SN56 cells were transiently transfected with βAPP-paGFP, GalT-CFP, and LAMP1-mRFP. Cells
were alternately photoactivated with 405 nm light and imaged in the Golgi for 15 minutes, and
then imaged every 30 seconds for 1 hour. a) Shows the accumulation of photoactivated APPpaGFP in the lysosome after 15 minutes, follow by its near complete clearance after 45 minutes.
Arrowheads denote areas of colocalization (See Video 2.1). b) Transiently transfected SN56 cells
were pretreated with 100 μM chloroquine for 30 minutes prior to imaging. After chloroquine
treatment APP is still visible in lysosomes after 45 minutes (See Video 2.3). c) Cells treated with
0.5 μM L685, 458 (γ-secretase inhibitor) overnight prior to photoactivating/imaging. L685, 458
treatment substantially increases the accumulation of photoactivated βAPP-paGFP in lysosomes,
and substantially decreases its cleance. Scale bars represent 5 μm (See Video 2.4). d) Cleavage
of βAPP-paGFP was determined by measuring the loss of FL-APP (black open triangles) and
βAPP-paGFP (black closed circles) from LAMP1 labeled compartments. Values were averaged
and normalized to begin at 100%. Overlaid in green squares is the loss of fluorescence of EGFP
in the identical imaging protocol. Error bars represent SEM. (* = p < 0.05). (e) Shows the
clearance of photoactivated APP-paGFP cells that were treated with 100 μM chloroquine for 30
minutes before imaging (n = 9) or with 0.5 μM L685, 458 (γ-secretase inhibior) (n = 9). Error
bars represent SEM.
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Figure 2.8: Trafficking of full-length APP-paGFP to LAMP1-mRFP labelled compartments
SN56 cells were transfected with GalT-CFP, FL-APP-paGFP, and LAMP1-mRFP. Cells were
photoactivated in the GalT labelled compartments and imaged for 15-minutes for 15-minutes.
The cells were chased for a further 45-minutes to follow the clearance of APP from the cell. The
images shown below are from the 0, 15, and 45-minute time points. Scale bar represents 5m.
White arrows point to colocalized pixels between FL-APP-paGFP and LAMP1-mRFP.
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Figure 2.9: De-acidification of lysosomes with chloroquine.
SN56 cells were preloaded with 75nm Lysosensor™ Green after transfection with LAMP1mRFP. The cells were imaged by confocal microscopy before and after treatment with
chloroquine. Scale bars represent 5m.
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Figure 2.10: Cleavage of βAPPsw-paGFP
βAPP-paGFP, βAPPsw-paGFP, and full-length APP-paGFP are cleaved by that γ-secretase in a
similar manner. SN56 cells were transiently transfected with plasmids expressing GFP, FL-APPpaGFP, βAPP-paGFP, or βAPPsw-paGFP. Twenty-four hours before harvesting protein for
western blotting, cells were treated with DMSO or with L685, 458. Cell lysate was run on a 12%
SDS polyacrylamide gel, and transferred onto nitrocelluose membrane. Membrane was probed
for APP using APP C-terminal antibody (Sigma). Membranes were reprobed for α-tubulin, as a
loading control.
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2.3.4

The Swedish mutation dramatically increases APP clearance from
the lysosome, but not the Golgi apparatus

The Swedish mutation (APPsw) is a double mutation at codons APP 670/671 (numbered in
APP695) adjacent to the β-secretase cleavage site that increases the rate of β-cleavage of APP by
up to a factor of 10, and has been suggested to alter the trafficking of APP [22,63,64]. To
examine the effect of the Swedish mutation on intracellular APP trafficking, we transiently
transfected SN56 cells with βAPPsw-paGFP along with plasmids expressing compartment
markers for the Golgi apparatus and lysosomes. Protein from SN56 cells transfected with βAPPpaGFP, FL-APP-paGFP, or βAPPsw-paGFP was harvested and separated by SDS-PAGE. By
SDS-PAGE, the expression level of βAPP-paGFP and βAPPsw-paGFP was similar (Figure
2.10). The pulse-chase paradigm, as performed with wild-type βAPP-paGFP, was performed on
these cells, targeting the GalT-CFP labeled Golgi apparatus to photoactivate βAPPsw-paGFP.
Unlike cells transfected with the wild type construct, green fluorescence did not accumulate in
cells transfected with βAPPsw-paGFP in a LAMP1-labeled compartment. Instead, these cells
rapidly developed diffuse green fluorescence throughout the entire cell body (Figure Figure
2.11a; Video 2.5). The diffuse cytoplasmic appearance of paGFP fluorescence suggests that APP
is being rapidly cleaved, with the APP C-terminal fused to paGFP diffusing rapidly into the
cytosol. This likely reflects the higher rate of β-cleavage of Swedish mutation [65,66].
It has previously been suggested that secretase cleavage of the APPsw might occur in the Golgi
apparatus. In order to examine APP cleavage in the Golgi apparatus, we repeated this experiment
after treating the cells with nocodazole and cytocholasin D (Figure 2.11b; Video 2.6). In
dramatic contrast to untreated cells, virtually all of the paGFP fluorescence remains localized to
the Golgi apparatus during the photoactivation period. Cells were then followed for up to 1-hour
post photoactivation, during which most of the green signal remains in the Golgi apparatus. It
was not possible to quantify the clearance of βAPPsw-paGFP from the Golgi apparatus in this
experiment, because of photobleaching of the GalT-CFP marker. Although it is not possible to
say from this data that there is no cleavage of APP in the Golgi apparatus, the Golgi apparatus
does not appear to facilitate the majority of APP processing.
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In order to examine lysosomal processing of βAPPsw-paGFP, we treated cells with chloroquine
and L685,458. After treatment with chloroquine, there was rapid trafficking of βAPPsw-paGFP
signal to the lysosome where it accumulated in the photoactivation phase and then gradually
decreased in brightness in the chase phase (Figure 2.11; Video 2.7). This result was also seen
after treatment with the γ-secretase inhibitor L685, 458 (Figure 2.11b; Video 2.8). The loss of
fluorescence signal in the chase phase as linear for both of these treatments was not significantly
different from GFP photobleaching (Figure 2.11c and 2.9d). Together, these data suggest that the
Swedish mutation accelerates the cleavage of APP at the lysosomal membrane, but does not have
an effect on APP trafficking to the lysosome.
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Figure 2.11: The Swedish mutation causes rapid clearance of APP from lysosomes.
SN56 cells were transiently transfected with βAPPsw-paGFP, GalT-CFP, and LAMP1-mRFP.
Scale bars represent 5 μm. a) βAPPsw-paGFP was photoactivated for 15 minutes in the GalTCFP labeled compartment, and chased for 45 minutes. βAPPsw is cleaved nearly instantaneously
and appears in the cytoplasm. b) Cells were treated for 5 minutes before imaging with 66 μM
nocodazole and 10 μM cytochalasin. GalT-CFP is false colored red to provide better contrast,
and LAMP1-mRFP has been false coloured blue. Photoactivated βAPPsw-paGFP accumulates in
the Golgi and does not appear to be cleaved. c) Cells were treated acutely with 100 μM
chloroquine (See Video 2.7) which results in photoactivated βAPPsw-paGFP accumulating in
lysosomes. White arrowheads represent βAPPsw-paGFP colocalized with LAMP1-mRFP d)
Cells were treated with 0.5 μM L658, 458 (See Video 2.8), which also causes photoactivated
βAPPsw-paGFP to appear in lysosomes. Scale bars represent 5 μm. Quantitation of colocalized
green pixels with LAMP1-mRFP show that the clearance of βAPPsw-paGFP from the lysosome
proceeds linearly after treatment with e) chloroquine (n = 8), or with f) L658, 458 (n = 9). Error
bars represent standard deviation.
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2.3.5

APP interacts with adaptor protein AP-3

AP-3 is an adaptor protein that is integral to the direct delivery of lysosomal membrane proteins
(LMPs) from the Golgi apparatus [67-71]. First, we sought to determine whether APP and AP-3
colocalize in neurons. Cortical neurons dissected from E15 mice were immunostained (DIV7)
for the APP C-terminal and AP-3 δ subunit, demonstrating colocalization. When analyzed by
Imaris, 42 ±3% (Mean±SEM) of APP fluorescence was colocalized with AP-3 signal. We then
depleted the δ subunit of AP-3 in SN56 cells using siRNA, as this has been shown to cause
instability and degradation of the entire AP-3 complex [72]. We found that cells transfected with
this siRNA expressed only 22 ±12 % (Mean±SD) of the AP-3 δ subunit on Western blots
(p<0.05), while cells transfected with a control siRNA showed no significant change in AP-3 δ
expression (Figure 2.12a and b). We also observed this effect by immunostaining; cells
transfected with siRNA (visualized by the Alexa fluor 647 label on the 5’ end of the control
oligonucleotide) showed a marked decrease in AP-3δ staining while untransfected cells, or cells
transfected with fluorescently labelled negative control siRNA only were unaffected (Figure
2.12c).
To determine whether APP and AP-3 interact using the in situ proximity ligation assay (iPLA)
which allows the study of low affinity interactions in-situ and has comparable accuracy to coimmunoprecipitation [73,74]. Briefly, iPLA employs species-specific secondary antibodies
bearing complementary DNA strands. If the two antibodies are within 40 nm, the DNA strands
will hybridize, and the resulting sequence can be replicated, amplified, and labelled with
fluorescent oligonucleotides. Pairs of interacting proteins were detected as red fluorescent
dots/μm3.
SN56 cells were transfected with βAPP-CFP, and iPLA was used to determine the proximity of
APP and AP-3. Cells mock transfected or transfected with negative control siRNA both
demonstrate an interaction between APP and AP-3 (Figure 2.13b). Conversely, cells transfected
with siRNA against AP-3 δ showed a marked decrease (approximately 98%) in fluorescent
puncta signifying decreased interaction (Figure 2.13b and c).
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Figure 2.12: Knockdown of AP3 and AP1 by siRNA.
a) SN56 cells were transfected with fluorescently-tagged control siRNA or AP-3δ and
fluorescently tagged siRNA. Western blot demonstrating that AP-3δ siRNA decreases AP-3δ
protein. Blots were stripped and re-probed with anti-tubulin antibody as a loading control. b)
Western blots (from a) were scanned and analyzed using densitometry (ImageJ) and graphed.
Error bars represents standard error of the mean. (*p=<0.05). c) SN56 cells were transfected with
fluorescently tagged control siRNA or anti-AP-3δ and fluorescently tagged siRNA (purple).
Cells were the immunostained to detect AP-3δ (red). Fluorescent images overlayed with white
light images to delimit the cell body. (scale bars represents 5 μm). d) SN56 cells were transfected
with control siRNA or siRNA against AP-1γ. Western blot demonstrating that AP-1γ siRNA
decreases AP-1 protein. Blots were stripped and re-probed with anti-tubulin antibody as a
loading control. e) Western blots (from d) were scanned and analyzed using densitometry
(ImageJ) and graphed. Error bars represents standard error of the mean. (*=p<0.05).
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Figure 2.13: AP-3δ and APP colocalize and interact.
a) E15 mouse neurons were cultured and immunostained with antibodies against AP-3δ (SA4;
red) and APP (APP C-terminal; green). Arrowheads point to colocalized pixels. Scale bars
represent 5 μm. Inset shows magnified view of the cell body. b) Proximity ligation assay (PLA)
demonstrates the interaction of APP and AP-3δ. Cells were transiently transfected with βAPPCFP with no siRNA, control siRNA or AP-3δ siRNA. Cells were stained with mouse anti- AP3δ and rabbit anti-APP C-terminal antibodies. These were detected with secondary antibodies
conjugated to complementary DNA sequences. When proteins are within 40 nm, DNA is ligated
and replicated and detected by in-situ fluorescent red dots. AP-3δ siRNA substantially reduces
the number of red dots. (scale bars represent 10 μm) c) Quantification of PLA fluorescent dots in
SN56 cells normalized to cell volume (*p < 0.05).
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2.3.6

AP-3 Knockdown Disrupts Trafficking of APP to Lysosomes

We hypothesized that we could disrupt the trafficking of APP to lysosomes by siRNA mediated
knockdown of AP-3. As a control, we examined the effect of AP-1 knockdown by siRNA (both
AP-1a and AP-1b isoforms) (Figure 2.14). AP-1 belongs to the heterotetrameric family of
adaptor proteins, which includes AP-1, AP-2, AP-3, and AP-4. AP-1 mediates the cell surface
trafficking and basolateral sorting in epithelial cells [75,76] . As before, we co-transfected cells
with βAPP-paGFP, GalT-CFP and LAMP1-mRFP with the addition of siRNA against either AP1γ, AP-3δ, or a control siRNA. In cells transfected with active siRNA, a small amount of
fluorescently tagged negative control siRNA was included as a marker to identify transfected
cells. Cells were photoactivated in irradiation targets placed over the Golgi apparatus, and
transport of APP was imaged over a 15-minute period and then analyzed for colocalization of
photoactivated APP and LAMP1-mRFP. We found that cells transfected with control siRNA
alone did not change βAPP-paGFP trafficking to lysosomes, as compared to cells not transfected
with siRNA (37±5% vs 37±5%). However, the siRNA against δ3 reduced APP transit to the
lysosome to 16 ±3% after 15 minutes of photoactivation. AP-1γ knockdown did not change the
trafficking of APP from the TGN to lysosomes (34±4%; Mean±SEM) (Figure 2.14a and b).
Therefore, AP-3 mediates rapid transport of APP to the lysosome, while AP-1 is not involved in
the direct trafficking of APP to lysosomes, at least on the timescale examined here.
To determine the effect of AP-1 knockdown and AP-3 knockdown on APP processing, SN56
cells were transfected with βAPPsw-CFP and with negative control siRNA, AP-1 siRNA, AP-3
siRNA or a combination of AP-1 and AP-3 siRNAs. Two days after differentiation, culture
medium was taken from the cells and analyzed for Aβ40 and Aβ42 by ELISA (Invitrogen)
(Figure 2.15a). AP-1 siRNA did not significantly alter the levels of Aβ 40 [106%±7%
(mean±SEM)], as compared to control. AP-3 siRNA and combined AP-3 and AP-1 siRNAs
reduced the levels of Aβ40 54±3% and 63±6%, respectively (p<0.5). For Aβ42 (Figure 2.15d),
the control siRNA raised Aβ42 production slightly to 141±12% (not significant) while siRNAs
against AP-1 reduced Aβ42 levels in the medium to 75+14% (not significant). Inhibitory siRNA
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to AP-3 alone or AP-1 and AP-3 together reduced the levels of Aβ42 to 64±13 and 46±11%
respectively (P<0.5) (Figure 2.15b). Therefore, AP-3 KD reduced the levels of Aβ40 and 42 in
the media, and this effect was increased when AP-1 was knocked down as well.
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Figure 2.14: AP-3 mediates direct trafficking of APP to lysosomes.
a) SN56 cells were transfected with βAPP-paGFP, LAMP1-mRFP, GalT-CFP (n=9), and either
control siRNA (n=9), siRNA against AP-3δ mRNA (n=10) or siRNA against AP-1γ (n=9). Cells
were alternately photoactivated with 405 nm light and imaged in the Golgi for 15 minutes (scale
bar represents 5 μm). White arrowheads in the merged image (far right panel) denote colocalized
pixels. Scale bars represent 5 μm. b) Percent of βAPP-paGFP colocalizing with LAMP1-mRFP
at the end of the 15-minute photoactivation period. (* = p < 0.05; Error bars represent standard
deviation).
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Figure 2.14
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Figure 2.15: AP-3 mediates processing to Aβ.
SN56 cells were transfected with βAPP-paGFP, LAMP1-mRFP, GalT-CFP, and either control
siRNA, siRNA against AP-3δ mRNA or siRNA against AP-1γ. a) SN56 cells were cotransfected a plasmid expressing βAPPswe-CFP and with control siRNAs, siRNA against AP-1γ,
siRNA against AP-1γ and AP-3δ combined, or siRNA against AP-3δ. Conditioned media was
analyzed for a) Aβ40 or b) Aβ42 by ELISA. Experiments were performed 4 times, with each
experiment consisting of 2 replicates. (* indicates significantly different from control. p < 0.05;
** indicates significantly different from control and either AP-1 or AP-3 alone p < 0.05) Error
bars represent SEM.
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Figure 2.15
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2.4

Discussion

In this work, we demonstrate the use of paGFP to study the intracellular trafficking of and
clearance of APP. While paGFP has been used before to examine APP trafficking [39,40,70],
this is the first report to follow APP from the Golgi apparatus into identified downstream
compartments and examine its clearance pharmacologically. Although we had expected APP to
traffic to the lysosome primarily via the plasma membrane, instead we observed rapid transport
of APP to a LAMP1 compartment within seconds, similar to the behavior of LAMP1 [30].
Furthermore, we were able to follow the clearance of βAPP-paGFP in from lysosomes,
essentially performing a pulse-chase experiment in this organelle in single cells. We show that
βAPP-paGFP is cleared from the lysosome with first order kinetics, which is faster than the
linear loss of fluorescence observed during photobleaching. The clearance of APP from
lysosomes is sensitive to both chloroquine, a nonspecific inhibitor of lysosomal function, and
L684, 458, a specific gamma-secretase inhibitor. The direct trafficking of APP to this LAMP1
positive compartment is decreased by AP-3 knockdown. The depletion of AP-3 or AP-3 and AP1 together results in a substantial reduction of Aβ in the media.
Because intracellular compartment markers localizations are not absolute, lysosomal markers can
be found in endosomal compartments and vice versa [77,78]. However, several features suggest
that APP is moving to a bona fide lysosomal compartment. APP appears to be moving primarily
to LAMP1 positive compartments, with less moving to compartments labeled with Rab5 and
Rab9 (early and late) labeled compartments, suggesting that the main compartment receiving
APP is LAMP1 positive and negative for Rab5 and Rab9. Furthermore, after the inhibition of
degradation of APP with chloroquine or L685, 458, APP moves to LAMP1-labeled
compartments and accumulates in these compartments, implying that they are terminal
compartments of the endosomal lysosomal system. Furthermore, that AP-3 knockdown reduces
the production and secretion of Aβ42 by 36% and Aβ40 by 47% suggests that the lysosome is a
major site of APP processing and Aβ production. These features suggest that APP is delivered
predominantly to lysosomes.
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Prior to this study, most APP trafficking studies suggested that APP primarily moved to the
lysosome via the cell surface [79], however the evidence presented here suggests APP can traffic
intracellularly from the Golgi to lysosomes. Kuentzel et al. found that less than ~20% of nascent
APP is transported to the plasma membrane [80], suggesting that this direct lysosomal pathway
maybe a major processing pathway of APP. LMPs are known to traffic to the lysosome by at
least 2 different pathways. Some LMPs, like lysosomal acid phosphatase, transit first to the cell
surface, and then cycle between the plasma membrane and endosomes repetitively before
transport to the lysosome [81]. Other proteins, such as LAMP-1, transit intracellularly from the
Golgi apparatus to lysosomes, without appearing at the cell surface [82,83]. Our work is in
agreement with of Castor et al., who also demonstrated using a temperature-block paradigm that
APP in the Golgi apparatus rapidly appears in a LAMP1-positive compartment rapidly after
being released from the Golgi [84]. APP now has at least 4 distinct pathways to the lysosome :
one from the cell surface through endocytosis into endosomes [85], one directly to lysosomes
from the cell surface [50], one through autophagosomes [86], and finally the direct transport
from the Golgi apparatus demonstrated here. This suggests that APP is a normal resident
Lysosomal Membrane Protein.
This work is not intended to minimize the importance of APP’s cell surface trafficking. Indeed,
AP-1 knockdown, which is predicted to interfere with APP trafficking to the cell surface, is able
to substantially reduce Aβ production indicates that cell surface APP is still a significant source
of Aβ. APP transiting to the cell surface is likely not being well visualized in this study for a
number of reasons including: 1) activated APP-paGFP arriving at the membrane is diluted by a
large amount of non-fluorescent APP already at the membrane, 2) APP has a relatively short half
life at the membrane, estimated at 10 minutes [21,85] and 3) we are imaging confocal sections
and therefore seeing only a small fraction of the cell membrane itself. Indeed, Golgi apparatusphotoactivated βAPP-paGFP becomes visible at the plasma membrane when internalization is
inhibited with a γ-secretase inhibitor [61,87], demonstrating that APP can transit rapidly to the
cell surface [80].
Several studies have suggested the presence of γ-cleavage in the lysosome. Our own studies have
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demonstrated that γ-secretase proteins and activity are present in highly purified lysosomes.
Although many studies have observed γ-secretase function at neutral pH, we have found that γsecretase activity within isolated lysosomal membranes possesses an acidic optimal pH [13]. Our
findings are in agreement with previous findings that show a marked accumulation of APP in
lysosomes after disruption of lysosomal pH, and inhibit the production of Aβ [17]. Furthermore,
many other studies have documented the accumulation of APP fragments in lysosomes after
inhibition of lysosomal enzymes or inactivation of PS1 [16,18,20,88], suggesting a critical role
for lysosomes in γ-secretase cleavage of APP. However, this is the first study to visualize
accumulation of APP CTFs at the lysosomal membrane using a highly selective γ-secretase
inhibitor [89-91].
Some investigators have suggested that APP (particularly APPsw) undergoes cleavage in the
Golgi apparatus and in post-Golgi vesicles [63,92]. Our data appears to show APP and APPsw
accumulating stably in the Golgi apparatus when trafficking is blocked pharmacologically.
Although it is impossible to rule out some processing of APP in the Golgi apparatus with these
experiments, these data suggest that the Golgi apparatus is not a major site of Aβ production.
It is interesting that chloroquine and L684, 458 produce similar results. To our knowledge,
chloroquine has never been shown to specifically affect the γ-secretase directly in cell free
assays. Although our own data has suggests that γ-secretase functions at an acidic pH in the
lysosome [13], most authors use a neutral pH [93] or mildly acidic pH [94] for this enzyme.
However, efficient γ-secretase function requires the removal of the luminal domain of APP by βcleavage [95]. The β-secretase is known to transit to the late endosomal/lysosomal compartments
[96,97]. β-cleavage may also be performed by lysosomal cathepsins [98,99]. With a pH optimum
below 4.5 [5,100], β-secretase (like cathepsins) would function optimally in the lysosome.
Therefore, the accumulation of APP in the lysosome after chloroquine could be by nonspecifically inhibiting a luminal pH dependent β-secretase or β-like cleaving enzyme, which then
secondarily inhibits γ-cleavage. When β-cleavage is accelerated by the APPsw mutation, APPpaGFP is cleared so rapidly that it cannot be imaged in the lysosome. This suggests that, rather
than being a tightly controlled regulatory enzyme, the γ-secretase behaves more like a
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“proteasome of the membrane” whose job is to remove transmembrane stubs of proteins from the
membrane [101].
Our results also demonstrate that lysosomal trafficking of APP may be an important mechanism
of regulating APP cleavage. Specifically AP-3 knockdown reduces lysosomal trafficking of APP
from the Golgi apparatus and reduces Aβ production and this effect is additive to AP-1 knock
down. A wide range of other proteins likely also likely regulate APP processing by altering its
trafficking including GGA1 [102,103], X11a, Fe65 [104,105], AP-4 [106], VPS35 [25] and
SorLa [26,27,39]. These studies suggest that control of APP processing by intracellular
trafficking may be crucial for regulating Aβ production.
These findings may have broad importance for the pathophysiology of AD. This is because the
lysosome’s biochemical milieu and acidic pH make it the ideal environment for the nucleation of
amyloid fibrils [107,108]. In fact, the lysosome has been proposed to be a site of Aβ aggregate
seeding [109-111]. This development of Aβ aggregates has been shown to disrupt synapses [112]
and membranes[113], and can lead to lysosomal rupture leading to cell death [114,115]. Aβ may
be secreted in exosomes, which are intraluminal vesicles released from the endosomal/
lysosomal system [58,116]. Therefore, Aβ and its higher-order aggregates may be produced,
nucleated, and secreted from lysosomes. The lysosome sits at a crossroad, as a site for the
production and degradation of Aβ, as well as its fibrilogenesis. This work points to the
importance of the lysosomal system in APP processing and its regulation in developing
therapeutic treatments for AD.
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Chapter 3

3

Tyrosine Binding Protein sites regulate the intracellular
trafficking and processing of Amyloid Precursor Protein
through a novel lysosome-directed pathway

The amyloid hypothesis posits that the production of β-amyloid (Aβ) aggregates leads to
neurodegeneration and cognitive decline associated with AD. Aβ is produced by sequential
cleavage of the amyloid precursor protein (APP) by β- and γ-secretase. While nascent APP is
well known to transit to the endosomal/ lysosomal system via the cell surface, we have recently
shown that APP can also traffic to lysosomes intracellularly via its interaction with AP-3.
Because AP-3 interacts with cargo protein via interaction with tyrosine motifs, we mutated the
three tyrosines motif in the cytoplasmic tail of APP. Here, we show that the YTSI motif interacts
with AP-3, and phosphorylation of the serine in this motif disrupts the interaction and decreases
APP trafficking to lysosomes. Furthermore, we show that phosphorylation at this motif can
decrease the production of neurotoxic Aβ 42. This demonstrates that reducing APP trafficking to
lysosomes may be a strategy to reduce Aβ 42 in Alzheimer’s disease.

3.1 Introduction
Alzheimer’s disease (AD) is characterized by the accumulation of extracellular plaques in the
brains of AD patients composed of is β-amyloid (Aβ) peptides. Aβ is derived from the amyloid
precursor protein (APP), a type 1 transmembrane glycoprotein. To produce Aβ, APP is cleaved
first by the β-secretase, which releases the soluble APPβ ectodomain, leaving a 99-residue βcarboxyl terminal fragment (βCTF). The βCTF is then cleaved by γ-secretase to produce Aβ
species varying from 38-43 residues and an APP intracellular domain.

Currently, the

subcellular localization of these cleavage events is unclear. For example the the Golgi apparatus,
plasma membrane, and autophagosomes [1-4] have been implicated in Aβ production. However,
many studies show that nascent APP is cleaved after endocytosis from the cell surface into
endosomes and subsequently into lysosomes [2,5-8]. We have recently shown that APP can also
transit directly into lysosomes from the cell surface via macropinosomes [9,10]. We have also
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shown that APP and γ-secretase proteins are bona fide resident proteins of lysosome [11-13].
Furthermore, γ-secretase has an acidic optimal pH [11], and disruption of endosomal/lysosomal
pH by chloroquine or ammonium chloride decreases the production of Aβ [14-16].
Although many studies have examined the cell surface trafficking of APP, few have examined
APP’s intracellular transport. The advent of photo-activatable fluorescent proteins (pa-GFP)
provided a new tool to study the intracellular behavior of proteins [17-19]. Recently, we
demonstrated that a paGFP tag could be used to follow the intracellular trafficking of APP from
the Golgi. We uncovered a previously unknown direct trafficking pathway for APP from the
Golgi to the lysosome (via an interaction with the adaptor protein, AP-3), where it is cleaved to
form Aβ [20].
AP-3 is a heterotetrameric adaptor protein, which consists of a β3, δ3, μ3, and σ3 domains. The
μ3 domain of AP-3 recognizes tyrosine motifs of the form YXXƟ (where Ɵ is a bulky amino
acid and X is any amino acid) [21]. APP contains two YXXƟ motifs at 709YTSI712 and
738

YENP741 (using APP 751 numbering). These motifs interact with other known members of the

heterotetrameric adaptor protein family (AP-1, AP-2, and AP-4) [4,22-24]. The YENP motif is
part of a larger motif that contains an NPXY motif (738GYENPTY743)(Figure 3.1a), which has
been shown to be involved in endocytosis [6,8,25,26].
While the role of these tyrosine mutations in APP internalization is well documented, the effect
of these mutations on the intracellular trafficking from the Golgi to lysosomes remains to be
elucidated. Here, we use paGFP-tagged APP and live cell imaging to examine the role of these
cytoplasmic tyrosine motifs on the intracellular trafficking of APP. We show that the mutation of
Y709A or Y743A disrupt the transit of APP from the Golgi to the lysosome in live cells.
Furthermore, the 709YTSI712 motif is responsible for the interaction of APP with AP-3. This
interaction can be disrupted by phosphorylation of serine within the 709YTSI712 (S711), which
can be phosphorylated by protein kinase C (PKC) [27,28], and decreases lysosomal transport
from the Golgi. Furthermore, we demonstrate that PKCε activation can divert APP away from
lysosomes; possibly by S711 phosphorylation.
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3.2
3.2.1

Materials and Methods
Antibodies and Chemicals

Antibodies used were Mouse Anti-HA (Sigma, H9658), AP-3 (SA4, Developmental Studies
Hybridoma Bank) and APP C-terminal (Sigma, A8717). The PKC activator Phorbol-12myristate-13-acetate (PMA) was purchased from Sigma (P8139) and 8-[2-(2-pentylcyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) was purchased from (Sigma, D5318).
Staurosporine was purchased from Millipore (Cat No. 569397). Gö6976 was purchased from
Tocris Bioscience (Cat. No. 2253).

3.2.2

Cell Culture

SN56 cells were maintained Dulbecco’s minimal Eagle’s medium (DMEM, Invitrogen)
supplemented with 10% fetal bovine serum and 50ug/ml of penicillin/streptomycin, in an
incubator at 37°C with 5% CO2. Cells were split every 3-4 days; depending on confluency. For
microscopy, cells were seeded on glass-bottomed culture dishes (MatTek) one day before
transfection. Cells were transfected using Lipofectamine 2000 (Invitrogen) following
manufactures directions. After a 24hrs, cells were differentiated in DMEM using 1mM dibutyrl
cyclic AMP (dbcAMP; Sigma) and imaged or fixed.

3.2.3

Plasmid Constructs

A plasmid encoding the last 112 amino acids of APP with paGFP and CFP C-terminal tags was
previously designed [9,20]. The N-terminal of our construct is tagged with a HA epitope to
facilitate cell-surface internalization experiments. Mutations were generated using a site-directed
mutagenesis kit (Stratagene) and subsequently sequenced to ensure accuracy. Rab5-mRFP and
LAMP1-mRFP were generated as previously described [9].

3.2.4

Confocal Microscopy

Images were captured with a Zeiss LSM (laser-scanning microscope) -510 META with a Zeiss
63× 1.4 numerical aperture oil immersion lens (Carl Zeiss, Oberkochen, Germany). The
thickness of each optical section was set to 1 μM. Cyan fluorescent protein (CFP) was excited
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with a 458 nm laser and filtered with a BP 475-525 filter set. Alexa Fluor 488 and paGFP
fluorescence were excited with a 488 nm laser and filtered using a band pass (BP) 500-530-nm
emission filter set. Alexa Fluor 546, proximity ligation assay (PLA) red detection agent,
mCherry, and mRFP fluorescence were excited with a 543 nm laser and filtered with a BP 560–
615nm of LP 560nm filter set.

3.2.5

Live-Cell Imaging

Images were taken using a Zeiss LSM-510 META laser-scanning microscope using a Zeiss 63x
1.4 numerical aperture oil immersion lens (Carl Zeiss, Germany). Live cell imaging was
performed as previously described [20,29]. Briefly, SN56 cells were washed with PBS and
transferred to with pre-warmed to 37°C Hank’s Balanced Salt Solution (HBSS; Cat. No. 14025–
092, Invitrogen). The confocal plates were placed on a heated stage (PeCon GmbH) connected to
a Tempcontrol 37-2 digital 2-channel (PeCon GmbH), to maintain the cells at 37°C. ROIs were
drawn over the Golgi apparatus as demarcated by GalT-CFP fluorescence, using the Zeiss
Physiology package. As the cell can move and shift during the imaging period, the locations of
these ROI were carefully monitored to ensure they remained over the Golgi for the duration of
the photo-activation period. During typical experiments, the cell was alternatively imaged and
photo-activated for the 15-minutes. βAPP-paGFP was photoactivated with a 25 mW 405 nm
laser, set to maximum power in the pre-specified ROIs. The bleaching for each individual ROI
took approximately 50msecs. There were typically 4 ROIs drawn per cell for an approximately
4sec total photoactivation time. A time delay between frames was set accordingly to
photoactivate and capture an image every 30 seconds.

3.2.6

Colocalization Analysis

Colocalization analysis was performed using Imaris 7.0 Imaris Colocalization module (Biplane)
as previously described [20,29]. To analyze the vesicular trafficking of βAPP in live cells, Imaris
was used to create IsoSurfaces corresponding to paGFP and LAMP1-mRFP or Rab5-mRFP
fluorescence, following manufacturer’s instructions. This is a semi-automated method that
defines organelle distribution based on fluorescence intensity and estimated vesicle size. APP
vesicles and the compartment vesicles were demarcated using Imaris, and the amount of
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colocalization was calculated as a percentage of material (βAPP-paGFP) within the
compartment. The percentage of material value takes into account the number of pixels
colocalized, as well as the intensity of each individual pixel.
For images of fixed cells, the top 2% of the brightest pixels from each channel were thresholded,
and the colocalization was determined in Imaris [9]. The percentage of material colocalized was
recorded and plotted in Prism Graphpad 5.0b. Prism Graphpad 5.0b was used for all graphing
and statistical analysis. A One-way ANOVA was performed with a Bonferroni post-hoc test, and
P values under 0.05 were considered significant.

3.2.7

Proximity Ligation Assay

PLA was performed using a commercially available kit (Duolink; Olink Bioscience) according to
manufacturer’s instructions. Briefly, cells were permeabilized with 0.01% Triton in PBS and
blocked with 2% BSA/PBS and stained with primary antibodies overnight at 4°C. AP-3δ was
probed with the mouse SA4 antibody (DSHB) and APP was probed with the rabbit APP Cterminal (Sigma). Cells were washed and incubated with species-specific secondary antibodies,
with covalently attached single-stranded oligonucleotides. When antibodies are within 40nm, the
oligonucleotides are ligated and amplified. These are then detected by fluorescent
oligonucleotides.
Z-stacks were captured by confocal microscopy and the number of dots per cell was normalized
to cell volume. The results were graphed using Prism and one-way ANOVA was performed with
a Tukey’s post hoc test. P-values less than 0.05 were significant.

3.2.8

Internalization Assay

APP internalization was studied as preciously described [9,10]. Briefly, anti-HA antibody was
labeled using a Zenon 647 labeling kit (Invitrogen), as per manufacturer’s instructions. Cells
were washed with PBS and labeled with the antibody conjugate for 30 minutes on ice to tag cellsurface βAPP-CFP. The cells washed with PBS and the cells were incubated in pre-warmed
HBSS at 37°C and moved to an incubator at 37°C with 5% CO2 for 15 minutes. After 15
minutes, cells were fixed with 4% PFA, and imaged using confocal microscopy.
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3.2.9

Aβ40 and Aβ42 ELISA

SN56 cells were transfected with βAPPsw-paGFP (βAPP bearing the Swedish mutation),
βAPPsw S711A-paGFP, or βAPPsw S711E-paGFP. One set of cells transfected with βAPPswpaGFP and treated with DCP-LA. Cells were differentiated as described above and cell culture
media was collected two days after differentiation. Cell culture media was centrifuged at 200
RPM for 10 minutes at 4°C to remove large cellular debris and detached cells. Aβ40 and Aβ42
were detected with the Aβ40 ELISA Kit (KHB3482) or Aβ42 Ultrasensitive ELISA Kit
(KHB3544) from Life Technologies, according to manufacturer’s instructions.
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3.3
3.3.1

Results
Tyrosine Motifs and the Intracellular trafficking of APP

We have previously followed the intracellular trafficking of βAPP-paGFP from the Golgi
apparatus [20]. This shortened construct consists of the last 112 amino acids of APP; including
the β–cleavage site. We use a shortened construct to avoid the possibility that trafficking might
be altered by currently undefined luminal sequences on APP [30]. In our previous experiments
we demonstrated that the shortened βAPP-paGFP construct has the same trafficking pattern as
full-length APP-paGFP [9,20]. Furthermore, the shortened construct also undergoes β- and γcleavage [20]. The shorter construct was used for these experiments because they are more easily
expressed, which results in a stronger and more easily detectable fluorescence signal. The photoactivatable GFP (paGFP) is a form of GFP with low fluorescence after synthesis, but develops
green fluorescence after irradiation with 405 nm light [18,19]. Using the βAPP-paGFP chimera
we have previously demonstrated a direct trafficking pathway from the Golgi apparatus to the
lysosome [20].
We had previously demonstrated that the trafficking of APP from the Golgi to lysosomes is
dependent on an interaction between APP and AP-3. The interaction of AP-3 to cargo depends
on cytosolic tyrosine motifs of the form YXXƟ [21]. To determine the effect of tyrosine
mutations on intracellular APP trafficking, we introduced Y709A, Y738A, and Y743A mutations
into βAPP-paGFP (see Figure 3.1a). βAPP-paGFP was transfected into SN56 cells along with
the Golgi apparatus marker (Galactosyltransferase-CFP, GalT-CFP) and a marker of lysosomes
(lysosome associated membrane protein 1, LAMP1-mRFP) or early endosomes (Rab5-mRFP).
After differentiation, cells were transferred to a heated stage (set at 37 °C) on a Zeiss LSM510
confocal microscope. Regions of interest (ROI) were then drawn on the Golgi apparatus using
the GalT-CFP fluorescence as a target. Each imaging cycle consists of a brief irradiation of these
the ROI with 405nm laser light at full power (25 mW for 20 iterations per imaging cycle) (for a
demonstration of this technique, see videos at the Journal of Visual experimentation
http://www.jove.com/video/53153/imaging-the-intracellular-trafficking-of-app-with-
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photoactivatable-gfp [29]), followed by imaging of the cell. These cycles were repeated over a
15-minute period (See Video 3.1). In each imaging cycle, a small amount of APP-GFP was
activated in the Golgi apparatus and could then be seem as it traffics. The final images in these
time courses are shown in Figure 3.1b and 3.1c. Using Imaris software, we set thresholds to
delimit green fluorescence (photo-activated βAPP-paGFP) and red fluorescence (compartment
markers) to generate a colocalization channel (Figure 3.1 b and c bottom panels). We then
quantitated the amount of green fluorescence co-localized with the red signal (lysosomes or early
endosomes) (Figure 3.1d).
In these experiments, WT βAPP rapidly appeared in LAMP1-mRFP labeled compartments (30 ±
5% SEM, n= 5 independent experiments, 23 cells total) (Figure 3.1b and Video 3.1). In our
previous paper, we demonstrated that this transport was abolished by nocadazole and was
therefore dependent upon microtubule-related active transport and did not occur through
diffusion or accidental irradiation of endosomes or lysosomes [20,29]. It is important to note that
the resolution limit of confocal microscopy does not allow us to visualize the small trafficking
vesicles emanating from the Golgi. In contrast, the Y709A and Y743A mutations caused a
significant decrease (p<0.05, two-way ANOVA; Bonferroni post hoc) in βAPP-paGFP colocalization with LAMP1-mRFP after 15 minutes (11 ± 4% SEM, n=5 independent experiments,
21 cells total, and 12 ± 1% SEM, n=3 independent experiments 10 cells total, respectively)
(Figure 3.1b and Video 3.2 and 3.4, respectively). The Y738A mutation did not significantly
reduce trafficking to lysosomes as compared to WT βAPP (p>0.05, n= 4 independent
experiments, 11 cells total) (Figure 3.1b, d and Video 3.3).
We also analyzed cells transfected with Rab5 to determine whether tyrosine mutations shift APP
into earlier compartments in the endosomal/lysosomal pathway. In these experiments, relatively
small amounts of wild type βAPP trafficked to early endosomes (9 ± 2% SEM, n=5 independent
experiments, 16 cells total) (Figure 3.1c). In contrast, the Y709A and Y743A significantly
increased trafficking to the early endosome, (25 ± 3% SEM, n=4 independent experiments 16
cells total, and 29 ± 7% SEM, n=3 independent experiments 11 cells total), while the Y738A
mutation did not (21± 4% SEM, n = 4 independent experiments 16 cells total, Figure 3.1c and d)
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(p<0.05, two way ANOVA; Bonferroni post hoc). Therefore, the Y709A and Y743A both reduce
the intracellular trafficking of APP to lysosomes.
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Figure 3.1: Tyrosine mutations modulate the intracellular trafficking of APP.
a) Depiction of the carboxyl terminal of APP, with APP 751 numbering. The tyrosines and
serines studied in this paper are shown, and the tyrosine motifs underlined. SN56 cells were
transiently transfected with wild type APP or APP with mutations Y709A, Y738A, or Y743A
tagged with paGFP. Each cell was subjected to 15-minutes of sequential imaging. Before each
image, the cell was photo-activated within the Golgi (blue). b) Trafficking of APP to lysosomes
(LAMP-1) and c) early endosomes (Rab5) was studied. The top panels show representative
images from each cell after 15 minutes of photo-activation (Scale bars represent 5μm). The
bottom panels depict colocalized pixels. The white border demarcates the edge of the cell and
was drawn based on the white light images. Triangles point to colocalized pixels. d) Using a
semi-automated method, the APP vesicles and LAMP1 or Rab5 vesicles were selected and the
means were plotted using Prism 5.0b. Error bars represent SEM (*=p<0.05).
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3.3.2

Amyloid Precursor Protein Internalization

Mutagenesis of tyrosine-based trafficking motifs has been shown to alter the endocytosis of APP
[6,8,31]. We have shown that APP can be internalized into lysosomes by two pathways, one by
way of early endosomes and a second pathway directly from the cell surface [9,10] . To
determine if internalization into early endosomes was affected by mutations in C-terminal
tyrosines, SN56 cells were transfected with βAPP-CFP constructs and Rab5-mRFP. Our βAPPCFP constructs are tagged on the N-terminal with a HA epitope to facilitate internalization
experiments. βAPP-CFP was surface-labelled on ice with a Zenon-647 anti-HA antibody
conjugate. After a 15-minute internalization at 37 °C, 28 ± 2 % (SEM; n=5 independent
experiments, 73 cells total) of wild type βAPP-CFP was internalized into Rab5 positive
endosomes (Figure 3.2a). The Y709A mutation did not significantly affect the internalization of
βAPP into early endosomes (23 ± 2 % SEM, n=5 independent experiments, 55 cells total)
(Figure 3.2b, e). However, the Y738A and Y743A mutations significantly reduced the
internalization of βAPP into early endosomes (19 ± 1% SEM, n=5 independent experiments, 62
cells total and 14 ± 2% SEM, n=4 independent experiments, 53 total cells, respectively, p>0.05)
(Figure3. 2c, e) [10].
To follow the direct trafficking of APP to lysosomes, SN56 cells were transfected with βAPP
and LAMP1-mRFP, surface-labeled on ice with a fluorescent HA-antibody conjugate. This was
followed by a 15-minute internalization period at 37 °C before fixation. In cells expressing wild
type βAPP, 21 ± 1% SEM (n=5 independent experiments, 83 cells total) of βAPP was
internalized into LAMP1 labeled vesicles (Figure 3.3a and e). The Y709A and Y738 mutations
did not significantly change the internalization of βAPP into lysosomes (p>0.05, 19 ± 1% SEM,
n=5 independent experiments 70 cells total, and 23 ± 2% SEM, n n=7 independent experiments
95 cells total, respectively) (Figure 3.3b, c, and e). However, the Y743A mutation reduced
internalization to 12 ± 1% SEM (p<0.05, n=6 independent experiments 78 total cells) (Figure
3.3d and e). Therefore, the Y743A mutation disrupts βAPP internalization to both Rab5 and
LAMP1 compartments, while the Y709A mutation has no affect on internalization.
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Figure 3.2: Tyrosine disrupts internalization into early endosomes.
SN56 cells were transfected with βAPP-CFP (with or without tyrosine mutations) and Rab5mRFP. The HA-tag on our βAPP-CFP construct was fluorescently labeled using an anti HAZenon conjugate. a-d) Representative images of βAPP-CFP, bearing one of the tyrosine
mutations, internalized into Rab5-mRFP compartments after 15-minutes. The edge of the cell is
shown by the white border, and was drawn based on white-light images. Triangles point to
colocalized pixels. Scale bars represent 5μm. e) The percentage of APP co-localized with Rab5
was quantified using Imaris and graphed (*=p<0.05, error bars represent SEM).
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Figure 3.3: Y743A disrupts internalization into lysosomes.
SN56 cells were transfected with βAPP-CFP (with or without tyrosine mutations) and Lamp1mRFP. The HA-tag was fluorescently labeled using the anti HA-Zenon conjugate. The cells were
incubated at 37°C for 15 minutes and fixed and imaged. a-d) Representative images of βAPPCFP, bearing one of the tyrosine mutations, internalized into LAMP1-mRFP compartments after
15-minutes. The edge of the cell is shown by the white border, and was drawn based on whitelight images. Triangles point to colocalized pixels. Scale bars represent 5μm. e) APP colocalized with Lamp1 was quantified using Imaris and graphed (*=p<0.05, error bars represent
SEM).
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3.3.3

Amyloid Precursor Protein and AP-3 Interaction

Previously, we demonstrated that rapid trafficking of APP to lysosomes is dependent on APP
interaction with AP-3 [20]. To determine the tyrosine motif responsible for the APP/AP-3
interaction, we performed an in situ proximity ligation (iPLA) assay with βAPP-CFP bearing one
of the cytoplasmic tyrosine mutations. Briefly, if the proteins of interest are within 40 nm of each
other, antibody-conjugated single-stranded oligonucleotides anneal and can undergo rolling
circle amplification. The amplification product is detected by hybridization with fluorescent
oligonucleotides, which can be visualized by confocal microscopy. iPLA has been used to
confirm protein-protein interactions in situ, including weak or transient interactions that are
undetectable by co-immunoprecipitation [32-34].
SN56 cells were transfected with βAPP-CFP with or without tyrosine mutations and iPLA was
performed after fixation. A 3D-stack of images of each cell was acquired by confocal
microscopy. The βAPP-CFP /AP-3 interaction was quantified by counting the number of spots
per μm3. In cells transfected with WT βAPP-CFP, cells had 0.037 ± 0.006 dots/μm3 SEM (n=3
independent experiments, 28 cells total). The Y738A and Y743A mutations did not significantly
alter βAPP-CFP interaction with AP-3 (0.03 ± 0.004 dots/μm3 SEM n=3 independent
experiments, 36 cells total and 0.03 ± 0.007 dots/μm3 SEM n=3 independent experiments, 32
cells total, respectively) (Figure 3.4a and b). However, the Y709A mutation significantly
decreased the interaction of βAPP-CFP with AP-3 (0.02 ± 0.004 dots/μm3 SEM, n=3
independent experiments, 40 cells total) (Figure 3.4a and b). Therefore, it appears that the
Y709A mutation disrupts the interaction of APP with AP-3 to prevent APP delivery to
lysosomes.
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Figure 3.4: Tyrosine motif mutations affect on APP/AP-3 interaction.
SN56 cells were transfected with plasmids expressing wild type APP or APP with mutations
Y709A, Y738A, or Y743A. Cells were fixed and iPLA was performed to detect interaction
between APP with AP-3δ. a) Representative images are shown. The white border shows edge of
the cell and was drawn based on the white light images. Scale bars represent 5μm. b) The dots
per cell was counted using Imaris, normalized to cell volume, and graphed in Prism 5.0b
(p<0.05). SN56 cells were transfected with plasmids expressing wild type APP or APP bearing
phosphomimetic (S711E) or dephosphomimetic (S711A) mutations. Cells were fixed and iPLA
was performed to determine if there was an interaction between APP and AP-3. c)
Representative images of APP/AP-3δ interaction. The white border shows edge of the cell and
was drawn based on the white light images. Scale bars represent 5μm. d) The number of spots
per cell was counted and normalized to cell volume. Error bars represent SEM and *= p<0.05.
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3.3.4

Pseudo-phosphorylation of Serine 711

The 709YTSI712 motif is involved in APP endocytosis, basolateral (intracellular) sorting, and cell
surface delivery [6,23,35,36]. In the YTSI motif, the tyrosine and serine have been found to be
phosphorylated in the brains of AD patients [27,37]. While the effect of Y709 phosphorylation
on APP trafficking is unclear, S711 phosphorylation has recently been shown to regulate the
intracellular trafficking of APP [38]. Pseudo-phosphorylation of the S711 residue of APP was
shown to increase APP retrieval to the Golgi from the endosomal system and increased nonamyloidogenic processing of APP [38,39]. Furthermore, The S711 residue is the only residue in
the APP C-terminus that can be phosphorylated by PKC [27,28]. To test if S711 phosphorylation
affects the interaction of APP with AP-3, we introduced dephosphomimetic (S711A) and
phosphomimetic (S711E) mutations to the βAPP-CFP construct to determine their effect using
iPLA. We show that βAPP S711E-CFP interacted poorly with AP-3 (0.02 ± 0.004 dots/μm3
SEM, n=4 independent experiments, 46 cells total), as compared to WT βAPP-CFP (0.05 ±
0.004 dots/μm3 SEM, n=4 independent experiments, 51 cells total) (Figure 3.4c and d). The
dephosphomimetic (S711A) mutation did not significantly alter the interaction of βAPP with
AP-3 (Figure 3.4c and d, n= 3 independent experiments, 34 cells total). Therefore, pseudophosphorylation of βAPP, at S711, disrupts its interaction with AP-3.
To determine the effect of these phosphomimetic mutations on βAPP trafficking to lysosomes,
we introduced the S711A and S711E mutations into our βAPP-paGFP construct. We photoactivated βAPP-paGFP in the Golgi and followed its transport into downstream compartments.
The S711A mutation did not significantly disrupt βAPP trafficking to lysosomes, as compared to
WT βAPP-paGFP (one-way ANOVA, n= p>0.05) (25 ± 4% SEM n= 4 independent experiments,
13 cells total compared to 30 ± 4% SEM, n=5 independent experiments, 23 cells total) (Figure
3.5a and c and Video 3.5). However, the S711E mutation, which disrupts βAPP interaction with
AP-3, also significantly decreased the amount of βAPP trafficked to LAMP1 compartments (17
± 3% SEM, n=4 independent experiments, 17 cells total), as compared to WT APP (Figure 3.5a
and c and Video 3.6). To determine if S711 mutations disrupts trafficking to early endosomes,
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we repeated the intracellular trafficking experiments with Rab5-mRFP, a marker for early
endosomes. In these experiment, there was no significant difference in the amount of βAPP
delivered to early endosomes with both mutations (Figure 3.5b and c). Therefore,
phosphorylation of S711 impedes βAPP delivery to lysosomes likely through disrupting the
βAPP/AP-3 interaction.

3.3.5

PKC Activation Controls Intracellular Trafficking of APP

S711 residue can be phosphorylated by PKC [27,28]. PKC agonists are known to increase the
non-amyloidogenic processing of APP by increasing α-secretase cleavage of APP [40,41]. S711
phosphorylation has also been reported to increase the interaction of APP with members of the
retromer complex, and to divert APP from the lysosome to the Golgi [38]. Phosphorylation of
S711 has also been suggested to increase the secretory trafficking from the Golgi [39].
Therefore, we asked whether S711 phosphorylation could disrupt Golgi to lysosome transport,
through disrupting the APP and AP-3 interaction.
To examine the effects of PKC activation on βAPP trafficking, SN56 cells were transfected with
βAPP-paGFP, GalT-CFP, and a marker for the endosomes or lysosomes. After a one-hour
incubation with 300nM the PKC activator Phorbol-12-myristate-13-acetate (PMA), APP was
photo-activated in the Golgi apparatus to follow the transport of APP to downstream
compartments (Figure 3.6a). In untreated cells, 30 ± 4% SEM (n=5 independent experiments, 23
cells total) of nascent βAPP-paGFP is delivered to lysosomes. However, cells treated with
300nM PMA traffic 18 ± 3% SEM (n=4 independent experiments, 10 cells total) of APP to
lysosomes (one-way ANOVA, Bonferroni post hoc, p<0.05) (Figure 3.6c). Consistent with
phosphomimetic mutations to the YTSI motif, PMA treatment significantly increased the amount
of βAPP-paGFP directed towards Rab5 (early endosome) labeled compartments (WT= 9 ± 2%
SEM, n=5 independent experiments, 16 cells total vs. PMA treated 26 ± 6% SEM, n=5
independent experiments, 16 cells total) (Figure 3.6b and c).
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Figure 3.5: S711E disrupts trafficking to lysosomes.
SN56 cells were transfected with plasmids expressing wild type APP, S711E, or S711A.
Concomitantly, plasmids expressing LAMP1-mRFP or Rab5-mRFP and GalT-CFP were also
transfected. a) Representative images depicting trafficking of APP S711A or S711E to
lysosomes (LAMP1-mRFP) after photo-activation in GalT-CFP labeled compartments. b)
Representative images showing the delivery of APP S711A or S711E to early endosomes after
photo-activation. The edge of the cell is defined by the white line, and was drawn based on the
white light images. Scale bars represent 5μm. Triangles with circles denote photo-activation sites
at time 0. Triangles alone point to colocalized pixels. c) The percentage of APP colocalized with
either LAMP1 or Rab5 was quantified with Imaris. Error bars denote SEM. *=p<0.05.
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Figure 3.6: PMA treatment alters the intracellular trafficking of APP.
SN56 cells transiently transfected with βAPP-paGFP were treated or not treated with 300nM
PMA for 1-hour before imaging. Cells were photo-activated in the Golgi (GalT-CFP) for 15
minutes. Video of the live cells was taken during this 15-minute period to follow the trafficking
of APP. Frames from the beginning and the end of the time course are shown here for transport
to a) lysosomes (LAMP1) and b) early endosomes (Rab5). Far-right panels show colocalized
pixels between the βAPP-paGFP and LAMP1-mRFP channels. The edge of the cell is defined by
the white line, and was drawn based on the white light images. Triangles alone point to
colocalized pixels. Scale bars represent 5μm. c) The amount of APP colocalized with each
compartment was quantified using Imaris at the 15-minute time point, and the results were
plotted using Prism 5.0b. Error bars represent SEM and * denotes p<0.05.
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We also examined staurosporine treatment to inhibit PKC activity before PMA treatment.
Staurosporine (1μM) pre-treatment restored the trafficking of APP to lysosomes (35 ± 6% SEM,
n=4 independent experiments, 12 cells total) (Figure 3.7a and b). Importantly, staurosporine
treatment alone did not disrupt the trafficking of APP (31 ± 5% SEM, n=4 independent
experiments, 11 cells total). Therefore, activation of PKC diverts APP away from lysosomes and
towards early endosomes.
PMA and other phorbol esters activate PKCs through binding to the diacylglycerol (DAG)
binding site on PKC, and can activate conventional (α, βI, βII, and γ) and novel PKCs (δ, ε, η, and
θ). PKCα and PKCε have both been suggested to regulate APP metabolism [42-45]. To
specifically examine PKCα and other conventional PKC’s, we pretreated the cells with Gö6976
(inhibitor of conventional PKCs (PKC, βI, βII, and γ). Transfected SN56 cells were pretreated
with Gö6976 before stimulation with PMA. In these experiments, Gö6976 pretreatment was
unable block the effects of PMA (reducing βAPP-paGFP delivery to lysosome; Gö6976 and
PMA 18 ± 4% SEM n= 3 independent experiements 10 cells total vs. PMA only 18 ± 3% SEM
n=4 independent experiments 10 cells total) (Figure 3.7a and b). This suggests that conventional
PKCs are not major contributors in the diverting APP away from lysosomes.
Therefore, we turned our attention to the novel PKC family. However, we could not find a
specific inhibitor the nPKCs. Instead, we turned to a specific agonist for nPKCε. Previous studies
have suggested that PKCε promotes non-amyloidogenic cleavage of APP [44-46]. Recently, 8[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) was found to specifically
activate PKCε over other isoforms of PKC [47]. In fact, 500nM DCP-LA has previously been
shown to strongly and specifically activate PKCε and decrease Aβ production in SH-SY5Y cells
[46]. We treated our transfected SN56 cells with 500nM DCP-LA, to determine if DCP-LA
mediated activation of PKCε could regulate the trafficking of APP. DCP-LA significantly
reduced targeting of βAPP-paGFP to lysosomes (13 ± 3% SEM, n=4 independent experiments,
15 cells total), which was not significantly different from cells treated with PMA (p>0.05)
(Figure 3.8a and c, Video 3.7). In addition, treatment of SN56 cells with DCP-LA increased

191

delivery of APP to early endosomes, as seen with PMA treatment (Figure 3.8b and c) (WT= 9 ±
2% SEM vs. DCP-LA treated 30 ± 2% SEM n=4 independent experiments, 12 cells total).
Moreover, pretreatment of transfected cells with staurosporine abrogated the effect of DCP-LA
on trafficking of βAPP-paGFP to lysosomes (32 ± 2% SEM, n=3 independent experiments, 9
cells total). However, pretreatment with Gö6976 (13 ± 3% SEM, n=4 independent experiments,
10 cells total) (Figure 3.8d and e) could not abolish the effects of DCP-LA treatment. These data
suggests that the trafficking of APP away from lysosomes and towards early endosomes is
regulated by PKCε.
PKCε activation by DCP-LA can decrease Aβ production and reduce amyloid deposition in mice
[44,46]. To determine if we could recapitulate these results, we transfected cells with βAPPpaGFP bearing the Swedish familial mutation (βAPPsw-paGFP) and treated the cells with DCPLA. Cells were also transfected with either βAPPsw-paGFP YTAI or βAPPsw-paGFP YTEI to
determine if psuedophosphorylation at S711 could modulate Aβ production. Cell-culture media
was gathered from three independent experiments and analyzed by ELISA for Aβ 40 or 42. Aβ
42 production was not significantly reduced by transfection with APP bearing the YTAI
mutation. However, transfection of APP bearing the YTEI mutation or treatment with DCP-LA
significantly decreased Aβ 42 by ~30% (Figure 3.8f). Therefore, it appears that phosphorylation
of APP at S711 decreases the production of Aβ 42 by reducing lysosomal trafficking of APP.
There was no significant change in Aβ40 secreted into culture media.
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Figure 3.7: Staurosporine but not Gö6976 treatment restores trafficking of APP to lysosomes.
SN56 cells were pretreated for 1 hour with staurosporine or Gö6976 for 1 hour before treatment
with PMA. Cells were imaged as previously stated. Depicted in a) are representative images of
cells treated with PMA, with or without the indicated inhibitors. These images were taken from
live cell video of photo-activated cells 15 minutes after the start of imaging. Far-right panels
show colocalized pixels between the βAPP-paGFP and LAMP1-mRFP channels. The edge of the
cell is defined by the white line, and was drawn based on the white light images. Triangles point
to colocalized pixels. Scale bars represent 5μm. b) The amount of APP colocalized with LAMPmRFP was quantified using Imaris and plotted using Prism. Error bars represent SEM and *
denotes p<0.05 as compared to untreated cells and cells treated with staurosporine and PMA.
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Figure 3.8: DCP-LA treatment of SN56 cells diverts APP into early endosome compartments.
Cells were transfected with βAPP-paGFP, GalT-CFP, and a) LAMP1-mRFP or b) Rab5-mRFP.
Cells were pre-treated with DCP-LA for one hour before imaging, and photo-activated within the
Golgi. Far-right panels show colocalized pixels between the βAPP-paGFP and LAMP1-mRFP
channels. The edge of the cell is defined by the white line, and was drawn based on the white
light images. Triangles point to colocalized pixels. Scale bars represent 5μm. c) The amount of
APP colocalized with each compartment, with or without DCP-LA treatement, was measured
using Imaris and was plotted using Prism 5.0b. d) SN56 cells were treated with 1μM
staurosproine or 1μM Gö6976 before treatment with DCP-LA. The amount of APP colocalized
with LAMP1 was measured using Imaris and plotted using Prism 5.0b. * denotes p<0.05 as
compared to untreated. Representative images from the end of the photo-activation period are
shown in e). Images in the far-right panel show colocalized pixels between the LAMP1-mrFP
and βAPP-paGFP channels. Triangles point to colocalized pixels. Scale bars represent 5μm. f)
SN56 cells were transfected with βAPPsw-paGFP and treated with DMSO or DCP-LA. Two
other wells of cells were transfected with βAPPsw-paGFP containing either the YTEI and YTAI
mutation. The media was collected from the cells and used ELISA to analyze the amount of
Aβ42. Error bars in both graphs represent SEM. * denotes p<0.05 as compared to DMSO treated
cells.
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3.4

Discussion

In our previous study, we showed that siRNA-mediated knockdown of AP-3 can disrupt the
trafficking of APP to lysosomes [20]. In the present study, the Y709A decreased intracellular
trafficking to the lysosome while theY743A mutations significantly decreased the fraction of
APP delivered to lysosomes from the cell surface and by intracellular trafficking (Figure 3.1 and
Figure 3.3). The YTSI motif was critical for APP and AP-3 interaction (Figure 3.4), and
phosphorylating the serine residue in this motif reduced intracellular trafficking of APP to
lysosomes and reduced A42 production (Figure 3.5-3.8).
The YTSI motif is a canonical YXXθ motif. These motifs have roles in endocytosis, lysosomal
sorting, basolateral sorting, and retrograde sorting to the Golgi [21]. The YTSI motif has been
shown to regulate the endocytosis of a APP- transferrin receptor chimera [6]. However,
internalization experiments with APP show that the Y709A mutation to APP did not disrupt
endocytosis [8 and Figure 3.2]. The YTSI motif can also interact with AP-1 to sort APP to the
basolateral membrane [23].
Interestingly, recent studies have shown that the YTSI motif of APP can also regulate the transit
of APP through the Golgi [38,39]. Using a pseudophosphorylation strategy, similar to the one
used here, a phosphomimetic (S711E) increased the retrograde trafficking of APP to the TGN,
and decreases the trafficking of APP lysosomes. Conversely, a dephosphomimetic mutant
decreased retrograde trafficking to the TGN and increases trafficking of APP to lysosomes. The
enhanced retrograde trafficking of APP to the TGN was mediated by an enhanced interaction
between APP and VPS-35 (a member of the retromer protein trafficking complex) [48,49],
reducing APP delivery to lysosomes. Our findings concur with this data, in that
pseudophosphorylation of the serine disrupts the interaction of APP and AP-3 and lowers the
amount of APP trafficked to lysosomes (Figure 3.4 and 3.5). These findings suggest that
phosphorylation of APP at S711 enhances the interaction of APP with the retromer complex [38]
and destabilize its interaction with AP-3.
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Phorbol ester stimulation of PKC is well known to increase the secretion of the APP N-terminal
domain and decrease the production of Aβ [42,43,45,46,50]. Both PKCα and PKCε have been
implicated in regulating the metabolism of APP [43,46,51,52]. In agreement with these findings,
PMA or DCP-LA treatment reduced lysosomal trafficking seen with the phosphomimetic S711E
(Figure 3.6 and 3.8). Gö6976, an inhibitor of conventional PKCs, did not reduce lysosomal
targeting (Figure 3.7). While there was no specific pharmacological inhibitor of PKCε, a specific
agonist of PKCε (DCP-LA) also diverted APP trafficking away from lysosomes (Figure 3.8).
Furthermore, DCP-LA treatment or the phosphomimetic YTEI lowered the production of Aβ42,
suggesting a shift to non-amyloidogenic processing of APP (Figure 3.8f). Previous literature
suggests PKCε, an novel PKC, promotes non-amyloidogenic cleavage of APP [44-46]. DCP-LA
also decreased Aβ secreted in cell culture [46], and reduce the plaque burden in transgenic mouse
models of APP [44]. Furthermore, in AD patients, PKCε protein levels were decreased
fibroblasts and neurons [53].
While we show here that phosphorylation of S711 may control intracellular lysosomal
trafficking, it does not explain all of the observed behaviors related to PKC activation.
Specifically, the phosphomimetic did not increase APP trafficking to early endosomes, as seen
with PMA and DCP-LA treatments, which suggests other targets of PKCε are also involved in
APP sorting. PKC is known to regulate other steps in protein trafficking and proteolysis. PKC
can also phosphorylate AP-2 in the μ2 domain and regulate the endocytosis of NA+/K+ ATPase
[54].
PKCε, in particular, may also regulate secretory activity from the Golgi after being recruited to
the Golgi apparatus [55]. In addition to regulation of Golgi export to the secretory pathway,
PKCε also regulates the recycling of β1-integrins by phosphorylating vimentin (an integral part
of intermediate filaments) [56,57]. While the data presented here suggest a role for APP
phosphorylation in lysosomal trafficking and non-amyloidogenic metabolism, PKCs can interact
with a large number of proteins; so many other regulatory events might be participating. For
example, PKCs may influence the distribution of ADAM-10; a putative α-secretase [58] and are
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proposed to regulate proteolytic processing by secretase enzymes directly. ADAM 10 and 17
[59,60].
Although the alteration of APP processing by PKC has long been recognized, the effects of PKC
on the intracellular trafficking of APP are less well understood. Before the advent of photoactivatable fluorescent proteins, the intracellular trafficking of APP, of any protein, was very
difficult to visualize. Here, using paGFP that APP can transit directly from the Golgi directly to
to lysosomes. Furthermore we showing that PKC redirects APP from this novel pathway
away from the lysosome and reduces A42 production. This is the mirror image of retromer
dysfunction in AD, which is proposed to increased APP levels in the endosomal/lysosomal
pathway and increased A production [61]. These experiments demonstrate that this novel
direct-to lysosome pathway can be regulated pharmacologically and that reducing APP transit to
the lysosome is a strategy to lower A production.
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Chapter 4

4

Lysosomal secretion of beta-amyloid in neuronal cells

One of the hallmarks of Alzheimer's disease is the presence of amyloid plaques in the brain. The
major constituent of these plaques is -amyloid (A). A is known to bind to receptors on the
cell surface and mediate many of its cytotoxic effects. Work from our lab and others suggest that
A is produced through amyloidogenic cleavage in the endosomal/lysosomal system. However,
the mechanism behind the secretion of A, from intracellular stores, into the extracellular space
is unknown. Lysosomes are known to undergo exocytosis in a number of cell types, including
neurons. Therefore, lysosomes may serve to produce and secrete A into the extracellular space.
Here, using total internal reflection fluorescence microscopy (TIR-FM), we show that a
population of lysosomes are localized to the cell surface and can undergo exocytosis in SN56
cells. Furthermore, we show that SN56 cells transfected with mutants of Rab27b can decrease
the number of lysosomes at the cell surface and decrease lysosomal exocytosis. Furthermore,
these mutants can also decrease the amount of A secreted into the cell culture media. Taken
together, these data suggest that lysosomal exocytosis is capable of A secretion, and may prove
to be an important therapeutic target for limiting the effect of extracellular A aggregates.

4.1 Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disease in adults. The
Amyloid Hypothesis states that the β–amyloid (Aβ) production is a critical early event in the
pathogenesis of AD. In fact, amyloid deposition is required for a neuropathological diagnosis of
AD. Although Aβ was identified more that 30 years ago, there is no consensus as to how it is
secreted [1]. While it is widely accepted that neuronal activity results in Amyloid secretion, to
date A is not found in synaptic vesicles [2]. Although full-length APP and BACE are present in
synaptic vesicles, only APP was demonstrated to be secreted from synaptic vesicles [3]. A has
been shown to be secreted in exosomes (intraluminal vesicles from the endosomal/lysosomal
system) suggesting that these compartments might be responsible for Asecretion [3,4].
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Aβ is produced by the sequential cleavage of APP by β and γ-secretase. β-secretase cleaves APP
in ectodomain and leaves a 99-residue carboxy-terminal fragment, which is a substrate for γsecretase. Work in our lab has shown that γ-secretase protein complex is present in lysosomes
and γ-secretase’s catalytic activity functions at an acidic optimal pH [5]. Alkalization lysosomal
pH also lowers Aβ production [6]. Acidic environments, similar to those in lysosomes, have been
shown to promote Aβ aggregation [7]. In addition, disruption of APP trafficking to lysosomes
has been shown to decrease Aβ production [8-11]. The lysosomes promote formation of amyloid
seeds that promote Aβ aggregation [12], and many have proposed the lysosome as an important
early site of aggregation [13-16]. This evidence suggests that the lysosome might be a source of
secreted A.
Although lysosomes are widely viewed as digestive organelles, modified lysosomes (lysosomerelated organelles, LROs) are responsible for secretion in many cell types. LROs share a number
similarities with lysosomes (organelle markers, low pH, hydrolases), but have cell-type specific
tasks that allow them to perform varied tasks, such as skin pigmentation and clotting [reviewed
in 17,18]. For example many dedicated-secretory cells (natural killer cells, melanocytes,
lymphocytes, platelets) use secretory LROs as important secretory granules (lytic granules,
melanosomes, azurophillic granules, platelet-dense granules) [17-30]. More recently, studies in
cells that are not dedicated secretory cells have also demonstrated the use of lysosomal secretion,
the secretion of conventional lysosomes can also be used for resealing damage to the plasma
membrane damage [31].
Although secretory lysosomes have been documented in many cell types, there have been few
reports of lysosomes playing a secretory role in neuronal cells [32,33]. Here we show, by TIRF
microscopy, that a population of lysosomes sits docked on the plasma membrane in neuronal
cells and primary mouse neurons are able to fuse with the plasma membrane following
stimulation. Furthermore, lysosomes accumulated amyloid and are able to secrete endogenous
Aβ into the extracellular space in a Rab27 dependent manner.
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4.2
4.2.1

Materials and Methods
Antibodies and Chemicals

Antibodies used were Mouse Anti-HA (Sigma, H9658), rabbit anti-LAMP1 (Sigma, L1418), rat
anti-LAMP1 1D4B, APP C-terminal (Sigma, A8717), and anti-Aβ (MOAB-2, Novus
Biologicals, Cat. # NBP2-13075). HiLyte Fluor 488 Aβ42 (Aβ42-488) was purchased from
Anaspec (Cat. # AS-60479-01). Bafilomycin was purchased from Calbiochem (CAS 88899-552).

4.2.2

Cell Culture

SN56 cells were maintained in Dulbecco’s minimal Eagle’s medium (DMEM, Invitrogen) with
10% fetal bovine serum (FBS) and 50ug/ml of penicillin/streptomycin. Cells were incubated in
an incubator at 37°C with 5% CO2. SN56 cells were split every 3-4 days at approximately 90%
confluence. To plate cells for imaging, SN56 cells were plated on glass bottom confocal plates
one day before transfection. Transfections were performed using Lipofectamine 2000 according
to manufacturer’s instructions. In order to differentiate SN56 cells, transfection media was
switched to DMEM with 1mM dibutyrl cyclic AMP (dbcAMP; Sigma) 24 hours after
transfection. Cells were differentiated for one day and imaged or fixed and stained for imaging.

4.2.3

Plasmid Constructs

Rab5-mRFP, LAMP1-mRFP, and βAPP-CFP with the Swedish mutation have been described
previously [9]. The design and use of the CatD-mChFP plasmid have been been previously
described [34,35]. mApple-LAMP1-phLuorin was a kind gift of Michael Davidson (Addgene
plasmid # 54918). A construct encoding TIVAMP7 coupled to pHluorin was a gift from Dr.
Thierry Gali. Rab27bWT-GFP was a kind gift from Gottfried Mieskes [36]. The Rab27b GFPtagged mutants were obtained from Reinhard Jan [37].

4.2.4

Confocal Microscopy

Confocal microscopy images were obtained with a Zeiss LSM-510 META laser-scanning
microscope using a Zeiss 63x 1.4 numerical aperture oil immersion lens (Carl Zeiss, Germany).
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The thickness of the optical section was set to 1 μm. To visualize Cyan fluorescent protein
(CFP), CFP was excited with a 458 nm laser and filtered with a BP 475-525 filter set. pHluorin
fluorescence was filtered a band pass (BP) 500-530-nm emission filter set after excitation with a
488 nm. mCherry and mRFP fluorescence were excited with a 543 nm laser and filtered with a
BP 560–615nm of LP 560nm filter set. For fixed cells, the culture media was removed and cells
were washed with PBS before being fixed with 4% paraformaldehyde. When staining with 1D4B
for LAMP1 cells were permeabilized with 0.1% Triton in PBS. Non-specific binding was
blocked with 2% BSA and stained for LAMP1. The rabbit-anti LAMP1 antibody required
permeabilization with 1% saponin in 1% BSA in HBSS. Cells were stained with the rabbit-anti
LAMP1 antibody after permeabilization.
For live cell imaging, SN56 cells were washed and were switched to pre-warmed to 37°C
HBSS. Cells were kept at 37°C using a heated microscopy stage (PeCon GmbH) connected to a
Tempcontrol 37-2 digital 2-channel (PeCon GmbH). To prevent reacidification, lysosomes were
treated with 1μM of bafilomycin for 20 minutes. Lysosomal exocytosis was stimulated with 5μM
of ionomycin. A time course was set to capture an image every minute to follow lysosomal
exocytosis, as denoted by increased TIVAMP-pHluorin fluorescence.
To semi-quantitatively measure the amount of exocytosis after transfection with the
Rab27b-GFP constructs, cells were treated with 5μM ionomycin for five minutes and
immediately placed on ice. Cells were washed and fixed with 4% paraformaldehyde.

4.2.5

Total internal reflection fluorescence microscopy (TIR-FM)

TIR-FM images were captured using a Leica AM TIRF MC using an HCX PL APO 63X oil
immersion objective with numerical aperture of 1.47. In order to image the cell surface
population of organelles. SN56 cells were plated on a glass-bottom confocal plate. Cells were
fixed after transfection with the denoted plasmid.
For live cell trafficking experiments, SN56 cells were plated on a glass-bottom confocal plate.
The differentiation media was removed and cells were washed with PBS. The media was
replaced with HBSS pre-warmed to 37°C. The confocal plate was then transferred to the
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microscope stage pre-warmed to 37°C. Live cell TIR-FM videos were acquired with a Leica AM
TIRF MC using an HCX PL APO 100X oil immersion objective with numerical aperture of 1.47.
All fluorescence emitted from 405/488/561 and 635nm lasers was captured after filtering through
a Quad-band filter cube (Emission: BP 450/50, BP 525/36, BP 600/32, BP 705/72). To capture
blue fluoresce protein (BFP) emission, BFP was excited with a 405 nm laser and could be
detected using Quad-band filter cube. The microscope lacks a 458 nm laser, but excitation of
CFP with a 405 nm laser was adequate for detecting CFP fluorescence. GFP and pHluorin were
excited with a 488 nm laser. Dextran tetramethylrhodamine was excited with a 561 nm laser.
Zenon 647 detection reagent was detected after excitation with a 635 nm laser.
To inject ionomycin onto the sample, a glass micropipette was attached to a FemtoJet
microinjection system (Eppendorf, Mississauga, ON, Canada) and placed at the desired position
over the cells. To capture rapid exocytic events, the imaging time for each wavelength was set to
50 ms. Due to hardware movement between wavelength, the total imaging time for one frame
was 112ms. Video was captured for 3-5 minutes after ionomycin treatment. The videos were
analyzed for exocytic vesicles one minute after ionomycin treatment.

4.2.6

Counting vesicles at the cell surface

The number of vesicles in each TIR-FM image was quantified using a semi-automated method in
Imaris using the built-in spot algorithm. The average size of the vesicle is determined by the user
and Imaris searches for the vesicles in the image. The threshold can be manually adjusted, as
required, to accurately select all vesicles. The Imaris program provides the number of vesicles.
Using Imaris, a rough estimate of background can also be determined using a semi-automated
method. The cell body typically has a higher level of noise than areas of the coverslip that are
empty. IsoSurfaces can be created in Imaris based on this background fluorescence, which
provides an estimate of cell size. From the IsoSurface, the approximate area of the cell touching
the glass coverslip can be determined. By dividing the number of vesicles at the cell surface by
the area of the cell on the glass, the number of vesicles per cell can be normalized to surface
area.
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4.2.7

Detecting Exocytosis

Lysosomal exocytosis was detected by manually tracking lysosomes in single- or dual-colour
images using ImageJ [38] and the ‘Manual Tracking’ plugin. A custom-written Matlab script
(Mathworks, Natick, Massachusetts) was then used to detect putative exocytosis events. Briefly,
the mean intensity of each lysosome was determined by averaging the pixel values around each
manually tracked point, at each time point in the track, over a disk approximately the size of
lysosomes in the image (radius of 5 pixels). Each track was then normalized to its minimum and
maximum intensity, the intensity data smoothed over 10 time-points, and the derivative (slope)
of the smoothed intensity graph calculated. Putative exocytosis events were defined as derivative
values less than 2 times the standard deviation of the derivative plot (i.e. > 2 standard deviation
decrease in lysosome intensity). Tracks containing putative exocytosis events were then flagged
and manually curated to detect bona fide exocytosis events. To compare the proportion of
vesicles secreted between luminal and membrane cargos, a χ2 analysis was used to compare the
luminal and membrane cargos.

4.2.8

Neuronal Culture

All animal experiments were conducted in accordance with the University of Western Ontario
Animal Care Committee. Alzheimer’s disease mice were B6C3-Tg
(APPswe/PSEN1ΔE9)85Dbo/J mice, which carry the human APP with Swedish mutation and
human presenilin 1 gene with the DeltaE9 mutation. Primary cortical neurons were obtained
from E18 embryos, as previously described [39]. Glass-bottom confocal plates (Matek) were
coated with poly-L-lysine and seeded with neurons. The neurons were maintained in Neurobasal
medium supplemented with 1X B25 and 0.8X N2 supplements, 2mM glutamax and 50U/mL
penicillin/streptomycin (Life Technologies). Neurons were grown in a humidified incubator at
37°C with 5% CO2. Neurobasal media was replenished once every 4 days.
After 14 days in vitro (DIV), neurons were fixed with 4% paraformaldehyde HBSS
supplemented with 4% sucrose for 15-minutes. Cells were stained for Aβ and LAMP1 and
imaged with confocal microscopy. Colocalization was analyzed as described below.
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4.2.9

Colocalization Analysis

Colocalization analysis was performed on using Imaris 7.2.1 Imaris Colocalization module
(Biplane). For fixed cells, the brightest 2% of pixels from each channel was chosen and
colocalized [9].

4.2.10

APP internalization into lysosomes

We have previously shown that APP can be labelled on the cell surface and internalized rapidly
into lysosomes [39]. SN56 cells were transfected with full-length APP-695 and LAMP1-YFP
according to the protocol described above. After transfection and differentiation, the culture
media was removed and cells were washed with PBS. To label APP on the cell surface, a Zenon
Alexa Fluor 647 was conjugated with the 6E10 antibody. SN56 cells were placed on ice and
labelled with the Zenon-6E10 conjugate. After labelling for 30 minutes, the bound antibody
conjugate was internalized for one hour at 37°C. The exocytosis of internalized antibody was
observed by TIR-FM after treatment with 5μM ionomycin.

4.2.11

Staining of LAMP1 at the Cell Surface

SN56 cells transfected with Rab27b WT, T23N, N133I, or Q78L tagged with GFP. Cells were
treated with 2.5μm ionomycin for five minutes and fixed with 4% PFA. After fixation, cells were
stained for LAMP1 with the 1D4B antibody without permeablization. Cells were imaged by
confocal microscopy with the optical slice set to 5μm, in order to maximize the amount of
fluorescence captured.
The relative fluorescence intensity was measured in ImageJ. Transfected cells were selected with
the freeform drawing/selection tool. The area and mean fluorescence intensity was measured for
each cell and plotted in Prism 5.0b.

4.2.12

Aβ40 and Aβ42 ELISA

SN56 cells were transfected with βAPPsw-CFP (βAPP bearing the Swedish mutation). Cells
were differentiated and cell culture media was collected two days after differentiation. To
remove the large cellular debris, the collected media was spun at 200 G for 10 minutes at 4°C.
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Aβ40 and Aβ42 were detected with the Aβ40 ELISA Kit (KHB3482) or Aβ42 Ultrasensitive
ELISA Kit (KHB3544) from Life Technologies, and used according to manufacturer’s
instructions.

4.2.13

Statistical Analysis

Prism Graphpad 5.0b was used for all graphing and statistical analysis. A One-way ANOVA was
performed with a Bonferroni’s post-hoc test, and P values <0.05 were considered significant.

4.3
4.3.1

Results
Lysosomes at the cell surface

To determine whether lysosomes are membrane docked organelles in neuronal cells, we
examined organelles in cultured SN56 cells neuronal cells. The SN56 cell line is a hybrid cell
line generated by fusing dissociated embryonic mouse septal neurons with N18TG2
neuroblastoma cells. SN56 cells possess a neuronal morphology and cholinergic phenotype when
differentiated and express endogenous APP [40,41]. SN56 cells were transfected with a panel of
fluorescent-tagged organelle markers, including synaptophysin-GFP (synapses), LAMP1-mRFP
(lysosomes), Cathepsin D -mCherryFP (CatD-ChFP, a luminal lysosomal enzyme), Rab5-mRFP
(early endosomes), Rab9-chFP, (late endosomes), and Galactosyltransferase-CFP (GalT-CFP,
trans-golgi network). SN56 cells were imaged using total internal reflection fluorescence
microscopy (TIR-FM) to visualize organelles within 110nm of the cell surface and count the
number of vesicles per μm2. We found that lysosomes were docked at the plasma membrane, as
shown by CatD-mChFP and LAMP1-mRFP fluorescence (0.14 ± 0.016 vesicles/μm2 SEM n=4
independent experiments, 59 cells total and 0.28 ± 0.050 vesicles/μm2 SEM n=3 independent
experiments, 39 cells total, respectively) (Figure 4.1a and b). CatD-chFP was found at the cell
surface at similar levels to Rab5-mRFP (0.14 ± 0.0082 vesicles/μm2 SEM, n=4 independent
experiments, 73 cells total), Rab7-mRFP (0.12 ± 0.018 vesicles/μm2 SEM, n=3 independent
experiments, 41 cells total), Rab9-chFP (0.16 ± 0.007 vesicles/μm2 SEM, n=4 independent
experiments, 60 cells total), and synaptophysin-GFP (0.16 ± 0.0070 vesicles/μm2 SEM, n=4
independent experiments, 60 cells total). As expected, no GalT-CFP fluorescence was detectable
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at the cell surface. Interestingly, the numbers of LAMP1 positive vesicles at the cell surface are
significantly higher than any other organelle marker. Therefore, in SN56 cells, lysosomes are
among the resident organelles at the cell surface.

214

Figure 4.1: Neuronal lysosomes are found at the plasma membrane.
SN56 cells were transiently transfected with a panel of organelle markers (GalT-CFP,
synaptophysin-GFP, Rab5 mRFP, Rab7-mRFP, Rab9-chFP, LAMP1-mRFP, or Cathepsin DmChFP). a) Cells were imaged using TIR-FM to determine the number of vesicles within 110nm
of the cell surface. Vesicles and cell area were determined using ImageJ and the number of
vesicles per µm. b) TIR-FM images of LAMP1-mRFP and CatD-mChFP images at the cell
surface are shown scale bars represent 10µm. c) Cells were transfected with Rab27bWT-GFP,
Rab27b Q78L-GFP, Rab27b N133I-GFP, or Rab27b T23N-GFP. TIR-FM imaging was used to
determine if Rab27b mutants affected the number of lysosomes docked at the cell surface. Cells
were stained for LAMP1 using 1D4B. Representative TIR-FM images (within 110nm of the cell
surface) of cells transfected with Rab27b mutants and stained for LAMP1. Scale bars represent
5µm. d) Using ImageJ, the number of vesicles was counted and normalized using cell area and
graphed. Scaled bars represent SEM (*=p<0.05). White lines denote the edge of individual cells.
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4.3.2

Rab27b Mutants Reduce Number of Lysosomes at Cell Surface

Rab27a and Rab27b have been implicated in the delivery and docking of lysosome-related
organelles LROs to the cell surface in several cell types [42,43]. Rab27 is a regulatory protein
that at rest is inactive and binds GDP. When Rab27 is activated, this GDP is exchanged for
GTP, which is eventually hydrolyzed GDP, moving the protein back to its inactive state. Rab27a
silencing has been shown to decrease the number of dense-core vesicles at the plasma membrane
of PC12 cells [43]. Rab27b has been shown to be involved in the proper distribution of
melanosomes, docking of secretory granules, and exosome secretion [36,42,44,45]. As the
Rab27b isoform is more highly expressed in the brain [42], we wanted to determine if Rab27b
was important for lysosomal docking at the cell surface of neuronal cells. SN56 cells were
transfected with Rab27bWT-GFP or with one of the following mutants mutants; constitutively
active, which is defective in GTP hydrolysis (Q78L) or dominant negative mutants defective in
GTP binding (N133I or T23N) [45,46].
We then fixed the cells, stained them with an antibody against LAMP1, and imaged using TIRFM. Cells transfected with wild-type (WT) Rab27b had 0.20 ± 0.014 vesicles/μm2 SEM, n= 8
independent experiments, 90 cells total). This was not significantly different from the number of
LAMP1 vesicles docked at the membrane of untransfected cells (0.23 ± 0.015 vesicles/μm SEM,
n= 3 independent experiments, 54 cells total) (Figure 4.1c and d). However, transfection of
Q78L, N133L, or T23N mutants all significantly reduced the number of docked lysosomes
(0.095 ± 0.0073 vesicles/μm2 SEM, n= 5 independent experiments, 53 cells total, 0.069 ±0.0092
vesicles/μm2 SEM, n= 3 independent experiments, 30 cells total, and 0.094 ±0.0053 vesicles/μm2
SEM, n= 3 independent experiments, 32 cells total, respectively, p<0.05) (Figure 4.1c and d).
The reduced number of lysosomes in SN56 cells transfected with mutant versions of Rab27b
suggests that Rab27b is involved in lysosome delivery to the cell surface.
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Figure 4.2: Neuronal lysosomes can undergo stimulated exocytosis.
a) SN56 cells were transfected with Rab27b-GFP or one of its mutants. Cells were treated with
2.5μM ionomycin for 5 minutes and fixed. LAMP1 at the cell-surface was stained with 1D4B,
without permeabilization. Scale bars represent 30μm. b) The fluorescence intensity was
quantified for each cell in ImageJ, and graphed using Prism Graphpad. Error bars denote SEM.
(*=p<0.05) c) Neuronal cells were cultured and stimulated with 2.5μm ionomycin and stained
for cell-surface 1D4B. Cells treated with ionomycin show a prominent cell-surface stain for
LAMP1. Scale bars represent 50μm.
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4.3.3

Rab27b Mutants Interefere with Lysosomal Exocytosis

We then sought to determine whether lysosomes were capable of secretion, and if Rab27b played
a role in this lysosomal secretion. SN56 cells were transfected with Rab27b, or one of its
mutants, and treated with 2.5μM ionomycin for 5 minutes. In order to only label the cell surface
membrane of lysosomal origin, cells were fixed and stained without cell permeabilization.
Because the antibody used targeted a luminal epitope on LAMP1 (1D4B) and the cells were not
permeablized, cells would only be stained if LAMP1 were placed on the plasma membrane. In
this experiment cells treated with DMSO showed a low basal level of cell-surface LAMP1
staining (Figure 4.2a). However, cells transfected with Rab27b WT and treated with ionomycin
demonstrated significantly increased cell-surface LAMP1 staining as compared to DMSO treated
cells. We quantified the cell surface staining of LAMP1 on these cells by measuring the
fluorescence in transfected cells, and these results are displayed in figure 4.2b. In accordance
with the docking results in Figure 4.1, cells transfected with Rab27b mutants exhibited a
significant decrease in cell-surface LAMP1 staining at the cell surface. To confirm our findings
in neurons, primary mouse neurons were treated with 2.5μM ionomycin for 5 minutes and cellsurface stained with anti-LAMP1 antibody. Cells treated with ionomycin resulted in prominent
cell surface staining of LAMP1. Conversely, there was little staining on control cells (Figure
4.2c). Therefore, the Rab27b mutants decrease the number of docked lysosomes at the cell
surface and decrease number of lysosomes undergoing exocytosis in response to the calcium
ionophore ionomycin.

4.3.4
4.3.4.1

Live-cell Video tracking of Lysosomal Secretion
Lysosomal Cargo Release

We performed live-cell imaging experiments in SN56 cells to visualize lysosome exocytosis. As
previously shown, luminal and membrane cargo have different release kinetics [47]. Luminal
contents, such as dextran, can be freely released, which makes luminal contents amenable for the
detection of kiss-and-run and full exocytotic events. Conversely, membrane cargo is not released
during exocytosis, but rather disperses longitudinally during full exocytosis. During kiss-and-run
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exocytosis, the membrane cargo should remain concentrated on the lysosomal membrane [48].
To elucidate the underlying kinetics of lysosome exocytosis in SN56 cells, we transfected cells
with CatD-mChFP or with LAMP1-mRFP, a membrane cargo. To increase the number of
exocytic events, cells were treated with 5μM ionomycin and TIR-FM video was recorded.
Immediately after treatment of ionomycin, there was a delay of 1-2 minutes before an increase in
the number of exocytic events. Putative exocytic events were detected in a semi-automated
method using ImageJ and Matlab and labelled as kiss and run exocytosis, full exocytosis, or not
exocytic. Kiss-and-run fusions had a significant drop in vesicle intensity, however intensity did
not drop to background (Figure 4.3a). Conversely, vesicle intensity also showed a significant
drop in intensity to background levels (Figure 4.3b). From at least three independent
experiments, a total of 719 CatD positive vesicles from 4 cells were tracked and a total of 192
LAMP1 positive vesicles were tracked from 3 cells. By χ2 analysis, there was a significant
relationship between the vesicular cargo and the type of exocytosis. As expected, there was a
greater number of kiss-and-run exocytic events detected by the luminal (26.7% of CatD-mChFP
events) cargo as compared to LAMP1-mRFP (8.33% of events). Concomitantly, there were
fewer full fusions observed with CatD-mChFP cargo (2.4% of events) as compared to LAMP1mRFP (9.9% of events). The decrease is likely due to a difficulty in detecting partial fusions with
a membrane cargo.
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Figure 4.3: Kiss-and-run exocytosis and Full exocytosis.
SN56 cells were transiently transfected with CatD-mRFP and treated with 5μm ionomycin and
exocytosis was imaged using TIR-FM. Red arrows point to the corresponding frame on the
graph. Green lines on the graph point to possible exocytosis events. A white line demarcates the
edge of the vesicle. a) An example of a vesicle undergoing kiss-and-run exocytosis. b) A vesicle
undergoing full exocytosis.
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Figure 4.4: Detection of Lysosomal Secretion with pHluorin
SN56 cells were transiently transfected with plasmids expressing Lamp1-mRFP and VAMP7pHluorin. a) Deacidification of lysosomes with 100μM chloroquine for 30 minutes revealed that
TIVMP-pHluorin is colocalized with LAMP1-mRFP in SN56 cells. b) Cells were pre-treated for
20 minutes with 1μM bafilomycin, and lysosome exocytosis was stimulated with 5μM
ionomycin. SN56 cells were imaged once every minute for 3 minutes. The image on the far right
shows the merge of the two channels. Colocalized voxels are yellow and denoted by a white
arrowhead. Scale bars represent 5μm.
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4.3.4.2

pHluorin Detection of Secreting Lysosomes

To further confirm lysosomal exocytosis in a neuronal cell line, we turned to a construct
encoding tetanus-insensitive vesicular membrane protein (TIVAMP) fused to a pH-sensitive
mutant of GFP called pHluorin. Briefly, pHluorin is a mutant form of GFP that is relatively dark
in the acidic environment of the lysosome. Neutralization of the luminal pH, for example by
fusion with the plasma membrane, results in a dramatic increase in fluorescence [49]. Recent
work has shown that TIVAMP is associated with lysosomes and is involved in lysosome
exocytosis [23,50]. In order to confirm the colocalization of TIVAMP in lysosomes, LAMP1 in
SN56 cells, cells were transfected with treated with 100μM chloroquine for 30 minutes to
deacidify the lysosomal lumen. Cells were then imaged live using confocal microscopy, which
revealed that LAMP1-mRFP and pHluorin were highly co-localized (Figure 4.4a).
To determine if lysosomes dock with the cell surface, SN56 cells transfected with LAMP1mRFP and TIVMP-pHluorin and were treated with bafilomycin for 20 minutes to prevent reacidification after exocytosis. Therefore, TIVAMP-pHluorin in bafilomycin treated cells would
specifically label lysosomes that have formed a pore or contacted the cell surface. Initially cells
were treated with bafilomycin alone to confirm that this treatment would elevate pHluorin
fluorescence, confocal images were taken immediately before and after bafilomycin treatment.
Bafilomycin alone only resulted in a minor increase in pHluorin fluorescence. The same cell was
then treated with 5μM ionomycin, and imaged once every minute for three minutes. Within one
minute after the addition of ionomycin, LAMP1 vesicles began to fill with pHluorin
fluorescence, and were filled by three minutes (Figure 4.4b).
Transfection of multiple plasmids into a cell may result in over-transfection or different ratios of
constructs. In order to avoid some of the effects of over-transfection and to be certain that the
TIVAMP and LAMP1 proteins were perfectly stoichiometrically co-localized, we obtained a
chimeric protein that expresses pHluorin in the luminal domain and modified apple fluorescent
protein (mAppleFP) (mApple-LAMP1-phLuorin). In between the two fluorescent proteins, there
is a transmembrane domain and the sorting signal of the LAMP1. In SN56 cells, this protein
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colocalized with LAMP1 detected with antibody 1D4B, which identifies a LAMP1 luminal
epitope not present in the construct. Furthermore, chloroquine treatment deacidified lysosomes
and increased fluorescence (Figure 4.5). Therefore, the mApple-LAMP1-phLuorin chimera was
properly sorted to lysosomes and is responsive to changes in luminal pH. To follow the
trafficking of mApple-LAMP1-phLuorin, transfected SN56 cells were imaged using TIR-FM.
After treatment with 5μM ionomycin, exocytic vesicles could be visualized (Supplementary
Video 1). In these movies, vesicles (red) can be seen coming up to the plasma membrane.
Vesicles that come into communication with the plasma membrane have their luminal contents
come to a more neutral pH, and also turn green.
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Figure 4.5: Localization of mApple-LAMP1-pHluorin.
SN56 cells were transfected with a plasmid encoding the construct mApple-LAMP1-pHluorin.
To confirm the correct targeting of this construct to lysosomes, SN56 cells were also transfected
with LAMP1-CFP. Before treatment of cells with chloroquine, mApple fluorescence can be seen
colocalizing with LAMP1-CFP fluorescence. After chloroquine treatment, the pHluorin
increases in fluorescence due to deacidification of the lysosomal lumen. The green fluorescence
can be detected in compartments positive for LAMP1-CFP and mApple. Scale bars represent 5
µm.
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4.3.5

Intracellular Accumulation of Aβ

While extracellular aggregates of Aβ are one of the hallmarks of AD, there is emerging evidence
suggesting that intracellular aggregates of Aβ may be pathologically relevant [51-54]. Previous
work has demonstrated that these intracellular aggregates accumulate in the
endosomal/lysosomal system [51,55-60]. To confirm the intracellular accumulation of Aβ in
lysosomes, we incubated SN56 cells with 250nM of HiLyte Fluor 488 Aβ42 (Aβ42-488)
(Anaspec) and determined its colocalization with LAMP1-mRFP. As expected, 60% of Aβ42488 colocalized with LAMP1 labeled compartments, suggesting that the majority of Aβ42-488 is
localized to lysosomes (Figure 4.6a).
To determine if endogenously produced Aβ could be detected intracellularly, we cultured
cortical neurons harvested from newborn transgenic mice expressing human APP with the
Swedish mutation and the deltaE9 mutation of the human PS1 gene. DIV7 cortical neurons were
fixed and stained for Aβ and LAMP1. Colocalization analysis found that 55 ± 4 SEM% of Aβ
colocalized with LAMP1 labelled compartments (Figure 4.6b, n=3)
In order to follow the secretion of Aβ in live cells, SN56 cells were transfected with full-length
APP-695. After differentiation, cells were surface labelled with a Zenon-6E10 antibody
conjugate and internalized for one hour. Our previous work has demonstrated that a portion of
APP can be internalized into lysosomes after 15-minutes [9,39]. After labelling, live cells were
treated with ionomycin and imaged by TIR-FM. Our analysis found that 2.4% of vesicles
underwent full exocytosis and 18.5% of vesicles underwent kiss and run exocytosis.
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Figure 4.6: Aβ accumulates in lysosomes.
a) SN56 cells were transfeceted with LAMP1-mRFP. Cells were loaded with 250nM. HiLyte
Fluor 488 Aβ42 (Aβ42-488) for 24 hours, and imaged. b) Primary cultured neurons from a
mouse bearing PS1 delta exon 9 mutation and APP-Swe mutations were fixed and
immunostained with and antibody against Aβ. Scale bars represent 5μm.
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4.3.6

Rab27b Mutants Decrease Aβ Secreted into Culture Media

To determine whether Rab27b affected Aβ secretion into the media, SN56 cells were transfected
with βAPP-CFP with the Swedish mutation and a Rab27b-GFP mutant. Medium was collected
after 48 hours and analyzed by ELISA. From each experiment, the amount of Aβ secreted was
normalized to that in cells that were only transfected with βAPP-CFP. In these experiments, the
amount of Aβ40 secreted is should in Figure 4.7a, was significantly reduced by all 3 of the
Rab27b mutants compared to controls (Q78L: 67 ± 12 SEM %, N133I: 61 ± 6 SEM %, T23N: 61
± 9 SEM %, n= 5). We determined the amount of Aβ 42 secreted by ELISA and found that only
Rab27b construct bearing the T23N dominant negative mutation significantly reduced, as
compared to Rab27b WT, the amount of Aβ 42 released to 60 ± 10SEM % as compared control
(p<0.05). The amount of Aβ 42 released was not affected by the other mutants (Q78L:77 ± 11
SEM %, N133I: 104 ± 7 SEM %, n= 4) (Figure 4.7a and b).
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Figure 4.7: Rab27b inhibits Aβ releases in SN56 cells.
Cells were transfected with Rab27bWT-GFP, Rab27b Q78L-GFP, Rab27b N133I-GFP, or
Rab27b T23N-GFP. To determine if Rab27b affects Aβ secretion, SN56 cells were transfected
with Rab27b mutants and βAPPswedish-CFP. Media was collected after 48 hours and a) Aβ40
and b) Aβ42 levels were determined by ELISA. (*=p<0.05).
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4.4

Discussion

Although lysosomes are commonly used for secretion in many cell types, little is known about
secretory lysosomes in neurons. Here, we present data demonstrating that a population of
lysosomes resides within 110 nm of the plasma membrane. After depolarization with
ionomycin, the lysosomal marker LAMP1 can be imaged at the plasma membrane. These
lysosomes are able to fuse with the plasma membrane, as indicated by a pH sensitive marker
pHluorin, which demonstrates green fluorescence at neutral environment pH. Furthermore, these
lysosomes contain neurotoxic Aβ. Exocytosis can be imaged in live cells using TIRF
microscopy, and occurs in neurons.
Although lysosomes are typically thought of as degradative organelles, lysosomes are able to
contribute to secretion in many cell types [17]. Many authors have demonstrated that lysosomes
are capable of secretion in professional secretory cells (platelets, neutrophils, melanocytes, and
macrophages) [17,18]. In addition, conventional lysosomes fuse with the cell surface for plasma
membrane wound sealing [61,62]. There is also evidence suggesting that neuronal lysosomes are
secretory. For example, primary neurons isolated from sympathetic cervical ganglia depend on
lysosomes for neurite extension [33].
Here, we used a semi-automated detection method to show that approximately 30% of tracked
vesicles in SN56 cells are secretory as detected by CatD-mChFP. The majority of these secretory
events appear to be kiss-and-run fusion (Figure 4.3a). Conversely, when exocytosis was detected
with a membrane cargo there was a ~10% drop in the number of fusion events detected.
The decrease in number of detected in these events was due to the lower detection of kiss-andrun fusions. The difference in the proportion of vesicles detected is likely due to the difference in
release kinetics of soluble and membrane cargo [47]. Soluble cargo would be expected to be
released in partial and full fusions. In kiss-and-run fusions, there would be a drop in cargo
fluorescence intensity, albeit not to background levels. Conversely, membrane cargo
fluorescence would only decrease after complete fusions. During full fusions, membrane cargo
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will diffuse laterally resulting in decrease fluorescence. However, during partial fusions,
membrane cargo will stay concentrated in a vesicle, and not lead to a significant decrease in
fluorescence [47].
Our data also show that Rab27b is involved in lysosomal docking and secretion. Previous work
has shown that Rab27b is highly expressed in the brain [42,45]. Furthermore, over-expression of
dominant-negative mutants of Rab27b into PC12 neuroendocrine cells decreased secretion from
dense core granules [45]. In our studies, we show a decrease in the number of LAMP1 positive
vesicles within 110nm of the membrane after transfection with constitutively-active and
dominant-negative mutants of Rab27b, which suggests a deficit in vesicle docking or trafficking
to the cell surface (Figure 4.1c). Consequently, there was also an observed decrease in the cellsurface labelled LAMP1 after ionomycin treatment (Figure 4.2a and b). The Rab27b mutants
decreased the secretion of Aβ40 into the culture media, as determined by ELISA, even when in a
constitutively active state (Figure 4.7a). Although we do not know the reason for active forms of
regulatory GTPases to be inhibitory, it has been proposed that they can have indirect inhibitory
effects by occupying/consuming other regulatory proteins. Interestingly, Aβ42 secretion was
decreased only by the true dominant-negative Rab27b T23N mutant (Figure 4.7b), suggested that
the negative effects seen in previous experiments were indirect..
The involvement of Rab27b in lysosomal secretion are in agreement with previous literature that
demonstrated the importance of Rab27 and its effectors in granule secretion. Work from the
Thery laboratory [44] demonstrated that Rab27b silencing by shRNA resulted in the perinuclear
localization of CD63 (a late endosome/lysosome marker). These findings are echoed in
melanocytes from patients with Griscelli syndrome (deficient in Rab27a). These melanocytes
accumulate melanosomes in the perinuclear region, and melanosome sorting the cell periphery
can be restored by the expression of exogenous Rab27a [63]. The Rab27-mediated trafficking
and docking of lysosomes likely depends on a number of Rab27 effectors [reviewed in detail in
64,65]. For example, Rab27a interacts with melanophilin and interacts with the plus-end of the
microtubule, which provides a possible mechanism for melanosome delivery to the periphery
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[66]. Myosin Va also interacts with Rab27, and is involved in rearranging the actin at the cell
periphery to capture and dock melanosomes [66].
Once at the membrane, Munc 13-4 proteins interact with Rab27a and are involved in the docking
of lysosomes at the membrane [67]. Munc proteins also form a critical part of SNARE complex
for synaptic vesicles and regulates synaptic vesicle fusion [68]. The formation of a unique
SNARE complex for lysosome secretion in neurons. However, the protein participants remain
unclear. One of the leading candidates is synaptotagmin 7, which is critical for lysosomemediated neurite extension [33]. Previous work has also demonstrated that synaptotagmin 7
controls the fusion pore size, and silencing of synaptotagmin 7 leads to a higher proportion of
full lysosomal fusions [47]. Synaptotagmin 7 can from SDS-resistant complexes with sensitive

factor attachment protein 23 (SNAP23), TIVAMP, and syntaxin 4 [69]. TIVAMP has
also been shown to be involved in lysosome secretion in neurons and astrocytes [32,50].
SNAP-23 and syntaxin 4 have also been implicated in lysosomal secretion in platelets
[70]. However, the existence and physiological relevance of this complex in neurons and
Aβ secretion remains to be determined.
Work from our lab and others have demonstrated that endosomes and lysosomes are critical in
the production of Aβ [5,8,10,39]. Taken together with the current findings, these data suggest
that lysosomes may be responsible for the production and secretion of Aβ. The acidic
environment of the lysosomes is conducive to the aggregation of Aβ [7]. Aβ is also known to
accumulate intracellularly and form seeds that can promote the extracelular formation of fibrils
[12]. Recent work has also demonstrated that Aβ can be secreted in association with exosomes
(intraluminal vesicles in endosomes and lysosomes) [4]. Furthermore, APP, APP CTFs,
ADAM10 and BACE have also been detected in exosomes [71]. Interestingly, Aβ can be
detected in multi-vesicular bodies from the brains of AD patients and transgenic mice [55,56].
While the evidence for lysosomal production and secretion of Aβ is compelling, at least one
study has identified full-length APP and BACE on the synaptic vesicle membrane [3]. It was
shown that full-length APP can be secreted from synaptic vesicles, although the secretion of Aβ
and other cleavage products was never directly identified [3].
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The work presented here suggests that Aβ is produced, stored, and secreted from lysosomes in a
Rab27b dependent manner. However, the physiological significance of this pathway is unclear.
The secretion of Aβ from lysosomes may simply be an attempt for neurons to clear themselves of
indigestible Aβ. Intraluminal accumulation of Aβ has been demonstrated to destabilize the
lysosomal membrane and cause the leakage of luminal contents to the cytosol [72], with the
release of lysosomal contents into the cytosol leading to cell death [73-75]. Alternatively, release
may modulate brain activity. For example, Aβ release has also been increased in response to
synaptic activity and can modulate synaptic activity [76]. The Aβ secretion in response to
synaptic activity can be inhibited by blocking endocytosis [77]. Therefore, the lysosomal
secretion of Aβ appears to be physiologically and pathologically important and will need to be
further explored.
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Chapter 5

5

Discussion
5.1

Summary of Novel Observations

In this thesis, I set out to characterize the trafficking of APP and link this to A production and
secretion. Although most APP processing experiments focused on internalization of APP to
endosomes before processing, our laboratory has demonstrated that APP can also transit from the
cell surface to lysosomes directly before processing into A. 1) We have expanded these
experiments to follow intracellular APP trafficking using APP tagged with a photoactivatable
form of GFP. With this construct, we have characterized a novel trafficking pathway for APP to
be transported directly from the Golgi apparatus to lysosomes, where it is processed into A by
secretase-like enzymatic activities 2) This novel trafficking pathway is dependent on an
interaction between AP-3 and APP.. 3) Furthermore, this interaction is mediated through an
interaction with the YTSI motif in the cytoplasmic tail of APP and can be decreased by
phosphorylation of the serine in they YTSI motif. 4) Finally, we demonstrate that lysosomes are
secretory organelles, even in neuronal systems, and are able to secrete their contents, including
A.
The importance of protein sorting has been well recognized in AD [reviewed in 1,2], with many
authors contending that APP sorting can directly control A production. One reason trafficking
plays a role in Aβ is because this process is dependent on amyloidogenic cleavage of APP by βand γ-secretases. While the γ-secretase has been localized to the ER, Golgi, plasma membrane,
and endosomes [reviewed in 3], the localization of γ-secretase activity is the most critical to
understanding the production of Aβ. Work in human embryonic kidney cells, transiently
transfected with a fluorescent reporter of γ-secretase activity, suggests that γ-secretase activity is
localized at endosomes and plasma membrane [4]. However, a careful isolation of lysosomes
from rat livers revealed that APP and γ-secretase as full length proteins at the lysosomal
membrane [5].
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The role of APP trafficking to and from lysosomes can regulate the production of Aβ. Inhibition
of endocytosis or mutagenesis of APP internalization signals decreases the production of Aβ
[6,7]. Recent work has also demonstrated that retromer mediated recycling of APP from
endosomes to the Golgi can lower the amount of Aβ produced and likely plays an important role
in AD pathology [8-11]. Therefore, an understanding of protein sorting is important for
understanding pathology in AD.

5.2

APP intracellular trafficking

Much of our understanding of APP sorting comes from studies of internalization of APP from
the cell surface, due to the ease of labeling APP exposed on the cell surface. This has lead to the
belief that all APP is first presented at the cell surface before internalization to endosomes, the
putative site of Aβ production [12]. Despite these confident claims, very few studies have
actually followed the intracellular movement of APP. To follow the intracellular trafficking of
APP, we took advantage of a photo-activatable mutant of GFP, which has almost no basal
fluorescence [13,14]. We tagged a truncated version of APP (last 112 amino acids) with paGFP
and transiently transfected SN56 cells with our βAPP-paGFP construct. After accurate
photoactivation within the TGN, we found that βAPP-paGFP trafficked rapidly to lysosomes
without transiting through the cell surface. Furthermore, APP accumulated in lysosomes, after
alkalinisation, and is not processed into A.
An intracellular pathway for APP between the Golgi and lysosomes has been previously
suggested [15-17]. Kuentzel et al. [15] demonstrated that secretase release of the N-terminal
domain occurs before APP appears at the cell surface, suggesting that secretase cleavage of APP
may occur completely intracellularly. Unfortunately, the time course of Aβ production was not
followed in this study [15]. More recent findings suggest that APP is released from the Golgi
apparatus to an endosomal intermediate before appearance at the cell surface [16,17]. These
findings suggest that APP can trafficking directly to the endosomal and lysosomal system from
the Golgi apparatus.
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Our work suggests that APP is processed rapidly after appearance at the lysosomal membrane.
SN56 cells treated with L685, 458 (a γ-secretase inhibitor) or chloroquine (an alkalinizing agent)
caused an accumulation of photo-activated βAPP-paGFP at the lysosomal membrane. APP has
been postulated as a cell-surface receptor [18]. Indeed, antibodies against the extracellular
domain of APP can activate intracellular signalling [19,20]. Full-length APP can also
homodimerize and heterodimerize, with other members of the APP family, and participate in
cell-cell adhesion [21]. Therefore, there may be a mechanism for the delivery of full-length APP
from the lysosomal membrane to the cell surface. It has been suggested that APP can be sorted
from endosomes into synaptic vesicles for delivery to the cell surface [22]. APP has been
localized to synaptic vesicles and appears at the cell surface at sites of synaptic activity [22]. In
studies with A2780 human ovarian cancer cells, Rab25 and Chloride Intracellular Channel
Protein 3 (CLIC3) worked cooperatively to recycle α5β1 integrin from late endosomes and
lysosomes to the cell surface at the rear of migrating cell [23]. More recent work demonstrated
that CLIC3 is also involved in the recycling of Matrix metalloproteinase-14 from late endosomes
and lysosomes to cell surface [24]. Alternatively, a proportion of APP may be delivered to the
cell surface from the Golgi. It has been demonstrated that the S655E phosphomimetic mutation
can increase the APP export to the cell surface from the Golgi apparatus [25]. However, in our
experiments, cell surface delivery of APP was never observed even with the S655E
phosphomimetic mutation. The fluorescence of APP at the cell surface may be under the
detection limit of our microscopy experiments.
The only situation where we observed significant cell surface APP was after treatment with
L685, 458. L685, 458 is thought to be a transition state mimic and occupy the aspartyl-protease
site of PS1 [26]. The inhibitor may disrupt the trafficking of APP by interfering with the
interaction of APP and γ-secretase, which has been shown to be involved in APP trafficking [2729]. PS1 and PS2 appear to be essential to the formation of vesicles from the TGN [28].
Furthermore, cells expressing various FAD mutants of PS1 decreased the formation of vesicles at
the TGN and lowered the cell-surface levels of APP [28]. Interestingly, over-expression of
phospholipase D1 interferes with the interaction of γ-secretase components, suggesting that an
intact γ-secretase complex is required for proper APP trafficking [29]. PS1 and PS2 also appear
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to be involved in APP internalization from the cell surface. Expression of non-functional PS1
delays the internalization of APP from the cell surface [30]. Therefore, the appearance of APP at
the cell-surface, after treatment with L685, 458, may result from altered trafficking of APP from
lysosomes to the cell surface. Alternatively, APP may accumulate at the cell surface due to
disrupted internalization.
Indeed, a direct pathway between Golgi and lysosomes is well known for other lysosomal
membrane proteins. For example, LAMP1 is transported directly from the Golgi to the
lysosomes, without appearing at the cell surface [31,32]. The direct transport of lysosomal
proteins is dependent on AP-3. When cells are deficient in AP-3, LMPs, such as LAMP1 and
CD63, are still sorted to lysosomes. However, instead of a direct pathway, LMPs in AP-3
deficient cells are first delivered to the cell-surface before being internalized sorted to lysosomes
[33,34]. In agreement with these findings, siRNA-mediated silencing of AP-3 in our SN56 cells
decreased the amount of APP trafficking to lysosomes, and decreased the amount of Aβ
produced.

5.3

Manipulating the Intracellular Trafficking of APP

AP-3, and other members of the heterotetrameric adaptor protein family, are known to interact
with tyrosine sorting motifs in the cytoplasmic domain of transmembrane proteins [35]. Previous
work has demonstrated that mutagenesis of these motifs can disrupt internalization of APP from
the cell surface [6,36]. Furthermore, the YTSI motif and the non-canonical YKFFE motif have
been shown to interact with AP-1 and AP-4, respectively, and regulate intracellular APP
trafficking [37,38]. In agreement with previous mutagenesis studies, our studies demonstrated
that mutations to tyrosines in the GYENPTY internalization motif decreased internalization to
early endosomes and lysosomes [6,36]. While the NPXY motif has been shown to be involved in
cell-surface protein internalization through an interaction with AP-2 [39], the GYENPTY motif
is critical for the interaction with various adaptor proteins. Many of these adaptors can control
the metabolism of APP. For example, the APP interacting protein, Mint1, is important in APP
internalization and Aβ production [40]. Dab2, which also binds the NPTY motif, can interact
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with AP-2, thereby linking APP to the clathrin endocytosis pathway [41]. Furthermore, APP can
also interact with LRP, via a Fe65-intermediate, to facilitate APP internalization [42,43].
While previous work has carefully studied the internalization of APP, the role of these sorting
motifs in APP egress from the Golgi is unstudied. In this thesis we presented evidence
suggesting that these tyrosine motifs are critical in the intracellular trafficking of APP from the
Golgi to the lysosome. Specifically, we showed that the Y709A and Y743A mutation decreased
the delivery of APP to lysosomes, but increased early endosome localization. Furthermore, the
Y738A and Y743A mutation prevented rapid internalization of APP from the cell surface to
lysosomes. This suggests that Y743A mutation may participate in the trafficking of APP to the
lysosome, while the Y709A and Y738A mutation work in specific sub-cellular locales.
Furthermore, we demonstrated that the Y709A mutation could decrease interaction of APP with
AP-3, which suggests the YTSI motif is critical for APP delivery from the Golgi to the lysosome.
Recently, there has been more interest in APP trafficking between the Golgi and endosomes,
which has revealed a number of protein adaptors that regulate the trafficking of APP. However,
many of these trafficking studies were performed in non-neuronal cells, therefore, the
generalizability of these results to neuronal cells is unclear. In HeLa cells, APP can recruit Mint3
to the Golgi membrane and facilitates Golgi export of APP to LAMP1 labelled compartments
[16]. Interestingly, these experiments demonstrated that Y687 was critical for Mint3 recruitment
and rapid trafficking to LAMP1 compartments [16]. Conversely, our own experiments found no
effect of Y687 trafficking from the Golgi to the lysosomes. These differences may be the result
of differential expression of trafficking proteins in neuronal cells.
AP-4 has also been implicated in the delivery of APP to endosomes [37]. Silencing of AP-4
disrupts the delivery of APP from the Golgi to endosomes [37]. In support of these findings, the
data presented here demonstrate that mutation of the YKFFE motif to AKFFE causes a decrease
of APP sorting to lysosomes. However, other work has demonstrated that AP-4 cannot be
recruited to the Golgi after APP expression [16]. Therefore, the role of AP-4 in APP trafficking
remains to be determined.
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While the studies mentioned above have focussed primarily on cytoplasmic sorting signals, a
recent study has demonstrated that APP may depend on luminal sorting signals as well. A recent
study that added short glycosaminoglycans (GAG) to the luminal portion of APP increased APP
sorting to the cell-surface and decreased APP endocytosis [17]. Conversely, APP without the
addition of GAG was sorted to an endosomal intermediate before appearing at the cell surface.
In addition to the sorting of APP to the endosomal/lysosomal system, APP can also be recycled
back towards the endosomes. The recycling of APP to the Golgi depends upon the retromer
complex. The retromer complex has a cargo-recognition complex, which consists of vacuolar
protein sorting (VPS) 35, VPS26, and VPS29 [44,45]. An AD mouse model of VPS35
haploinsufficiency causes an increase in Aβ production and plaque accumulation [11].
Furthermore, the brains of AD patients had a decrease in VPS35 and VPS26 protein expression
[46]. shRNA silencing of VPS35 in mouse hippocampal cultures increased the amount of APP
localized to early endosomes [47]. Phosphorylation of APP at S655 can increase the interaction
between APP and VPS35, which decreases sorting of APP to lysosomes in preference for the
Golgi [9]. These findings are in agreement with the present work, which demonstrated that
phosphorylation of APP can decrease the trafficking of APP to lysosomes. The interaction
between APP may depend upon the interaction with the VPS10 family proteins [48]. The VPS10
family protein SorLA has been shown to be genetically associated with AD [49]. Furthermore,
APP can interact with SorLA, which mediates its retrograde trafficking from endosomes to
lysosomes [9,10].
Similarly, our work also demonstrates that PKCε activation or mutagenesis of sorting signals can
cause an increase in trafficking to early endosomes from the TGN and decrease Aβ production.
APP can be phosphorylated on S655 (by APP 695 numbering or S711 by APP 751 numbering)
by PKC [50,51]. The work presented here demonstrates that pseudo-phosphorylation of APP can
decrease the interaction of APP with AP-3. The loss of this protein interaction decreased the
amount of APP delivered to the lysosome from the Golgi and increased the proportion of APP
trafficked to the early endosome. Therefore, phosphorylation of APP on S655 may serve as a
molecular ‘switch’, which regulates the final destination of APP. Previous work has
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demonstrated that PKC activation, by phorbol ester or receptor activation, causes an increase in
non-amyloidogenic α-secretase cleavage of APP [52-57]. Recent work has shown that α- and βsecretase are localized in synaptic vesicles and the trafficking of α- and β-secretase can also be
altered by PKC activation [58,59]. ADAM17 enzyme activity can be up regulated by PKCε
activation [60]. In addition to these factors, we suggest that the alteration of the intracellular
itinerary of APP may be another aspect in increasing non-amyloidogenic α-secretase cleavage.

5.4

Lysosomal secretion of Aβ

The question of Aβ release is lost in the literature of AD. In fact, to our knowledge Aβ has never
been imaged in a secretory compartment. Our work here suggests that Aβ stored in lysosomes
can be secreted by a Rab27b dependent mechanism. Previous work has demonstrated that
neuronal lysosomes are critical in providing the membrane required for neurite extension [61].
Rab27 has been shown to be involved in the delivery and docking of lysosome-related organelles
in melanocytes and cytotoxic T lymphocytes [62-64]. Previous work has also suggested that Aβ
is secreted in association with exosomes from N2A cells [65]. Exosomes were first suggested to
be a mechanism for post-mitotic cells to clear undegraded proteins from the cell. More recent
work suggests that exosomes can participate in intercellular signalling. For example, mRNA and
microRNAs have been shown to be shuttled between cells and regulate protein expression in the
receiving cell [66,67]. Neurons have also been shown to secrete exosomes in response to
neuronal activity [68,69]. Furthermore, exosomes secreted from N2A cells can be internalized by
rat cortical neurons [69]. Exosomes have also been shown to the responsible for the intercellular
transfer of other neurodegenerative proteins, such as α-synuclein and PrpSc [70-73]. AD
pathology appears to have a regimented transneuronal spread between pyramidal neurons from
different brain regions [74]. Therefore, it is not surprising that the lysosome is a source of Aβ
release, and Aβ released from exosomes may be a mechanism for interneuronal spread of
amyloid pathology in AD.
The production and accumulation of amyloid in endosomes and lysosomes bears a striking
resemblance to the formation of fibrillar structures in melanosomes. These fibrillar structures are
formed by the sequential proteolytic cleavage of the precursor protein Premelanosome protein
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(PMEL) [75]. The first cleavage is by proprotein convertase and is followed by a second
juxtamembrane cleavage [75]. The second cleavage has been suggested to be carried out by
BACE2, ADAM10, or ADAM17 [76,77]. The identity of the enzyme responsible for the
cleavage may depend upon the individual cell lines studied. The amyloid fibrils gain pigment by
the deposition of melanin and are subsequently secreted and taken up by keratinocytes by a
poorly understood mechanism [75]. These observations have lead to the suggestion that amyloid
may be a naturally occurring product [78]. Indeed, Aβ has been shown to be secreted in nonpathological situations and may perform a normal physiological function [79]. For example, Aβ
has been shown to have antimicrobial functions and can bind to Escherichia Coli and inhibit its
growth [80]. Furthermore, Aβ can also regulate neuronal activity. It is well known that Aβ
oligomers can inhibit long-term potentiation [81,82]. However, low (picromolar) levels of Aβ
can potentiate long-term potentiation [83]. It has also been previous demonstrated that the
production and secretion of Aβ is increased after synaptic activity [84]. These findings have led
to the suggestion that Aβ may play a role in maintaining the stability of the synapse (homeostatic
plasticity).

5.5

Conclusion

The present work follows the intracellular itinerary of nascent APP. Starting at the site of
production (the Golgi), we have demonstrated that APP can traffic rapidly to the lysosomal
membrane using an AP-3 dependent mechanism. This is reminiscent of the trafficking of other
lysosomal membrane proteins, which utilize the intracellular trafficking pathway. We further
explored the control of this trafficking, showing that PKC phosphorylation of APP at S655 can
regulate the interaction of APP with adaptor proteins responsible for facilitating APP trafficking
[9]. Finally, we show the first evidence of a mechanism for Aβ secretion from intracellular
lysosomal stores.
These data suggest that the routing of APP to lysosomes can promote the production of Aβ. This
lysosomal amyloid can then fibrilize and form aggregates. Such intracellular aggregates have
been found in animal models and human patients have evidence of intracellular aggregates of Aβ
and can seed the formation of extracellular aggregates [85,86]. This thesis suggests that the
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lysosome produces Aβ and is the missing secretory organelle for Aβ (Figure 5.1). This work is
critical for understanding the underlying cellular physiology of APP and potentially reveals
additional therapeutic targets for the treatment of AD.
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Figure 5.1: APP trafficking and Aβ production and secretion.
APP is synthesized in the endoplasmic reticulum and in the Golgi. 1a) After synthesis, APP can
be presented at the cell surface or 1b) delivered rapidly and directly to the lysosome. 2a) After
presentation at the cell surface, APP can be internalized in a clathrin dependent manner (clathrin
depicted as gray shading) into early endosomes. 2b) Alternatively, APP can be internalized
rapidly to lysosomes from the cell surface, in a macropinocytosis dependent manner. 3) APP is
eventually delivered to lysosomes and processed to form Aβ. 4) Through an interaction with the
retromer complex, APP can also be recycled to the Golgi from the endosome. 5) After cleavage
of APP by γ-secretase, Aβ remains in the lysosomal lumen. From the lysosome, Aβ can be
secreted into the extracellular space in a Rab27b dependent manner. Note: The red boxes
represent novel contributions to our understanding of APP trafficking, with the appropriate
chapter reference included. The grey numbers indicate previously studied trafficking pathways,
which are thoroughly discussed in Chapter 1 of this thesis.
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Figure 5.1
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Appendices
All the videos associated with this thesis stored at the School of Graduate and Postdoctoral
Studies' Electronic Theses & Dissertation site (http://ir.lib.uwo.ca/etd/).
Appendix A: Figure Legends to Chapter 2 Videos
Video 2.1: APP is trafficked rapidly to the lysosome and cleared.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPP-paGFP. Irradiation targets (circles) were drawn over the
Golgi apparatus and the were irradiated with 405 nm laser light, alternating with imaging for 15
minutes (indicated by the green word ‘photoactivating’ on the images. Cells were then followed
in a ‘chase period’ imaging every 30 seconds for the time indicated.
Video 2.2: APP paGFP is accurately photoactivated in the Golgi apparatus.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPP-paGFP and were treated with Nocodozole to block exit
from the Golgi. Irradiation targets (circles) were drawn over the Golgi apparatus and the were
irradiated with 405 nm laser light, alternating with imaging for 15 minutes (indicated by the
green word ‘photoactivating’ on the images. Cells were then followed in a ‘chase period’
imaging every 30 seconds for the time indicated. Photoactivated βAPP-paGFP can be seen
accumulating in the Golgi.
Video 2.3: APP processing in the lysosome is blocked by Chloroquine in the lysosome.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPP-paGFP. Cells were pretreated with 100 μM chloroquine
30 minutes before imaging. Irradiation targets (circles) were drawn over the Golgi apparatus and
the were irradiated with 405 nm laser light, alternating with imaging for 15 minutes (indicated by
the green word ‘photoactivating’ on the images. Cells were then followed in a ‘chase period’
imaging every 30 seconds for the time indicated. Photoactivated βAPP-paGFP can be seen
accumulating in lysosomes.
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Video 2.4: APP processing in the lysosome is blocked by L685, 458 in the lysosome.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPP-paGFP. Cells were pretreated with 0.5 μM L685, 458
overnight. Irradiation targets (circles) were drawn over the Golgi apparatus and the were
irradiated with 405 nm laser light, alternating with imaging for 15 minutes (indicated by the
green word ‘photoactivating’ on the images. Cells were then followed in a ‘chase period’
imaging every 30 seconds for the time indicated. Photoactivated βAPP-paGFP can be seen
accumulating in lysosomes.
Video 2.5: APPsw trafficking is rapidly processed.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPPsw-paGFP. Irradiation targets (circles) were drawn over
the Golgi apparatus and the were irradiated with 405 nm laser light, alternating with imaging for
15 minutes (indicated by the green word ‘photoactivating’ on the images. Cells were then
followed in a ‘chase period’ imaging every 30 seconds for the time indicated. APPsw is cleaved
so rapidly that it is unable to accumulate in any compartment.
Video 2.6: APPsw is not cleared in the Golgi apparatus.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPPsw-paGFP and were treated with 66 μM nocodazole and
10 μM cytochalasin. Irradiation targets (circles) were drawn over the Golgi apparatus and the
were irradiated with 405 nm laser light, alternating with imaging for 15 minutes (indicated by the
green word ‘photoactivating’ on the images. Cells were then followed in a ‘chase period’
imaging every 30 seconds for the time indicated. Photoactivated βAPPsw-paGFP can be seen
accumulating in the Golgi.
Video 2.7: APPSw processing in the lysosome is blocked by chloroquine.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPPsw-paGFP and were treated with 100 μM chloroquine.
Irradiation targets (circles) were drawn over the Golgi apparatus and the were irradiated with 405
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nm laser light, alternating with imaging for 15 minutes (indicated by the green word
‘photoactivating’ on the images. Cells were then followed in a ‘chase period’ imaging every 30
seconds for the time indicated. Photoactivated βAPPsw-paGFP can be seen accumulating in
lysosomes.
Video 2.8: APPSw processing in the lysosome is blocked by L685, 458; γ-cleavage occurs in the
lysosome.
SN56 cells were transiently transfected with GalT-CFP to identify the Golgi apparatus, LAMP1mRFP to identify lysosomes, and βAPPsw-paGFP and were treated with 0.5 μM L685, 458
overnight. Irradiation targets (circles) were drawn over the Golgi apparatus and the were
irradiated with 405 nm laser light, alternating with imaging for 15 minutes (indicated by the
green word ‘photoactivating’ on the images. Cells were then followed in a ‘chase period’
imaging every 30 seconds for the time indicated. Photoactivated βAPPsw-paGFP can be seen
accumulating in lysosomes.
Appendix B: Figure Legends to Chapter 3 Videos
Video 3.1: APP is trafficked rapidly to lysosomes from the Golgi.
SN56 cells were transiently transfected with βAPP-paGFP (green), LAMP1-mRFP (lysosome
marker, red), and GalT-CFP (Golgi marker, blue). APP was photo-activated in the Golgi (blue)
with 405nm light, alternating with imaging for 15 minutes (indicated by green word ‘Photoactivating’). The white circles appearing over the Golgi denote the initial ROIs for βAPP-paGFP
photoactivation. These ROIs are carefully monitored and adjusted to remain on the Golgi during
the photoactivation period. Cells were then chased imaging every 30 seconds for the indicated
time.
Video 3.2: APP bearing the Y709A mutation does not traffic to lysosomes.
SN56 cells were transiently transfected with βAPP Y709A-paGFP (green), LAMP1-mRFP
(lysosome marker, red), and GalT-CFP (Golgi marker, blue). APP was photo-activated in the
Golgi (blue) with 405nm light, alternating with imaging for 15 minutes (indicated by green word
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‘Photo-activating’). White circles appearing over the Golgi denote the initial ROIs for βAPPpaGFP photoactivation. Cells were then chased by imaging every 30 seconds for the indicated
time.
Video 3.3. APP bearing the Y738A mutation traffics to lysosomes.
SN56 cells were transiently transfected with βAPP Y738A-paGFP (green), LAMP1-mRFP
(lysosome marker, red), and GalT-CFP (Golgi marker, blue). APP was photo-activated in the
Golgi (blue) with 405nm light, alternating with imaging for 15 minutes (indicated by green word
‘Photo-activating’). Photo-activation ROIs in the Golgi are denoted by white circles in the video.
Cells were then chased by imaging every 30 seconds for the indicated time.
Video 3.4. APP bearing the Y743A mutation does not traffic to lysosomes.
SN56 cells were transiently transfected with βAPP Y743A-paGFP (green), LAMP1-mRFP
(lysosome marker, red), and GalT-CFP (Golgi marker, blue). APP was photo-activated in the
Golgi (blue) with 405nm light, alternating with imaging for 15 minutes (indicated by green word
‘Photo-activating’). White circles appearing over the Golgi denote the initial ROIs for βAPPpaGFP photoactivation. Cells were then chased by imaging every 30 seconds for the indicated
time.
Video 3.5. APP bearing the dephosphomimetic (S711A) mutation traffics to lysosomes.
SN56 cells were transiently transfected with βAPP S711A-paGFP (green), LAMP1-mRFP
(lysosome marker, red), and GalT-CFP (Golgi marker, blue). APP was photo-activated in the
Golgi (blue) with 405nm light, alternating with imaging for 15 minutes (indicated by green word
‘Photo-activating’). The white circles appearing over the Golgi denote the initial ROIs for βAPPpaGFP photoactivation. Cells were then chased by imaging every 30 seconds for the indicated
time. This movie has been intentionally cropped to focus on the trafficking around the Golgi.
Video 3.6. APP bearing the phosphomimetic (S711E) mutation does not traffic to lysosomes.
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SN56 cells were transiently transfected with βAPP S711E-paGFP (green), LAMP1-mRFP
(lysosome marker, red), and GalT-CFP (Golgi marker, blue). APP was photo-activated in the
Golgi (blue) with 405nm light, alternating with imaging for 15 minutes (indicated by green word
‘Photo-activating’). Photo-activation ROIs in the Golgi are denoted by white circles in the video.
Cells were then chased by imaging every 30 seconds for the indicated time. This movie has been
intentionally cropped to focus on the trafficking around the Golgi.
Video 3.7. DCP-LA treatment disrupts APP trafficking to the lysosome.
SN56 cells were transiently transfected with βAPP-paGFP (green), LAMP1-mRFP (lysosome
marker, red), and GalT-CFP (Golgi marker, blue) and treated with 500nM DCP-LA. APP was
photo-activated in the Golgi (blue) with 405nm light, alternating with imaging for 15 minutes
(indicated by green word ‘Photo-activating’). White circles in the video denote photo-activation
ROIs in the Golgi. Cells were then chased imaging every 30 seconds for the indicated time.
Appendix C: Figure Legends to Chapter 4 Videos
Video 4.1. Lysosomal secretion detected by mApple-LAMP1-phLuorin.
SN56 cells were transfected with mApple-LAMP1-phLuorin and imaged using TIR-FM after
treatment with ionomycin. Vesicles positive for mApple (red) and activated pHluorin (green) are
circled in white. Scale bar represents 5 μM. Images were taken every 112 ms.
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